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Abstract 
Background: The effects of morphine on immune cells include reduced NK 
cell cytotoxicity and reduced lymphocyte proliferation but human prospective 
in vivo clinical research has been inconclusive. This study aims to define the 
changes in intraoperative lymphocyte gene expression in patients receiving 
morphine. 
Methods: mRNA gene expression was analysed in CD4+, CD8+ and NK cells 
from 40 patients undergoing gynaecological laparotomies, using the 3’ 
Affymetrix microarray. Patients matched by BMI, age, operation duration and 
pain levels received morphine or control analgesia. Genes demonstrating 
differential expression (fold change≥±2; p-value≤0.05) following ANOVA 
were further investigated. Gene expression analysis was confirmed 
functionally through investigation of serum cytokine concentration 
(cytometric bead array), serum cortisol concentration (ELISA) and NK cell 
cytotoxicity (NK cell degranulation assay). Finally, statistical analyses were 
performed to evaluate the relative importance of individual genes highlighted 
following analysis.  
Results: Microarray analysis identified differential expression of 450 unique 
genes by morphine at 2 hour and 460 unique genes by oxycodone at 6 hour. 
Genes were transiently deregulated by morphine and enriched in processes 
suggestive of lymphocyte anergy. Genes induced by oxycodone were subject 
to a more sustained deregulation and enriched in processes related to normal 
immune functioning. Greater increases in IL-6 and IL-10 concentrations were 
induced by morphine, supportive of a greater TH2 shift. NK cell degranulation 
results were inconclusive and should be repeated with more samples. Cortisol 
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concentration did not significantly change between timepoints. Statistical 
analyses suggested that AGPAT3, TPK1 and TIAM1 might be important in 
mediating morphine-induced changes. 
Conclusion: This study demonstrates altered lymphocyte gene expression in 
patients receiving intraoperative morphine compared to control analgesia. 
The greater morphine-induced TH2 shift suggested by gene expression 
analysis was confirmed functionally, consistent with and extending current 
knowledge of morphine-induced immunosuppression. 
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 Chapter 1 
Introduction 
1.1 Morphine 
1.1.1 Historical use  
Opium and the poppy Papaver somniferum have been used for thousands of 
years, for pain relief and ‘to bring forgetfulness of every sorrow’. Opium is 
found in the dried latex of Papaver somniferum [1] and its use predates 
written history; poppy images were found on Sumerian artefacts in modern-
day Iraq, dating from 4000BC. Helen, daughter of Zeus, ‘cast a drug into the 
wine of which they drank to lull all pain and anger and bring forgetfulness of 
every sorrow’ in Homer’s Odyssey, written around 1000BC; the drug is now 
thought to be morphine [2]. In the 17th century Thomas Sydenham 
recommended laudanum, a concoction of opium and sherry, for pain, 
sleeplessness and diarrhoea. In 1806 the chemist Friedrich Sertürner isolated 
the active ingredient from opium [3], naming it morphine after Morpheus, 
god of dreams.  
The Opium wars of 1830-1860 were precipitated by the importing of opium 
to China [4]. In 1852, the modern hypodermic needle and syringe was 
developed [5], allowing administration of subcutaneous and subsequently 
intravenous morphine; initially, the benefits of intravenous administration 
were not appreciated [6].    
In 1897, the first evidence to suggest that morphine might be 
immunosuppressive was published by Coronedi et al, showing that high doses 
of morphine made dogs unusually susceptible to Diplococcus lanceolatus [7]. 
This was followed shortly after by evidence of altered phagocytosis and 
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leukocyte trafficking in guinea pigs given morphine, published by 
Cantacuzene [8, 9]. Within the next decade, clinicians saw links between 
recreational use of morphine and increased infection rates in humans [9-11], 
although this was commonly attributed to associated co-morbidities and 
lifestyle. Further recent research (Section 1.6) has demonstrated conclusively 
that morphine does indeed suppress the immune system, but the 
mechanisms, magnitude and clinical relevance are not yet fully described. 
Due to the prevalent use of morphine in clinical medicine, it is vital to elicit 
the mechanisms of immunosuppression to enable its modification or 
replacement with an alternative, if deemed clinically necessary.  
1.1.2 Structure 
The structure of morphine was discovered in 1902. It has a modified 
phenanthrene (three linked benzene rings) structure, of two planar rings and 
two aliphatic (or non-benzene) rings at right angles to the rest of the molecule 
[1]. Substitution of either the free hydroxyl on the benzene ring at position 
C3 or C6 produces other pharmacologically active compounds, for example, 
diamorphine and oxycodone.  
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The structure of morphine 
 
Figure 1.1: the structure of morphine [1] 
 
1.1.3 Pharmacokinetics 
Morphine is not very soluble in water so is normally administered as a salt. 
In this study, morphine sulphate was given intravenously. It has a half-life of 
3-4 hours and is converted by UGT2B7 in the liver to 2 metabolites, 
morphine-3- and morphine-6-glucuronide (M3G and M6G), by a conjugation 
of glucuronide to the C3 or C6 -OH group position [1]. M6G is an active 
metabolite that has higher analgesic abilities than morphine, and may be 
involved in immune suppression [12]. The glucuronides are excreted in urine.  
1.1.4 Opioid receptors 
Morphine is a ligand for opioid receptors, of which there are four subtypes. 
Each is named after its first discovered ligand; hence morphine gave its name 
to the µ opioid peptide receptor (MOR), ketocyclazocine to κ receptor (KOR), 
mouse vas deferens to δ receptor (DOR) and nociceptin to NOR (56). 
Although other molecules have been postulated as opioid receptors, they 
have been discounted as they are not blocked by naloxone [13], a pure opioid 
antagonist.  
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Opioid receptors were identified over 30 years ago [14-16], then later studies 
provided the evidence needed to group opioid receptors into at least three 
types [17]. In any case, it had long been suspected that there were multiple 
receptor subtypes based on in vivo observations that opioids produce a wide 
range of effects including analgesia, pupillary constriction, respiratory 
depression and constipation. Morphine binds to all three opioid receptors, 
with the highest affinity for MOR.  
1.1.5 Pharmacodynamics 
Morphine is a partial agonist for MOR and also acts on KOR and DOR. It 
probably produces analgesia via activation of opioid receptors in the CNS: 
morphine injection into specific brain nuclei produces analgesia. Supraspinal 
analgesia may involve endogenous opioid peptide release and, at the spinal 
level, 5-HT release from descending inhibitory fibres may be involved in 
analgesia as physical disruption of fibres reduces analgesia [1]. Morphine acts 
both presynaptically, to inhibit neurotransmitter release from primary 
afferent fibres, and post-synaptically to reduce excitability.  
1.2 Structure and function of opioid receptors 
The opioid receptors are G protein-coupled receptors (GPCRs): a single 
polypeptide chain with seven transmembrane α-helices, an intracellular C-
terminal domain and an extracellular N-terminal domain that induces 
intracellular signalling via a G-protein. All opioid receptors are rhodopsin 
GPCRs, meaning they have a shorter extracellular tail and ligand binds either 
on this tail or a transmembrane domain. The G protein (subunits α, β, γ and 
GDP molecule) is attached to the cell membrane and interacts with the 
guanine nucleotides GDP and GTP [1]. Ligand binding induces a 
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conformational change in the intracellular domain, giving it high affinity for 
the αβγ complex. The complex and domain associate and αβγ exchanges GDP 
for GTP then cleaves into α-GTP and βγ. These activated forms of G protein 
induce intracellular signalling, ending when GTP is hydrolysed to GDP by the 
GTPase activity of α subunit [1].  
Functional selectivity describes the ability of a ligand to induce a unique 
combination of intracellular responses most likely through conformational 
changes in the receptor [18]. In mice, morphine and M6G but not oxycodone 
induced analgesia that was blocked by a JNK inhibitor, suggesting that opioid 
analgesic tolerance is induced via a JNK-dependent pathway in morphine and 
M6G but not oxycodone [19]. Morphine and fentanyl were shown to cause 
MOR desensitization via 2 different methods, activating JNK either without 
the need for arrestin, or arrestin-dependently, respectively [20]. It is possible 
that the immunosuppression induced by morphine but not by oxycodone is 
reflective of a difference in the intracellular conformation change induced by 
the ligand.  
1.3 Receptor location 
There are several variants of MOR which exist both pre- and post-synaptically 
in the CNS (periaqueductal gray, dorsal horn of the spinal cord, olfactory 
bulb, nucleus accumbens, cerebral cortex and the amygdala) and in 
peripheral nerves as part of the ascending pain pathway. It is also found in 
the gastrointestinal tract, where it causes constipation upon activation. Most 
importantly to this study, MOR has also been found in immune cells, including 
T cells, B cells and macrophages [21] [22].  
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DOR receptors are found in the CNS (pontine nuclei, amygdala, olfactory 
bulb, deep cortex) and peripherally in sensory neurons. Activation of DOR 
produces some analgesia, possibly bradypnea and has antidepressant effects.  
KOR receptors are found in the CNS (hypothalamus, periaqueductal gray and 
claustrum), in the substantia gelatinosa in the spinal cord, and peripherally 
in sensory neurons. Activation causes analgesia, sedation, dysphoria, 
anticonvulsant and antidepressant effects, dissociative effects, miosis and 
diuresis.  
NOR receptors are found in the cortex, amygdala, hippocampas, septal nuclei, 
habenula, hypothalamus and spinal cord. Activation results in anxiety, 
depression and increased appetite. It can also be involved in the development 
of tolerance to MOR agonists.  
1.4 The mechanism of action of morphine 
Morphine primarily binds to MOR, causing analgesia, euphoria, sedation, 
pruritis, bradypnea, nausea, miosis and decreased gut motility [1]. It 
activates KOR (analgesia, convulsions) and DOR (spinal analgesia, sedation, 
dysphoria, hallucinations) with a lower affinity.  
Following ligand binding, the activated G-protein opens membrane K+ 
channels while keeping voltage-gated Ca2+ channels closed [1].  The 
decreased intracellular K+ causes hyperpolarization and an inability to 
produce action potentials, reducing neuronal excitability. The decreased 
intracellular Ca2+ also reduces neurotransmitter release [1]. However, MOR 
activation does increase some neuronal activity, via disinhibiting inhibitory 
neurons, for example sensory nerve terminals in the periphery.  
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Activated opioid receptors inhibit adenylyl cyclase and activate MAPK, which 
phosphorylates serine, threonine and tyrosine, thus directing the cellular 
response to diverse stimuli – not only mitogens but also osmotic stress and 
proinflammatory cytokines – via gene expression, proliferation, mitosis and 
apoptosis.  
The varying effects of different opioids are related to the anatomical location 
of their activated receptors, the variation in their affinity for different receptor 
sub-types and possibly ligand-directed binding. Morphine predominantly 
activates MOR in areas related to analgesia: the PAG, RVM and nucleus 
accumbens in the CNS and the dorsal horn in the spinal cord. The PAG 
receives input from regions including the cortex; it is the main path that 
cortical and other information passes through to control the dorsal horn’s 
nociceptive gate [1]. PAG neurones project to the RVM then the dorsal horn 
as the descending inhibitory pathway; activation of MOR in the PAG both 
inhibits transmission in the dorsal horn and inhibits discharge of 
spinothalamic neurones, via pre-synaptic inhibition of 5-HT, enkephalin and 
GABA [1].  
In the nucleus accumbens, activation of MOR increases dopamine release, 
producing analgesia via the mesolimbic system. Activation of MOR in immune 
cells is likely to be a factor in morphine-induced immunosuppression, 
although it is likely that this also happens via a central route [23].  
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1.5 Immune system 
The human innate system responds rapidly to pathogens and involves 
nonspecific antimicrobial pathways that do not require pathogen pre-
exposure [24]. It is also used in the adaptive response. The adaptive system 
is activated by a particular pathogen and is centred around lymphocytes. 
Cells of the immune system 
Table 1.1: cells and humoural components of the innate v the adaptive 
immune systems 
 Cells Other 
Innate 
Monocytes Complement 
Neutrophils Lysozyme 
Basophils Acute phase proteins 
Macrophages Cytokines 
Eosinophils Interferons 
Mast cells  
NK cells   
Adaptive B cells Antibody T cells Cytokines 
 
1.5.1 Innate immune system 
The innate immune system consists of three parts: barriers, cells, and serum 
proteins and the complement system. Barriers are physical or chemical and 
include tight junctions between epithelial cells and sweat and sebaceous 
secretions on the skin producing a barrier and a hostile environment [24]. 
Mucus in gastrointestinal, respiratory and genitourinary tracts traps 
pathogens while cilia and the cough reflex expel them.  
Cells of the innate immune system include monocytes / macrophages, 
neutrophils, eosinophils, basophils and NK cells. Monocytes are the largest 
circulating blood cell and differentiate to become macrophages, living for 
years. They express toll-like receptors (TLRs) whose activation results in 
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transcription factor phosphorylation and cytokine production, as well as 
downstream kinase activation. Cytokine production subsequently activates B 
and T cells of the adaptive immune system (Section 1.5.3). Macrophages also 
activate the adaptive immune system via antigen fragments on their cell 
surface.  
Natural killer (NK) cells make up 5-10% of circulating lymphocytes and use 
cell surface receptors to identify and kill tumour cells and cells infected with 
intracellular pathogens, particularly viruses.  
Acute phase proteins (APPs) increase rapidly when the innate immune system 
is activated. They include lectins which themselves activate complement. 
Cells produce interferon (IFN) proteins when infected with a virus – IFNα and 
IFNβ protect nearby cells by inducing expression of genes encoding proteins 
to attack viral DNA. IFN-γ is produced by activated NK cells and activates 
additional NK cells and macrophages. The complement system consists of 
over 20 serum glycoproteins that circulate as pro-enzymes and recruit 
inflammatory cells to inflammation sites. Activation triggers a cascade 
resulting in cell lysis, inflammation, opsonization and finally clearance of 
immune complexes.  
1.5.2 Adaptive immune system 
Lymphoid cells originate in the bone marrow, where they differentiate into B 
and NK cells or travel to the thymus to become T cells. The three cell types 
can be distinguished by receptors and receptor ligands on their cell surfaces. 
B cells express a B cell receptor (BCR) whereas T cells express a T cell 
receptor (TCR).  
Cell surface ligands of B, T and NK cells 
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Table 1.2: Typical identifying markers found on lymphocytes. (CD = cluster 
designation, a membrane-bound molecule) 
B cells T cells NK cells 
B cell receptor T cell receptor CD-2 
CD-19 CD-2 CD-7 
CD-20 CD-3 CD-16 
CD-32 CD-4 CD-25 
CD-40 CD-8 CD-56 
HLA-DR CD-7 CD-57 
  CD-28 
 
1.5.3 T cells 
T cells are characterized by their receptors (TCRs) and their cellular function. 
TCRs are structurally similar to BCRs as they are made from 110 amino acid 
domains (α, β, γ and δ) folded seven or eight times with Ig folds. TCRs 
normally consist of a αβ subunit (95% of T cells) and rarely a γδ subunit, 
usually found on mucosal surfaces where they recognize antigen without the 
help of antigen-presenting cells (Section 1.5.3.2).  
However, normally TCRs cannot recognize antigen alone, only when 
presented by Major Histocompatibility Complex (MHC) on Antigen Presenting 
Cells (APCs). CD3, associated with the TCR, transduces the signal 
intracellularly. MHC is a general term; in humans the specific antigen is 
known as Human Leukocyte Antigen (HLA) and is involved in antigen peptide 
binding, processing and presentation. HLA molecules are present on antigen 
processing cells (APCs), which include macrophages, B cells and Langerhans 
cells. The cell processes the antigen then trafficks peptide fragments to MHC 
molecules on the cell surface. MHCII presents peptide fragments to CD4, and 
MHCI to CD8: CD4+ T cells respond to MHCII-linked peptide and CD8+ T cells 
respond to MHCI-linked peptide. T cells are subdivided into several types 
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include T helper (CD4+), T killer (CD8+), T regulatory (TReg), T memory and 
Natural Killer T cells.  
1.5.3.1 T helper 
T helper cells are identified by the presence of a CD4 molecule on their cell 
surface and activate B cells, cytotoxic T cells and macrophages.  
T helper cells are subdivided into T helper 1 (TH1) or T helper 2 (TH2) and T 
helper 17 (TH17). These subtypes are mutually antagonistic [24] as they 
each produce cytokines which regulate the opposing population downstream. 
TH17 cells, which are pro-inflammatory and produce TH17, are mutually 
antagonistic with TReg cells [25]. 
TH1 cells produce IL-2, IL-3, IL-10, IFN-γ, TNF, lymphotoxin and GM-CSF 
and are involved in inflammatory processes and macrophage activation. TH2 
cells secrete IL-3, IL-4, IL-5, IL-6, IL-10 and IL-13, TNF and GM-CSF and are 
involved in synthesis of antibody by B cells. The TH1 response is therefore 
deemed to be pro-inflammatory, and the TH2 response anti-inflammatory: 
TH1 response supports a cell-mediated immune response, and TH2 antibody-
mediated. Because T helper cells are important in immune functioning and 
influence cytokine profiles, we looked at gene deregulation in these cells.  
1.5.3.2 Cytotoxic T cells 
Cytotoxic T cells usually express CD8 on their cell surface and are known as 
CD8+ cells. They are involved in the killing of virally infected cells and, in 
their precursor state, can recognize antigen fragments associated with MHCI 
on APCs. CD8+ cells normally also require a TH cell to kill infected cells; both 
TH and CD8+ cell will bind to an APC, TH via MHCII and CD8+ via MHCI. IL-
2 and IL-6 are then released by TH and stimulate the CD8+ precursor to 
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differentiate into an antigen-experienced effector CD8+ cell. Once activated, 
the CD8+ cell delivers cytoxic granules containing perforin and granzymes 
onto the target cell (APC) at the point of contact between the 2 cells, ensuring 
killing is specific. Death occurs via induction of apoptosis and also through 
activation of a nuclease which produces DNA breaks. A second, minor, killing 
pathway exists via Fas ligand on CD8+ and its receptor on the target cell. 
Binding of Fas ligand initiates activation of caspase-8 which propagates the 
death signal [24]. CD8+ cells are subdivided into those that secrete IFNγ and 
those that secrete IL-4. We also investigated gene deregulation in CD8+ T 
cells due to their importance in immune functioning.  
1.5.4 Antibody-mediated immune response 
IL-1, produced by activated macrophages, consists of IL-1α and IL-1β and is 
a pro-inflammatory cytokine involved in cell proliferation and differentiation. 
It induces COX2, which is involved in inflammatory pain hypersensitivity. IL-
10 is an anti-inflammatory cytokine secreted by cells including monocytes 
and TH2 cells whose receptor consists of two IL-10R1 and two IL-10R2 
subunits [26]. Ligand binding phosphorylates the cytoplasmic tails of the 
receptor to induce STAT3 signalling, which activates transcription and 
increases induced TReg differentiation [27].  
IL-6 is a pro-inflammatory cytokine, produced by many cell types including T 
and B cells. As it is rapidly cleared from plasma, its regulation is at the 
expression level and it is modulated via transcription factors including NF-κB. 
It induces production of APPs and facilitates neutrophil trafficking to initiate 
and maintain inflammation [28].  
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1.5.5 Natural Killer cells 
Natural Killer (NK) cells differentiate in the bone marrow and are large 
granular leukocytes instrumental in death of virus-infected cells via their 
Killer Activating Receptor (KAR). This receptor is activated by a high 
molecular weight glycoprotein on the infected cell causing granule movement 
towards it; granule contents are released into the extracellular space, 
inducing apoptosis. The Fas-Fas ligand complex can also induce apoptosis via 
the Fas receptor on the target cell as a minor killing strategy. NK cells also 
express a Killer Inhibitory Receptor (KIR), which recognizes MHCI (not 
normally present in virally-infected or tumour cells) and is dominant over 
KAR, thus avoiding autoimmunity. Tumour cells expressing low or no MHCI 
are especially susceptible to NK cell killing. NK cells also kill tumour cells via 
their Fc receptor, which is a receptor for IgG and activated by IL-2 or IFN-γ.  
NK cell cytotoxicity (NKCC), or the ability of NK cells to induce apoptosis in 
target cells, was measured indirectly in this study using NK cell degranulation. 
This assay uses flow cytometry to measure NK cell surface CD107a, normally 
found intracellularly in cytolytic granule membranes.  
The ability of NK cells to remove tumour cells and the demonstrated reduction 
in NKCC following morphine administration [29-31] suggests that NK cells 
should be investigated in this experiment. Reduced NKCC is particularly 
relevant in the period following surgical resection when tumour cells and their 
fragments may disseminate in the blood.  
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1.6 The immunomodulatory effects of morphine 
In 1897, the first definitive literature on morphine-associated immune 
changes was published [7], but despite the wealth of publications since then, 
the mechanisms remain unconfirmed. Morphine abuse has been linked to 
immunosuppression and increased infection rates [32], and clinical use to an 
increase in infection rates in humans [33], immunosuppression [34, 35], and 
cancer metastases, although some reports have been contradictory [36, 37]. 
However, it is an important analgesic and recommended on the WHO 
analgesic ladder as a first-line step three analgesic [38] [39].  
As well as observational data, prospective animal and in vitro research has 
confirmed the link between morphine and immune suppression [40], 
indicating possible mechanisms including NKCC suppression [31, 41]. The 
influence of the surgery-related stress pathway involving the hypothalamus-
pituitary-adrenal (HPA) axis may be important [42, 43]. Prospective human 
in vivo research has been varied and immunosuppression is not always found, 
possibly due to the presence of confounding factors such as pain, surgical 
trauma and anaesthesia, which also produce immunosuppression. Non-
operative administration of morphine has the advantage of fewer confounding 
factors but tends to be chronic; tolerance may develop to the 
immunosuppressive as well as analgesic effects [44]. 
Nevertheless, despite the equivocal results in some human studies, it is now 
generally accepted that morphine can suppress immune function.  
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1.6.1 Opioid structure and immunosuppression 
As well as morphine, other opioids are thought to suppress the immune 
system. Opioids with hydroxyl (-OH) groups at C3 and C6 positions 
(nalorphine) may be the most immunosuppressive, modification at C3 
(codeine) produces some loss of immunosuppression while further C6 
modification by substitution with a carbonyl group (oxycodone) may remove 
immunosuppressive qualities [31]. Following opioid administration in mice, 
morphine induced a decrease in splenocyte proliferation, IL-2 production and 
NKCC; codeine induced only a slight decrease in NKCC and IL-2 production; 
and hydromorphone (a MOR agonist) and oxycodone showed no change. 
Nalorphine, a mild analgesic, induced a decrease in all parameters, while 
naloxone and naltrexone both increased proliferation and IL-2 production. 
The immunosuppressive and analgesic effects do not appear to be correlated 
[31].  
1.6.2 Morphine-linked immunosuppression in 
humans 
PHA is a mitogen that induces calcium mobilisation and proliferation in T cells 
[45-47]. Patients given morphine post-surgically showed a prolonged 
suppression of PHA-stimulated proliferation compared to those given 
tramadol. The tramadol group also showed increased NKCC but there was no 
change in the morphine group [48]. A healthy volunteer crossover study with 
fentanyl, buprenorphine, tramadol or morphine showed different intracellular 
phosphorylation patterns for fentanyl and morphine. Early activation of 55-
60 kDa membrane-associated signalling proteins was seen with these 
analgesics but not seen with buprenorphine or tramadol [49]. Exposure of a 
separate group of healthy volunteers to continuous morphine for 36 hours 
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produced suppression of NKCC at 2 hours that lasted until twenty-four hours 
[29], although no control data was available. In patients undergoing 
abdominal surgery, the pre-anaesthetic induction addition of noradrenaline 
to morphine prolonged the NKCC suppression until postoperative day 7, 
compared to a day 2 recovery in those given morphine alone [50, 51], 
suggesting a role for the HPA axis.  
1.6.3 Tolerance to morphine induced 
immunosuppression 
Tolerance develops to some variables of immune suppression; rats receiving 
long-term oral saline followed by subcutaneous morphine showed a greater 
NKCC suppression compared to the long-term oral high dose morphine 
followed by subcutaneous morphine [41]. However, no tolerance developed 
to mitogen-stimulated T or B cell proliferation or splenic T cell IFNγ 
production, suggesting the presence of several morphine-induced 
immunomodulatory mechanisms [41]. Murine macrophages exposed to C 
albicans in vitro, together with a MOR / DOR / KOR agonist, showed a 
suppressed dose-dependent capacity to ingest and phagocytose, blocked by 
the relevant antagonist [52]. PMN cells from Rhesus macaques subjected to 
repeated increasing morphine doses, showed a maintained ingesting ability 
but suppressed killing ability, after exposure to yeast blastospores [53]. 
Morphine suppresses phagocytic function, measured as cell count and index 
and microbial killing properties, in bone marrow phagocytes of mice exposed 
to infection; chronic administration increased LD50 almost 2-fold [44]. Higher 
doses of morphine or nalorphine reduced con-A-stimulated lymphocyte 
proliferation, NKCC and T cell IL-2 production in mice; the opioid antagonists 
naloxone and naltrexone had the opposite effects [31].  
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In advanced cancer patients, those already taking morphine upon study entry 
showed a possible tolerance to the immunomodulatory effects of morphine. 
For these patients, no correlation was found between plasma M6G 
concentrations and PHA-stimulated lymphocyte proliferation or plasma 
immunoglobulin. However, in those patients not already taking morphine, a 
negative correlation was found [12]. Conversely, heroin (diacetylmorphine) 
abusers randomized to either methadone (an acyclic analogue of morphine) 
or buprenorphine showed an overlapping raised cytokine profile, suggesting 
that both drugs stimulated the previously suppressed immune system [54] 
or that they preserve immune function. Rodents showed greater bacterial 
growth and bacteraemia when given more morphine doses as opposed to 
fewer [55], suggesting that several mechanisms may be relevant to 
immunosuppression caused by chronic morphine administration. 
In summary, morphine-induced immunosuppression is probably mediated in 
part via MOR and involves a shift towards a TH2 cytokine profile and cytokine-
mediated immunity, thus including suppression of NKCC and decreased 
phagocytic activity. 
1.6.4 Morphine and microglia 
Macaques acclimatized to morphine and then exposed to Simian 
Immunodeficiency Virus (SIV) showed a higher plasma and CSF viral load 
with increased CNS virus build, compared to saline and SIV animals [56]. 
Previous work showed that SIV uses the chemokine receptor CCR5 (found on 
T cells and macrophages), for entry into macrophages. CCR5 was up-
regulated by morphine in murine microglia [56], suggesting a possible 
mechanism for increased SIV viral load in morphine-exposed macaques.  
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Mice given morphine +/- naltrexone and then infected with bacteria had a 
higher organ bacterial load and mortality rate than those in the naltrexone 
only or placebo groups; they also had higher levels of pro-inflammatory 
cytokines but lower levels of IL-17a. However, a sub-study of IL-17a knock-
out mice did not show an increased susceptibility to bacterial infection. [40]. 
Finally, bovine microglia exposed to morphine then infected with M bovis 
bacteria had a reduced capacity to induce γδ T cell proliferation, compared to 
the control group [57], suggesting a change in the functioning of microglia 
may be important.  
1.6.5 Immune cell opioid receptors 
In 1979 Wybran et al showed the existence of immune cell opioid receptors 
in humans, following incubation of human PBMCs with morphine [58]. 
Rosetting, the method used to show receptor existence, has largely been 
replaced by modern tests, and describes the arrangement of erythrocytes 
around a central cell, often a lymphocyte, to identify a cell surface receptor. 
Morphine-treated PBMCs showed reduced rosetting with sheep erythrocytes 
compared to non-morphine controls, suggesting that morphine modulated a 
cell surface receptor (now known to be CD2). As rosetting was blocked by 
pre-incubation with naloxone, a MOR antagonist, it is likely that the changes 
were mediated via MOR. Unexpectedly, incubation with the endogenous MOR 
and DOR opioid agonist met-enk showed the opposite effect and increased 
rosetting [59].  
1.6.6 Opioid receptor knockout 
Triple opioid receptor knockout (KO) mice showed a differing cytokine profile 
to wild-type mice [60]. With decreased IL-2 and IFNγ levels, but increased 
Mary Elizabeth Demopoulos                                                               Introduction 
© Mary Demopoulos 2010–2017 42
IL-4 and IL-10 levels, KO mice had a profile more aligned to TH2 than TH1 
cytokines compared to wild-type mice. This suggests that KO mice are 
immune suppressed and that opioid receptors are important in immune 
modulation. In humans, postoperative (and therefore immune suppressed) 
patients show a TH2 rather than TH1 profile [61, 62], suggesting that non-
suppressed humans may favour a TH1 profile over TH2. These results suggest 
that modulation of the cytokine profile is an important part of morphine-
induced immunomodulation.  
1.6.7 Cytokines 
IL-4 induces opioid receptor expression in T cells in vitro [63]; anti-CD3 and 
anti-CD28 antibodies induce IL-2 production via activation of the TCR. 
Healthy human PBMCs and cells from the JURKAT line (an immortal T cell line 
whose cells produce IL-2) were incubated with IL-4 then anti-CD3 and anti-
CD28 antibodies. Those cells exposed to morphine and the MOR and DOR 
endogenous agonist beta-endorphin showed reduced IL-2 mRNA production 
[56] compared to controls. This effect was blocked by MOR but not DOR 
antagonists, confirming the importance of MOR in IL-2 production [64].  
Morphine given for post-incisional pain in mice reduced TNFα, G-CSF and KC 
levels (normally increased post-incision) and reduced wound neutrophil 
infiltration [65]. These two effects had different mechanisms as mice in the 
lowest morphine group showed a huge drop in cytokine levels but no 
concurrent effect on neutrophil numbers [65].  
1.7 Intraoperative confounding factors 
Acute administration of morphine differs to chronic administration in its 
immunomodulatory effects. The predominantly post-surgical nature of acute 
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clinical morphine use involves more confounding factors, which may also 
influence the immune response post-surgically.  
1.7.1 Anaesthesia 
Although anaesthetic agents are known to modulate the immune system, this 
is difficult to quantify in clinical research due to the difficulties of separating 
analgesic from anaesthetic effects. 
For example, the large scale MASTER study in Australasia found no advantage 
of epidural anaesthesia / analgesia over general anaesthesia (GA) and opioid-
induced analgesia, using clinical outcomes as an endpoint, even with analyses 
of subgroups [37, 66, 67]. However, the epidural group received pethidine 
and the anaesthetic fentanyl (only 5.6% of patients had a pure epidural 
infusion) and the opioid group received morphine, pethidine and fentanyl. 
Fentanyl has been shown to induce NKCC suppression (see below; [68]), 
possibly preventing the observation of any advantages of epidural 
administration or disadvantages of morphine administration.  
Other studies have delivered a non-opioid group versus a GA + opioid group, 
but any immunosuppressive effects attributed to the opioid could equally be 
due to the GA. Patients undergoing breast tumour resection and receiving a 
levobupivacaine paravertebral block showed a different cytokine profile to 
those given sevoflurane and morphine PCA [69, 70]. The levobupivacaine 
group showed lower IL-1β, MMP3, MMP9 and IL-10 levels, indicating a 
possible protective effect of levobupivacaine compared to GA + morphine in 
terms of tumour progression [69]. Lower IL-1β can reduce tumour growth in 
vitro [71] while higher levels of MMPs and IL-10 are associated with tumour 
expression and metastasis [72-74]. However, it is not known if 
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levobupivacaine, sevoflurane or morphine caused the difference between 
groups.  
Retrospectively, levobupivacaine given as a paravertebral block alongside GA 
during mastectomy was shown to have a possible immune-sparing effect, 
conferring a 94% recurrence free survival at 3 years compared to 77% in the 
GA only group [75]. This may be due to a reduced need for morphine and 
GA, a direct effect of the levobupivacaine, or due to reduced pain, as the 
paravertebral group also had a lower median pain score.  
High dose fentanyl caused prolonged NKCC suppression when compared to 
low dose fentanyl, following abdominal surgery for both malignant and benign 
indications. This was reversed by IL-2 and partially reversed by IFN-α/β [68], 
suggesting cells could be re-activated [76]. Rats given ketamine, thiopental 
or halothane all showed reduced NKCC and increased tumour cell retention 
and lung metastases, whereas propofol did not produce these effects. 
Ketamine was associated with the greatest increase in metastases, a finding 
the authors attributed to its relative NKCC suppressive effects [77]. Patients 
undergoing spinal (bupivacaine) anaesthesia during TURP (transurethral 
resection of the prostate) showed a shift to a TH1 profile while total TH cell 
numbers remained constant, compared to the GA group (propofol + morphine 
/ fentanyl) group [62]. As propofol has not been shown to reduce cell-
mediated immunity, the TH1 shift is most likely to due the lack of opioid. TH1 
cytokines are involved in cell-mediated immunity and protective against 
tumour spread and viral infections [62], advantageous in the post-surgical 
period, when tumour fragments may have disseminated in the circulation.  
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1.7.2 Surgery & trauma (the neuroendocrine 
stress response) 
The trauma of surgery has immunosuppressive effects via the hypothalamic 
– pituitary – adrenal (HPA) axis. Cytokines released at the incision site (IFN-
γ, TNF, IL-1, -2, -6, β-endorphin) act on the hypothalamus to stimulate 
corticotropin-releasing hormone and arginine vasopressin release. These 
then stimulate adrenocorticotropic hormone (ACTH) and glucocorticoid 
release from the pituitary and adrenal glands respectively. Cytokines also act 
directly on the pituitary and adrenal gland [61]. Increased levels of 
glucocorticoids can shift cells to a TH2 profile, seen as a change in cytokine 
release from stimulated PBMCs [78, 79].  
Laparascopic surgery is advantageous over open surgery. Patients 
undergoing laparoscopic cholecystectomy showed a 2 hour reduction in IL-4 
secretion from PHA-stimulated PBMCs and fewer circulating CD23+ B cells 
(up-regulated by IL-4 in vivo), when compared to their age-, sex- and BMI-
matched open surgery cohort [61]. This indicates that the surgery-induced 
immunosuppressive effect is influenced by incision size [61] and may involve 
a TH2 shift. Cholecystectomy patients given perioperative ibuprofen showed 
smaller and more transient changes in plasma ACTH, cortisol and glucose 
compared to the placebo group [80], indicating both a therapeutic use for 
ibuprofen in surgery and the importance of the neuroendocrine stress 
response.  
However, it may not be a key factor in surgical immunosuppression; rats 
given experimental surgery showed increased plasma corticosterone, 
reduced by morphine treatment; the same rats showed a greater lung tumour 
cell retention in the non-surgical morphine group compared to the surgical 
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morphine group, concurrently with a 50% drop in corticosterone [81]. It is 
possible that morphine-induced suppressed NKCC rather than the HPA axis 
caused tumour cell retention.  
1.7.3 Suppression of NK cell cytotoxicity post-
surgery 
NKCC suppression is seen postoperatively in patients undergoing solid 
tumour resection [82] and in non-cancer patients undergoing surgery; non-
cancer patients also showed suppressed postoperative NKCC following IFNα 
cell stimulation [83]. It is not always clear if surgery, anaesthesia, analgesia 
or a combination of factors resulted in reduced NKCC.  
1.7.4 Hypothermia 
Maintenance of body temperature is important intraoperatively, as general 
anaesthetics reduce core temperature [84], which can affect drug 
metabolism: serum morphine levels were elevated in neonatal patients 
undergoing experimental hypothermia for hypoxic ischaemic encephalopathy 
compared to the normothermic group [85]. Hypothermia in rats suppresses 
NKCC and promotes metastases following injection of lung tumour cells; total 
NK cell numbers were unchanged and the suppressive effects were probably 
initiated in vivo, as NK cells from both groups were cooled and maintained at 
23°C prior to functional assay [86]. 
 
1.7.5 Pain 
Pain has an immunosuppressive effect, but it may be outweighed by that of 
morphine; rats given intraperitoneal ketamine or morphine following soft 
tissue injury showed an increased 48 hour mortality rate and reduced LPS-
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induced TNF response, compared to the saline group [87]. Conversely, 
anaesthetised rats undergoing surgery with morphine analgesia showed less 
NKCC suppression compared to saline surgical controls [88]. Following 
tumour cell injection, operated animals showed increased tumour cell 
retention compared to non-surgical controls, attenuated by morphine and 
suggesting that pain not morphine may be more immunosuppressive. The 
same group showed an increase in metastases in surgical compared to non-
surgical rats following tumour cell injection, possibly a result of suppressed 
NKCC. This was prevented by morphine, but non-surgical controls were 
unaffected, suggesting that poorly controlled pain contributes to the spread 
of metastases [89]. Pre- and postoperative morphine reduced surgery-
induced increases in lung metastatic colonization [89, 90] and lung retention 
of tumour cells [81, 88]. The greatest reduction occurred in the pre-operative 
morphine only group, although its analgesic duration was the shortest [81].  
Indomethacin is a COX inhibitor and therefore prevents conversion of 
arachidonic acid to prostaglandins by cyclooxygenase (COX); prostaglandins 
have a role in peripheral and central sensitization. Rats given indomethacin 
intraoperatively and tumour cells injection post surgery showed a reduction 
in tumour cell retention compared to placebo, an effect not found seen in the 
anaesthetized non-surgery group. NKCC was reduced by surgery and 
increased by indomethacin administration in a sex-dependent way; in 
females indomethacin prevented surgery-induced suppression of NKCC [91] 
whereas in males it increased NKCC in both operated and non-operated 
animals. These results suggest that the pain experienced by rats was 
important in suppressing NKCC [91].  
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1.8 Experimental design 
1.8.1 Pain model 
To attempt to reduce confounding variables, we chose a homogenous surgical 
group; female patients undergoing open non-cancer gynaecological surgery 
with a Pfannenstiel incision. Non-cancer surgery was chosen to prevent an 
influence of cancer-related immune changes. These patients tended to have 
myomectomies, and therefore a similar level of surgical trauma and surgery 
duration. Precise surgery was not specified so that recruitment was possible 
within the required timeframe. A Pfannenstiel incision induces sufficient pain 
to warrant the use of strong opioid (laparoscopic surgery is unlikely to justify 
morphine) and also tends to be a uniform length of approximately 8-12 cm 
[92]. Abdominal surgery is amenable to epidural analgesia, previously used 
successfully as a control for morphine-induce immunosuppression studies.   
1.8.2 Analgesia 
Morphine sulphate, oxycodone hydrochloride and epidural bupivacaine were 
the 3 analgesics used. Morphine was the study drug of interest, oxycodone is 
a non-immune modulating opioid and epidural bupivacaine is a non-immune 
modulating non-opioid. Patients were prospectively randomised to receive 
only 1 of these 3 analgesics. 
1.8.2.1 Oxycodone 
Oxycodone has a similar modified phenanthrene basic structure to morphine 
[1]; the C6 hydroxyl group moves to C3 on the same ring, with a new O atom 
at the C6 position. The hydroxyl group at C3 on the second benzene ring is 
replaced with H3CO. 
Structure of oxycodone 
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Figure 1.2: the structure of oxycodone [1] 
 
Although oxycodone was traditionally believed to be primarily a MOR agonist 
with a lower affinity than morphine, it may have a different receptor binding 
profile. Oxycodone and morphine showed unique activity profiles of analgesia, 
respiratory depression and constipation following intracerebroventricular 
administration in rats [93] and radioligand binding studies suggest that 
oxycodone is mainly a κ-opioid receptor (KOR) agonist with a weak affinity 
for MOR [94]. Oxycodone crosses the blood brain barrier more efficiently than 
morphine accounting for its more potent analgesia [95]. Activation of KOR 
mediates analgesia, dysphoria, anticonvulsant and antidepressant effects, 
dissociative effects, miosis and diuresis [96]. MOR activation in the 
presynaptic afferent neurons in the dorsal horn of the spinal cord, and in the 
PAG in the midbrain and rostral ventromedial medulla (RVM) mediates 
analgesic and sedative effects. Efferent outflow from the PAG and RVM 
inhibits nociceptive transmission in afferent fibres in the dorsal horn, using 
noradrenaline and 5-HT [13].  
Oxycodone has a half-life of 3-4.5 hours and its metabolites include 
oxymorphone, produced by the enzyme CYP2D6. Although oxymorphone has 
Mary Elizabeth Demopoulos                                                               Introduction 
© Mary Demopoulos 2010–2017 50
a high affinity for MOR, it is only produced to a small degree in humans and 
therefore has a limited contribution to analgesia [97].  
1.8.2.2 Bupivacaine 
Like other local anaesthetics, bupivacaine has the basic structure of an 
aromatic group and an amine side chain [85] linked by an amide group. 
Earlier anaesthetics were linked with an ester group; amide groups tend to 
give the anaesthetic more stability.  
Structure of bupivacaine 
 
Figure 1.3: the structure of bupivacaine [1] 
 
Bupivacaine binds to sodium channels intracellularly, preventing Na2+ influx 
into the cell and depolarization, particularly of thinner non-myelinated nerve 
fibres such as nociceptors. Low doses do not completely block depolarization, 
but reduce the rate of rise of the action potential (AP) due to the reduced 
intracellular Na2+ influx. This increases the duration of the AP and reduces 
the cell’s firing rate. Higher doses completely block APs. 
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1.8.3 Anaesthesia 
A propofol-only anaesthetic protocol was used due to previous work showing 
propofol to have no immune-modulating properties [77]. Anaesthesia was 
induced and maintained with propofol only and no other anaesthetics 
(intravenous or inhalational) were used.  
1.8.4 Blood sampling 
1.8.4.1 Timepoints 
Four sampling timepoints were used: pre-dose, then 2, 6 and 24 hours post-
induction. Previous work by this group found changes in phosphorylation 
patterns of membrane associated signalling proteins as early as 2 hours post-
morphine administration [49], and elsewhere, in laparoscopic versus open 
cholecystectomies, PBMCs showed a difference in secreted IL-4 at 2 hours 
only [61]. Early changes (probably by 1 hour) were seen in TH1: TH2 ratios 
in male patients undergoing TURP [62], and surgery-induced cytokines were 
reduced in the morphine group at 2 hours post incision in mice [65]. Ben-
Eliyahu et al found that NKCC remained suppressed at 6 hours post-
anaesthesia [86]. Finally, based on experimental practicalities, we chose 24 
hours as our last timepoint.  
1.8.4.2 Venepuncture and transfusions 
Venous blood was taken mainly by repeat venepuncture with a hollow metal 
hypodermic needle, rather than from in-dwelling catheter, as blood from the 
catheter route is prone to clotting, causing RNA degradation. No further 
experimental blood samples were taken from patients who required a blood 
transfusion, but samples already taken before the point of transfusion were 
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assayed if at least 3 samples were available. This was due to the unexpectedly 
large number of transfused study patients.  
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1.9 Aims 
As previous clinical research has produced equivocal results, and due to the 
wide use of morphine, further investigation of the immunosuppressive effects 
and mechanisms of morphine is warranted.  
We planned to use gene expression analysis to further investigate the 
previously published immunosuppressive effects of morphine. Our aim was 
to compare relative gene deregulation in mononuclear cells following 
morphine, oxycodone or epidural bupivacaine administration intra- and 
postoperatively in patients undergoing open gynaecological surgery via a 
standard Pfannenstiel incision. As yet, no clinical study has been published 
that successfully separates morphine from other analgesia intra- and 
postoperatively. We therefore aimed to create two non-morphine groups. 
Further, we aimed to confirm gene deregulation and morphine-induced 
immunosuppression using functional assays and to identify possible genes 
that could be used for prognostic tests to identify patients at higher risk of 
morphine-induced immunosuppression.  
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 Chapter 2 
Methods 
2.1 Clinical Methods 
2.1.1 Study approvals 
Ethics approval for the study: A single centre, parallel group, pilot study to 
investigate the effect of opioids on immunomarkers using gene expression 
profiling, was obtained from the Royal Marsden Research Ethics Committee, 
REC reference number 06/Q0801/135. 
The initial recruitment target was 45 patients, 15 per treatment group. 
Following the initial withdrawal of 11 patients, a protocol amendment was 
submitted to the MREC to increase maximum total patient numbers to 70. 
This was approved on 26 Sep 2011.   
Regulatory approval for the study: A single centre, parallel group, pilot study 
to investigate the effect of opioids on immunomarkers using gene expression 
profiling, was obtained from the MHRA and the Joint R&D office of Barts and 
The London NHS Trust and Queen Mary, University of London (reference 
number 4757 QM).  
2.1.2 Patient recruitment 
Patients were selected in advance from elective gynaecological surgery lists, 
for surgery at Barts and The Royal London hospitals. All patients who met the 
inclusion and exclusion criteria were consented prior to surgery. 
2.1.3 Randomisation and blinding 
Prior to study start, 45 slips of paper detailing treatment to be assigned (15 
per treatment group) were created and placed in individual envelopes. The 
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envelopes were mixed and stored in a box in a locked room. To randomize a 
patient, the consenting investigator chose an envelope from the box at 
random.  
Given a potentially high withdrawal rate (usually transfusion and analgesia-
related) and the anticipation that postoperative patient withdrawal would not 
be evenly spread across treatments, an additional envelope for the same 
treatment group was created and re-mixed for any patient who withdrew, to 
ensure sufficient completed patients in each group.  
Theatre, ward staff and investigators were unblinded to each patient’s 
treatment. Laboratory assays were conducted by staff blinded to the study 
group (TW and MD), who remained blinded until sample mRNA was prepared 
for hybridisation to chips, when unblinding was essential for appropriate 
stratifying of treatment groups.  
2.1.4 Patient population 
All patients were female, aged over 18 and recruited from elective non-cancer 
gynaecological surgery lists, for gynaecological surgery with a Pfannenstiel 
incision. All patients had surgery at Barts and The London NHS Trust (now 
Barts Health).  
Patients were recruited into the study only if they met all the Inclusion Criteria 
and none of the Exclusion Criteria (Sections 2.1.5 and 2.1.6).  
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2.1.5 Inclusion Criteria 
• Patients aged 18 years and above with a negative pregnancy test and not 
lactating 
• Patients who are ASA 1-3 
• Patients must be inpatients 
• Patients who are scheduled for elective gynaecological, non-cancer surgery 
(via a Pfannenstiel abdominal) incision under general anaesthesia 
• Patient has given written informed consent 
2.1.6 Exclusion Criteria 
1) Patients who are allergic to morphine, oxycodone or bupivacaine 
2) Patient with a history of anaesthetic complications 
3) Patients with a history of substance abuse 
4) Patients who have been on long-term opioid therapy, or have taken 
opioids within the last one month. 
5) Patients taking MAO-I or anti-depressant medications. 
6) Patients who have received blood transfusion in the last month 
7) Patients who have a history of immune or haematological/bone marrow 
disorder 
8) Known HIV-positive patients 
9) Patients with any contra-indications to epidural analgesia (e.g. back 
surgery, clotting abnormality, local infection or refusal) 
10) Patients having laparoscopic surgery 
11) Patient who have participated in another study in the past 90 
days. 
12) Patients who have received an IMP within the last 12 weeks prior 
to their surgery. 
Mary Elizabeth Demopoulos                                                                     Methods 
© Mary Demopoulos 2010–2017 57
2.1.7 Clinical study design 
Patients were treated as per protocol. Potentially suitable patients, scheduled 
to undergo gynaecological laparotomy, were identified and given the Patient 
Information Sheet (PIS). If agreeable, their written informed consent to the 
study was obtained and they were screened and randomised to a treatment 
group. All pertinent screening and study information was recorded in the CRF. 
Screening involved ensuring the patient met the inclusion and exclusion 
criteria. 
Upon admission, inclusion and exclusion criteria were rechecked, and medical 
history, concomitant medication and epidemiological data recorded. A 
physical examination was performed and vital signs, height and weight 
recorded. Four blood samples were taken, pre-dose (0 hour), at two hours 
post-induction (2 hour), six hours post-induction (6 hour) and 24 hours post-
induction (24 hour).  
Following the pre-dose blood sample, the epidural cannula was sited and the 
first epidural dose given for those patients assigned to the epidural group. 
Anaesthesia was then induced and maintained with propofol only, for patients 
in all three treatment groups. Morphine and oxycodone were given following 
induction for those patients assigned to these treatment groups respectively, 
and surgery was performed as normal. During surgery, all medication was 
recorded in the patient notes, and details for premedication, start and end 
times of anaesthesia, air flow and propofol dose were all transcribed to the 
CRF. The duration of surgery and the time of the patient’s return to the 
recovery ward were recorded.  
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At the time of subsequent blood samples, vital signs, any adverse events and 
total study drug administered were recorded. If the patient withdrew from 
the study, the reason for this was recorded.  
Except for the use of a propofol-only anaesthetic and analgesia given as per 
protocol, patients received standard care. Patients with a clinical need for 
extra analgesia, which could not be covered by their assigned analgesic, were 
withdrawn from the study and treated. Similarly, patients with a medical need 
for a blood transfusion were withdrawn from the study, as were patients who 
themselves chose to withdraw.  
2.1.8 Treatment groups 
There were 3 treatment groups – morphine, oxycodone and epidural 
bupivacaine. All three analgesics are licensed for use by the MHRA and were 
used as licensed. Patients were randomized to one treatment group and doses 
were as follows: 
Morphine sulphate: 0.1mg/kg intravenously intraoperatively then 1mg bolus 
intravenously as required both intraoperatively and by PCA postoperatively. 
Oxycodone hydrochloride: 0.1mg/kg intravenously intraoperatively then 1mg 
bolus intravenously as required both intraoperatively and by PCA 
postoperatively  
Bupivacaine: 0.25% strength plain bupivacaine (2.5mg/ml) administered as 
10ml bolus via the epidural route prior to surgery, with extra bolus doses as 
necessary, and then continued as a 0.125% epidural infusion postoperatively. 
This group received no opioid by any route for the 24 hours study period.  
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2.1.9 Postoperative analgesic administration 
Both morphine and oxycodone were administered as PCA postoperatively. 
The infusion rate of the epidural bupivacaine was continuous with the rate 
titrated by nursing staff according to pain scores and anaesthetic blockade. 
2.1.10 Opioid dose analysis 
Cumulative opioid doses were compared between morphine and oxycodone 
at each timepoint using an independent-samples 2-tailed t test. In addition, 
non-cumulative doses were also compared separately at each timepoint, 
again using an independent samples 2-tailed t test. Statistical analyses were 
performed in SPSS v22.  
2.1.11 Pain score analysis 
Pain scores were recorded at the same time as each blood sample using an 
11-point numerical rating scale (NRS), in which patients were requested to 
verbally score their pain on a scale of 0-10 (0 = no pain and 10 = the worst 
pain imaginable). The score was recorded in the patient’s Case Report Form 
(CRF). CRF pain scores were depicted graphically in box plots and analysed 
across treatment groups using both one-way ANOVA and Kruskal-Wallis (for 
non-parametric data) in SPSS v22.  
2.1.12 Obtaining blood samples 
40ml venous peripheral blood was obtained from subjects at each of the four 
timepoints either through pre-sited cannulae or using standard venepuncture 
technique. During the initial stages of the study, for the first 5 patients, blood 
was taken from pre-sited cannulae as well as via venepuncture. As cannula 
blood had a greater tendency to clot, we moved to a solely venepuncture 
method. For patients who were withdrawn from the study before their 4th 
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blood sample (but did not withdraw consent), no further blood was taken but 
samples that had been taken were analysed. 
Blood was taken directly into EDTA-spiked tubes for RNA extraction and cell 
collection, or gel-containing SST tubes for serum collection. EDTA tubes were 
inverted to mix then all tubes were stored at 4°C for processing.   
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2.2 Laboratory methods 
2.2.1 Allocation of blood samples 
Unclotted blood was collected for microarray and NK cell cytotoxicity assay 
at each timepoint, while serum from clotted blood was collected for cortisol 
ELISA and cytokine CBA at 0 and 6 hr.  
Table 2.1: Blood taken via venepuncture at each timepoint 
Timepoint Blood taken (mls) 
EDTA-spiked tubes Clot-activator tubes
0 hour 35 5 
2 hour 40 0 
6 hour 35 5 
24 hour 40 0 
 
2.2.2 PBMC extraction 
PBMCs were extracted from unclotted peripheral blood using the standard 
Ficoll-Hypaque technique, which involves the use of polysaccharide to grade 
cells by size; small dense red blood cells pass through the polysaccharide 
whereas the larger less dense white blood cells do not. Lymphoprep (a 
combination of sodium diatrizoate and polysaccharide) was used for this. 
Blood was initially diluted 1:1 with PBS then approximately 20ml diluted blood 
was layered carefully on top of 15ml Lymphoprep in a 50ml Falcon tube. 
Samples were centrifuged (1500 revolutions per minute (RPM), room 
temperature (RT), 25 min) with brakes off to prevent disruption of the layers 
that formed. Post centrifugation, the PBMC layer (formed as an interface 
between the plasma and lymphoprep layers) was removed with a pastette; 
care was taken to avoid removing lymphoprep with the cells, due to its 
deleterious effects on cells. Cells were washed with approximately 40ml PBS 
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then each cell pellet diluted in 2ml PBS prior to counting and viability 
assessment with the Beckman Coulter Vi-cell counter. 
Ficoll-hypaque technique 
 
Figure 2.1: layers formed by centrifugation 
 
2.2.3 Cell counting / viability 
Cells were counted both pre- and post-separation of PBMC sub-populations. 
100µl cell suspension of untouched PBMCs from each sample was mixed with 
400µl PBS and cells were counted in an automated cell counter (Figure 2.2) 
using the trypan blue dye exclusion method. Trypan blue crosses the cell 
membrane of dead cells causing them to appear blue under a microscope 
whereas the dye will not cross the membrane of live viable cells, preventing 
their colouration. 50 separate images of cells were recorded and average 
number of viable cells and percentage viability of all cells calculated. The 
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number of viable cells was used to calculate microbead volumes needed 
during the magnetic separation stage.  
 
Cell counting machine 
 
 
Figure 2.2: the Beckman Coulter Vi-Cell XR counter 
 
2.2.4 Positive magnetic cell separation 
2.2.4.1 Incubation stage 
PBMCs were isolated and counted as above. CD4+ and CD8+ T cells were 
separated using positive selection, following binding to anti-human CD4 / CD8 
antibodies conjugated to magnetic microbeads. MACS buffer, containing PBS 
pH 7.2, 0.5% BSA and 2mM EDTA, was made by diluting MACS BSA Stock 
solution 1:20 with autoMACS Rinsing solution.  
Cell suspensions were repelleted post-count (1300 RPM, 4°C, 5 min) then 
80μl MACS buffer per 107 viable PBMCs added to each aliquot. 20μl CD4 or 
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CD8 antibody/microbead solution per 107 viable PBMCs were added, and cell 
suspensions vortexed and incubated (4°C, 15 min). Pellets were washed with 
2ml MACS buffer and resuspended in 500μl MACS buffer in preparation for 
passing through magnetic columns.   
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2.2.4.2 Magnetic separation 
MACS LS columns and a QuadroMACS Separator magnet were used to 
separate magnetically-labelled cells from suspension. LS columns were 
placed in the QuadroMACS Separator, which contains a powerful permanent 
magnet. The matrixes of the LS columns are composed of ferromagnetic 
spheres, which amplify the magnet’s field by 10,000 times, inducing a high 
gradient within the column when in the QuadroMACS’ magnetic field. This 
gradient removes cells less well labelled by MACS microbeads [98].  
LS columns (one per aliquot) were placed in the QuadroMACS Separator, 
activated with 3ml MACS buffer, then cell suspensions were passed through. 
Following this, 9ml MACS buffer was added to each now-empty Falcon tube 
to collect any remaining cells and solution then passed through the relevant 
column. CD4+ and CD8+ T cells were positively selected and therefore 
captured in the magnetic column. Flushing out columns with 5ml MACS buffer 
with a plunger eluted cells. The effluent from the columns (ie cells which had 
passed through columns due to insufficient magnetic labelling) was 
discarded. 
Positively labelled cell suspensions were centrifuged thoroughly to pellet all 
cells (1500 RPM, 4°C, 20 min) then supernatant removed by inversion and 
tube blotting, prior to RNA extraction.   
2.2.5 Negative magnetic cell separation 
NK cells were separated using negative selection, via magnetic labelling of all 
other cells in suspension (T cells, B cells, stem cells, dendritic cells, 
monocytes, granulocytes, erythroid cells). All other cells were labelled with a 
cocktail of biotin-conjugated antibodies and a microbead cocktail then 
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removed via magnetic separation. This left untouched NK cells in the column 
effluent, ideal for later assays as no direct labelling of surface molecules had 
occurred.  
2.2.5.1 Incubation stage 
As with T cells, cell suspensions were repelleted following cell counting (1300 
RPM, 4°C, 5 min), then cells were incubated with 40μl MACS buffer per 107 
viable cells and 10μl NK Cell Biotin-antibody cocktail per 107 viable cells. Cell 
suspensions were vortexed to mix and incubated (4°C, 10 min). This stage 
labelled all the non-NK cells with a biotinylated antibody. 30μl MACS buffer 
per 107 viable cells and 20μl NK cell microbead cocktail per 107 viable cells 
was then added, to add a magnetic label to cells. After vortexing, suspensions 
were incubated again (4°C, 15 min). Cell suspensions were washed with 2ml 
MACS buffer then pellets resuspended in 500μl MACS buffer in preparation 
for passing through the magnetic columns. 
2.2.5.2 Magnetic separation 
Columns were prepared for NK cell separation as for T cells, and cell 
suspensions passed through the magnetic columns in the same way as CD4+ 
/ CD8+ positive selection, again with an extra 9ml buffer to collect any 
remaining cells. However, this time the flow through was saved as it 
contained the untouched NK cells. NK cells were centrifuged to pellet all cells 
(1500 RPM, 4°C, 20 min) and the supernatant removed by inversion and tube 
blotting prior to RNA extraction.  
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2.2.6 RNA extraction 
RNA was extracted from pelleted cells with the Qiagen RNeasy Mini Kit, using 
adapted standard procedures.  
2.2.6.1 Preparation 
Prior to extraction, buffer RLT was prepared in the fume hood by adding β–
Mercaptoethanol (β-ME) in a ratio of 1ml buffer RLT to 10μl β-ME, 1050μl per 
timepoint (β–ME irreversibly denatures RNases). The buffer mixture was 
vortexed for 1 minute. 70% ethanol was prepared by mixing 100% ethanol 
with RNase-free water in the fume hood; a total of 1050μl was prepared per 
timepoint. The laminar flow hood, Gilson pipettes, tube rack, pipette tip boxes 
and operator’s gloves were thoroughly cleaned with RNase Zap to remove 
any residual RNase.  
2.2.6.2 RNA extraction 
350μl buffer RLT mixture was added to each sample pellet, then pellets 
vortexed for 1 minute to lyse cells. Each lysate was pipetted into a labelled 
QIA shredder column and centrifuged (14000 RPM, RT, 2 min) to homogenize 
the cells and reduce viscosity. The QIA shredder was discarded and 350μl 
70% ethanol added to each sample, pipetted to mix and placed in an RNeasy 
spin column. Samples were centrifuged (14000 RPM, RT, 15s) and 
supernatant removed. 700μl buffer RW1 was added to each spin column and 
samples were spun (14000 RPM, RT, 15s) and supernatant discarded. 500μl 
buffer RPE was added to each sample, spun (14000 RPM, RT, 15s) and 
supernatant discarded, then this step repeated with a 2 minute spin. RNeasy 
spin columns were then placed in new collection tubes and 40μl RNase-free 
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water was added to each column. Samples were incubated for 5 minutes at 
room temperature then centrifuged (14000 RPM, RT, 1 min) to elute the RNA.  
The RNA quantity and quality of each sample was measured with a Nanodrop 
ND-1000 spectrophotometer (Section 2.2.7.1) and RNA was stored at -80°C 
in a clinical trials freezer prior to hybridisation. 
2.2.7 RNA quantification 
2.2.7.1 Nanodrop 
RNA quantity and quality was measured using UV absorption via a Nanodrop 
ND-1000 spectrophotometer. The spectrophotometer records absorbance of 
UV light across the spectrum and plots a curve using absorbance by the 
sample observed at 260 and 280nm. The concentration and therefore amount 
of RNA is calculated using Beer-Lambert law, which predicts a linear change 
in absorbance with concentration [99].  
1μl RNA per sample was used for measurements. The reading at 260nm is 
used to determine the RNA concentration, based on the assumption that a 
reading of 1.0 is equivalent to 40μg/ml of RNA [99]. The absorbance ratio of 
260nm: 280 nm indicates quality; the ideal absorbance is 2.0 when the buffer 
is at pH 8.0, and lower values indicate contamination with protein [100], also 
shown by unexpected peaks in the curve. The pH of the buffer used to 
resuspend RNA can affect 260/280 ratios with lower pHs showing lower 
ratios; RNase free water has a typical pH of 5.2 which tends to lower over 
time [101]. Attention should therefore be given to the buffer used for RNA 
resuspension when considering sample quality. Both RNA concentration and 
quality were recorded.   
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2.2.7.2 Bioanalyzer 
The Agilent 2100 Bioanalyzer measures RNA degradation via a lab-on-a-chip 
version of gel electrophoresis. Macromolecules are separated based on their 
size and charge following the application of an electric charge to gel; 
molecules move by travelling through pores in the gel. The Bioanalyzer chip 
consists of 16 wells with connecting microchannels into which a gel-dye 
mixture is pushed with a syringe. Sample is inserted in up to 12 wells and a 
ladder consisting of 6 differently-sized RNA fragments is inserted into the 
ladder well. The dye binds to the RNA and dye-RNA complexes can be 
detected later by fluorescence.  
The Bioanalyzer measures 18S and 28S subunits in ribosomal ribonucleic acid 
(rRNA - the main rRNA species in eukaryotes) and displays their abundance 
via two peaks in an electropherogram, together with that of smaller 
fragments. 18S and 28S subunits present in a ratio of 2.7: 1 in intact RNA; 
although the subunits have a 1:1 molecule ratio, their differing size gives a 
sedimentation coefficient of 2.7:1. A ratio of 2.1 is considered good RNA. RNA 
Integrity Number (RIN) measures RNA degradation and is calculated from the 
total area under the graph; intact RNA gives a RIN of 10.  
Prior to use, the ladder and samples were denatured in a heat block (70°C, 
2 min), reagents equilibrated to RT and the Bioanalyzer cleaned with RNase 
Zap. 9μl gel-dye mix (made from 65μl filtered gel and 1μl dye) was pipetted 
into each of 3 wells and pushed through the microchannels. 5μl of Nano 
marker was pipetted into all 13 wells followed by sample / ladder. The chip 
was vortexed for 1 minute (IKA Works Vortexer) then analysed in the 
Bioanalyzer.  
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RINs were measured after RNA extraction and just prior to amplification for 
hybridisation (all samples). They were also measured post-amplification and 
post-fragmentation to confirm that the experiment was progressing 
satisfactorily (16 amplified and 19 fragmented subjects, at least two 
timepoints for each subject). All data can be seen in Appendix B. 
2.2.7.3 RIN analysis 
One-way ANOVAs were performed in SPSS v22 to investigate any differences 
in RNA integrity at each timepoint between all treatment groups, and in each 
treatment group, between all timepoints.  
2.2.8 Cell freezing 
Cells kept for later use were initially frozen at -80ºC. 1ml freeze mix (4.75ml 
FCS and 0.25ml DMSO) was added to each cell pellet and vortexed. Resulting 
cell suspensions were placed in a 1.5ml Nalgene cryovial and gradually cooled 
overnight (-80ºC) in a Nalgene freezing container containing isopropanol. 
Samples were transferred to liquid nitrogen the following day for storage at 
-196ºC.  
2.2.9 Affymetrix microarray 
The Affymetrix GeneScan 3000 7G scanner was used in conjunction with 
Affymetrix GeneChip 3’ IVT Express Kit and U133+2.0 GeneChips for the 
hybridisation experiment. Each microarray contains 1.3 million 
oligonucleotide 25-base-pair probes for 47,000 transcripts, covering 33,000 
genes. Each probe is unique to a different section of a gene sequence, and 
as few as 11 probes are repeated to make one probeset.  
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Total RNA was transcribed to first strand then double-stranded DNA in two 
separate hybridisations. An overnight incubation produced amplified RNA, 
which was conjugated with biotin, hybridised to arrays and stained with 
Streptavidin Phycoerthyrin (SAPE) before scanning. Fluorescence was 
recorded as an expression value (Figure 2.3). 
The capacities of the machine and the core facility operator limited batches 
to 20 samples. Hybridisation of RNA to microarrays is known to be 
temperature sensitive, so samples were run in treatment-stratified batches 
to avoid any temperature-associated batch variation. Financial constraints 
meant RNA from cell sub-populations was recombined at each timepoint per 
patient, so a batch of 20 samples equated to 5 patients. Patients were 
allocated numerically to a batch, ie the lowest 2 subject numbers in morphine 
group + lowest 2 subject numbers in oxycodone group + lowest number in 
bupivacaine group made the 1st batch. For technical reasons, occasionally 
alternative patient samples were substituted, but treatment stratification was 
adhered to.  
The GeneChip 3’ IVT Express kit user manual was used for labelling and 
amplifying the RNA following the protocol recommended by the 
manufacturer. 50ng RNA from each of the three cell types per patient 
timepoint was used, to make a total of 150ng RNA per patient timepoint. This 
was within the recommended range of 50-150ng RNA per sample; we used 
the maximum amount of RNA advised, as recommended by Affymetrix when 
RNA quality and RIN is low.   
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Flowchart of the hybridisation of RNA to arrays 
 
Figure 2.3: Summary of the progression of RNA to raw gene expression data
   
 
2.2.9.1 Stratified treatment groups 
Eight sample groups were run on separate dates through the GeneChip 3000 
Scanner, with 2:2:1 of morphine, oxycodone and bupivacaine samples. 
Groups 4 and 7 were both run on two consecutive dates, as two samples in 
each group (52D and 55C in Group 4; 1D and 6B in Group 7) did not load 
properly into the autoscanner overnight so were rescanned the next day. 
However, as discussed in Chapter 3 (Section 5.1), no difference was imported 
by scan date. 
2.2.9.2 Preparing RNA for amplification 
RNA was defrosted on ice, vortexed and quantified using the Nanodrop 
spectrophotometer in case degradation had occurred. Sample volume needed 
to give 50ng RNA was calculated (assuming 40μl volume) and CD4+, CD8+ 
and NK RNA transferred to a labelled 1.5ml tube. The protocol required RNA 
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samples to be in a maximum volume of 3μl. Each sample was dehydrated 
then resuspended in 3μl RNase-free water. Dehydration was performed in a 
Savant DNA Speed Vac concentrator machine for 15-30 minutes after 
covering samples with needle-pricked (20-guage) parafilm. Samples were 
vortexed to mix and placed on ice.  
2.2.9.3 Preparing reagents and master mixes 
The dilutions table for the Poly-A RNA Control Stock gave dilution ratios based 
on amount of RNA used; 100ng dilution ratios were chosen as being the 
closest to our RNA weights of 150ng per sample. Serial dilutions were 
performed using Poly-A Control Stock and Poly-A Control Dilution Buffer as in 
the protocol. Master mixes of all solutions were made to achieve enough 
volume for all samples and to ensure uniformity: mixes were prepared for 21 
samples. Tetrad 2 Thermal Cycler was used for all incubations.  
2.2.9.4 Reverse transcription 
First-strand master mix was prepared on ice with 84μl First-Strand Buffer Mix 
and 21μl First-Strand Enzyme Mix (master mix for 21 samples). Contents of 
both the buffer and enzyme mix are proprietary. 2μl of diluted poly-A RNA 
Controls and 5μl of first-strand master mix were added to each 3μl RNA 
sample, samples pipetted and placed into an 8-well PCR strip on ice. Samples 
were vortexed, spun and incubated (42°C, 2 hr). After incubation, samples 
were spun down then placed on ice ready for the second-strand master mix.  
2.2.9.5 Second strand cDNA addition 
Second-strand master mix was prepared on ice during the 2-hour first-strand 
incubation: 273μl RNase-free water, 105μl second-strand buffer mix and 42μl 
second-strand enzyme mix were vortexed and kept on ice until needed 
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(master mix for 21 samples). Contents of both the buffer and enzyme mix 
are proprietary. 20μl second-strand master mix was added to each sample, 
samples vortexed and spun down, then transferred on ice to incubate in the 
pre-cooled incubator as failure to pre-cool could reduce the aRNA yield (16°C, 
1hr; 65°C, 10min; 4°C, ∞). Following incubation, samples were spun down 
then placed on ice ready for the amplification stage.  
2.2.9.6 Amplification  
IVT master mix was prepared during the second-strand cDNA incubation. 84μl 
IVT biotin label, 420μl IVT labelling buffer and 126μl IVT enzyme mix were 
added to a nuclease free tube at RT, vortexed then placed on ice. Contents 
of all reagents are proprietary and were at RT prior to mixing. 30μl IVT master 
mix was added to each sample, samples were vortexed, spun down and 
incubated (40°C, 16hr; 4°C, ∞). Post-incubation, RNA from a total of 16 
subjects (at least two timepoints) was quantified using the Nanodrop 1000 to 
ensure amplification had proceeded satisfactorily, both in terms of amount 
and quality.  
2.2.9.7 Purification of amplified RNA 
This stage involved removing unincorporated NTPs and salts to leave pure 
biotin-conjugated amplified RNA (aRNA). Solutions were prepared in 
advance: 1100μl aRNA elution solution was pre-warmed in a plate warmer 
(60°C, 30 min) and aRNA Wash Solution Concentrate was diluted with 
ethanol. aRNA binding mix was prepared by mixing 210μl RNA binding beads 
and 1050μl aRNA binding buffer concentrate at RT (amounts given are for 
21-sample master mix). Again, contents of all reagents are proprietary. 
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60μl vortexed aRNA binding mix was added to each sample, samples were 
pipetted then transferred to a U-bottom plate. 120μl 100% ethanol was 
added to each sample, samples were mixed, plate covered then mixed on a 
plate shaker (500 RPM, 2min) to allow the aRNA to bind the RNA binding 
beads. The U-bottom plate was moved to a magnetic plate stand to capture 
the magnetic beads, seen by the developing translucence of the mixture as 
the beads formed a ring against the magnets. The supernatant was aspirated 
carefully without disturbing the beads and discarded; the magnetic beads 
now contained the aRNA.  
The plate was removed from the magnet, 100μl aRNA Wash Solution added 
to each sample and shaken (700 RPM, 1 min). Magnetic beads were captured 
and supernatant aspirated and discarded. This was repeated with a second 
aliquot of 100μl aRNA Wash Solution; following aspiration, the plate was 
shaken (1000 RPM, 1min) to evaporate leftover ethanol and dry the beads.  
50μl aRNA Elution Solution was added to each well to elute aRNA from beads, 
then the plate was shaken (1000 RPM, 3 min) to disperse beads. Finally, the 
plate was moved back to the magnet to capture the magnetic beads; the 
supernatant now contained the aRNA and was aspirated into PCR strips. To 
check quality and quantity before fragmentation, each aRNA sample was then 
measured using the Nanodrop 1000 spectrophotometer (see Appendix B).  
2.2.9.8 Fragmentation of amplified RNA 
At this stage, the protocol required each sample to contain 15μg aRNA but 
not exceed 32μl in volume. The volume needed was calculated for each 
sample and samples were either dehydrated (see Section 2.2.9.2) then 
rehydrated with 32μl RNA-ase free water or the correct volume was taken 
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from the original sample. Once prepared, samples were transferred to a new 
8-well PCR strip for fragmentation. 8μl 5x Array Fragmentation Buffer was 
added to each sample, samples vortexed and spun down, then fragmented in 
the incubator (94°C, 35 min). Post-incubation, RNA from 19 subjects (at least 
two timepoints each) was measured with the Bioanalyzer to ensure successful 
fragmentation had occurred (see Appendix B).  
2.2.9.9 Hybridisation to probe array 
262.5μl 20X Hybridisation Control was pre-heated in a heat block (65°C, 5 
min) and the hybridisation cocktail master mix prepared in bulk by adding 
86.1μl control oligonucleotide, 2625μl 2X Hybridisation Mix, 525μl DMSO and 
1050μl Nuclease-free water at RT. (As before, contents of all reagents are 
proprietary and the master mix was for 21 samples). The cocktail was 
vortexed and split into 250μl aliquots (one per sample). 33.3μl of each sample 
was added, vortexed, spun down, then passed to the Affymetrix core facility 
operator for hybridisation to arrays. If not hybridized immediately, samples 
were stored at -20°C.  
The Affymetrix GeneChip Arrays were brought to RT. Samples in hybridisation 
cocktail were heated in 2 heat blocks: 99°C, 5 min followed by 45°C, 5 min. 
Samples were centrifuged (14000 RPM, RT, 5 min) to remove insoluble 
material from samples. Arrays (one per sample) were wetted with 200μl pre-
hybridisation mix through the septum and incubated (45°C, 10 min) while 
rotating. Pre-hybridisation mix was removed from each array and replaced 
with 200μl hybridisation cocktail plus sample, avoiding any insoluble material. 
Arrays were placed into the pre-heated hybridisation oven (60 RPM, 45°C, 16 
hr).  
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2.2.9.10 Washing, staining and scanning arrays 
Following hybridisation, arrays were taken from the oven and hybridisation 
cocktail removed. Each array was washed with wash buffer in the pre-primed 
automated GeneChip Fluidics station 450/250 to remove un-hybridised 
probes, then stained with SAPE. SAPE labels the biotinylated aRNA fragments 
that have hybridized to the array and fluoresces under laser. Arrays were 
scanned by the GeneChip 3000 Scanner, which can detect as few as 400 
phycoerthyrin molecules in a probe site. The GeneChip Command Console 
software then produces a value correlating to the intensity of each array spot. 
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2.2.10 Cortisol ELISA 
Cortisol ELISA was performed on serum samples at 0 and 6 hour, using the 
R&D Systems kit KGE008. The ELISA works on the principle of competitive 
binding, where any cortisol present in patient serum samples competes with 
horseradish peroxidase-labelled cortisol to bind to a mouse monoclonal 
antibody. The monoclonal antibody binds to a goat anti-mouse antibody 
already present on the 96-well plate during the incubation period, after which 
the plate is washed and substrate solution added. The enzymatic reaction 
induces a colour change that is stopped after a fixed period then measured 
via light wave absorbance. The intensity of the colour is inversely proportional 
to the concentration of cortisol [102].  
All kit reagents were brought to room temperature for 30 minutes before use. 
As saliva contains cortisol, a face mask was worn to avoid accidental 
contamination. Cortisol was prepared by reconstituting powder with distilled 
water, then resting for 15 minutes, to produce a stock solution of 100ng/ml. 
900µl Calibrator Diluent RD5-43 was pipetted to the 10ng/ml standard tube 
and 500µl into each subsequent standard tube. Standards were prepared via 
serial dilution; 100µl stock solution was added to the 10ng/ml standard tube, 
mixed, then 500µl of this standard pipetted into the 5ng/ml standard tube. 
The transfer of 500µl of each standard to the next lowest standard was 
repeated to complete the dilution series. 20ml Wash Buffer Concentrate was 
diluted with 480ml distilled water to prepare 500ml Wash Buffer. Serum 
samples were defrosted at room temperature and 30µl sample diluted with 
270µl Calibrator Diluent.  
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150µl Calibrator Diluent RD5-43 was added to each non-specific binding 
(NSB) wells (wells 1 & 2) followed by 100µl to each zero standard well (wells 
3 & 4). 100µl of either standard or sample was added to each well; all assayed 
in duplicate. 50µl Cortisol Conjugate was added to each well followed by 50µl 
Primary Antibody Solution to all wells apart from NSB wells. The plate was 
covered and incubated on a horizontal shaker (500 RPM, RT, 2 hr).  
Wells were aspirated in a hood then washed by filling each well with 400µl 
Wash Buffer. This was repeated three times, ensuring complete removal of 
supernatant each time. The plate was blotted with a paper towel and 
Substrate Solution prepared by mixing Colour Reagents A & B together. 200µl 
substrate solution was added to each well and samples incubated (RT, 30 
min). 50µl Stop Solution was added to each well and the plate was read in a 
BMG Labtech microplate reader with wavelength set to 450nm. Optical 
densities (ODs) were imported to Fluostar Optima software then copied into 
Excel for calculation of concentrations.  
2.2.11 Cytometric bead array 
Serum taken from patients at 0 and 6 hour was used for cytokine analysis. A 
cytometric bead array (CBA) kit (560484 - BD Biosciences) for TH1, TH2 and 
TH17 cells was used to measure the concentrations of the following cytokines 
in serum samples: IL-2, IL-4, IL-6, IL-10, TNFα, IFN-γ and IL-17a. Serum 
samples were used from patients across all three treatment groups, and both 
timepoints were used for each patient.  
A CBA is preferable to an ELISA as it allows simultaneous quantification of 
several cytokines, removing experimental variation, saving time and reducing 
the sample volume needed. Because CBA uses different fluorescing intensities 
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of a single fluorochrome, specialist equipment is not needed so it can be 
performed on a clinical flow cytometer. The fluorochrome Phycoerthyrin (PE) 
is attached to anti-antibodies specific for each cytokine’s antibody in varying 
intensities, giving the ability to perform multiplexing. 
Seven bead populations pre-coated with antibodies specific for the seven 
cytokines above were used. These are known as the capture beads and 
together form the bead array, which is mixed with sample / standard followed 
by PE-conjugated anti-antibodies specific for each antibody. Each population 
of anti-antibodies is incorporated with a different intensity of fluorescing PE, 
and the resultant sandwich complex, of cytokine conjugated to a bead-bound 
antibody bound to a fluorescing anti-antibody, was put through a flow 
cytometer. Fluorescing intensity emitted in red channel FL3/4 was then 
measured.  
 
2.2.11.1 Preparing standards, samples, bead and 
tubes 
One vial of standard was reconstituted with 2ml Assay Diluent and brought 
to room temperature. 300μl Assay Diluent added to each of 12 standard 
tubes. Serial dilutions were performed by transferring 300μl from the Top 
Standard to the 1:2 tube, mixing then transferring 300μl to the 1:4 tube, and 
repeating this until the final tube (1:256) was reached. The negative control 
was created with 300μl Assay Diluent. Samples were prepared by defrosting 
in a water bath at 37°C.  
10μl per bead per sample / standard of each of the seven capture bead 
suspensions were mixed and spun (200G, RT, 5 min). Supernatant was 
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removed then replaced with an equal volume of Serum Enhancement Buffer. 
Bead array were vortexed and incubated (RT, 30 min).  
2.2.11.2 Assay 
The bead array was vortexed and 50μl added to each standard / sample tube, 
followed by 50μl of each standard / sample and 50μl PE detection reagent. 
Tubes were incubated (RT, 3 hr), washed with 1ml wash buffer (200G, RT, 5 
min) and resuspended in 300μl wash buffer.    
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2.2.11.3 Cytometer setup and data acquisition 
Cytometer setup procedure was performed during sample incubation. 100μl 
Cytometer Setup beads and 400μl wash buffer were vortexed together (setup 
tube) and loaded into the LSR Fortessa (BD Biosciences). The FACSDiva 
software (BD Biosciences) was set up and the machine set to acquire 
information. Forward scatter (FSC), side scatter (SSC), PE and fluorescein 
(FITC) voltages were each adjusted to correct the bead population and 
settings were saved. Standards and samples were then fed through the LSR 
Fortessa.  
FCAP Array software v3 (BD Biosciences) was used to calculate Mean 
Fluorescing Intensities (MFIs) of the serially-diluted nine standards for each 
cytokine, generating a 5-parameter logistic (5PL) dose-response curve. 
Compared to a 4PL curve, 5PL has an extra parameter enabling the graph to 
be asymmetrical about the inflexion point. Sample concentrations were 
interpolated from the dose-response curve to produce MFIs, then averaged 
to give sample cytokine concentration.  
2.2.12 NK cell degranulation assay 
Traditionally, the gold-standard assay for measuring NK cell cytotoxicity 
(NKCC) was the 51Cr release assay. Target cells are labelled with 51Cr then 
exposed to NK cells; the amount of 51Cr in supernatant indicates the success 
of target cell killing by NK cells. However, this method is less safe for the 
operator due to radioactivity. Measuring degranulation is a surrogate marker 
of NKCC and safe for the operator. Circulating NK cells contain preformed 
granules in their cytoplasm filled with cytolytic proteins and lined with 
CD107a. Upon target cell binding, the granules are released at the cell 
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synapse and contents disgorged; CD107a can then be measured to determine 
levels of degranulation. NK cells at 0 and 6 hour were used, from all treatment 
groups (morphine n=7; oxycodone n=7; bupivacaine n=4) 
2.2.12.1 Reagent and cell preparation 
Staphylococcal enterotoxin B (SEB) was used to stimulate half of each sample 
and prime cells for degranulation. A stock solution was prepared by mixing 
1mg SEB powder with 1ml PBS; stock solution was then prepared for each 
assay by diluting 1μl in 9μl PBS. Samples were rapidly defrosted in a 37°C 
waterbath and washed with 10ml Dulbecco’s phosphate buffered saline (1500 
RPM, RT, 5 min) to remove DMSO from the freezemix. Samples were 
resuspended in 1ml pre-warmed complete medium (RPMI + 10% FCS + 2% 
gentamicin).  
2.2.12.2 Assay 
Samples were transferred to a 96-well plate and incubated overnight in a 
waterbath (37°C, 24 hr, 5% CO2). Following incubation, vortexed samples 
were split into two aliquots: one to be stimulated and one as the unstimulated 
control. 5µl SEB was added to each stimulated sample to give a concentration 
of 1µg/ml. 5µl anti-human CD107a-AF647 (clone H4A3) antibody was added 
to each sample (stimulated and unstimulated) then samples were incubated 
in a water bath (37°C, 1hr, 5% CO2). Following incubation, 3.3µl momensin 
at a concentration of 0.66µl/ml was added to each sample, giving a 1:10 
dilution. Samples were mixed then incubated in the waterbath (37ºC, 4hr, 
5% CO2). 
Following incubation, samples were aspirated into Falcon tubes and washed 
with 2-3ml PBS+2% FCS (1500 RPM, RT, 5 min). Following removal of 
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supernatant, 5µl PE-conjugated anti-CD56 (clone B159) and 5µl FITC-
conjugated anti-CD3 (clone UCHT1) were added directly onto each cell pellet. 
Samples were incubated (RT, 15 min), washed with 4ml PBS+2% FCS (1500 
RPM, RT, 5 min) and pellets resuspended in 250µl PBS+2% FCS prior to data 
acquisition.  
2.2.12.3 Compensation cells and data acquisition 
Human PBMCs from the National Blood Service (NBS) were used for 
compensation rather than beads, as their fluorescing intensity was expected 
to be more closely aligned to that of the experimental cells. Three samples of 
compensation cells each received PE-conjugated anti-CD56 antibodies, FITC-
conjugated anti-CD3 antibodies or APC-conjugated anti-CD107a antibodies. 
Cells were incubated (RT, 15 min), washed with 4ml PBS+2% FCS (1500 
RPM, RT, 5 min) and cell pellets resuspended in 250µl PBS+2% FCS prior to 
data acquisition.  
Samples were run on the LSR Fortessa acquiring 10,000 events per sample / 
compensation. FACSDiva (BD Biosciences) was used to perform gating and 
compensation, and data analysed with FloJo v10 (FloJo LLC). NK cells were 
identified as those cells which were CD3- and CD56+.   
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2.3 Statistical methods 
2.3.1 Affymetrix microarray 
2.3.1.1 Background noise removal and data 
normalization 
The volume of data generated in gene expression arrays means experimental 
variation and background noise will always exist, as a result of pipetting error, 
operator variation or experimental design. To eliminate background noise, 
Affymetrix arrays use a probe pairing system. Each perfect match (PM) 25 
base pair probe is paired with a mis-match (MM) probe, usually by changing 
base 13. Background noise can then be calculated by subtracting intensity 
values for mis-match binding, a result of non-specific background probe 
binding, from perfect match binding. This method can remove noise but lose 
information, as only up to 1/3 of MM values are below PM values and can be 
negative. Instead, robust multi-array average background correction was 
used, which calculates background-adjusted intensity separately per array, 
using PM values, assuming a strictly positive distribution.  
Normalisation aims to rescale the data, producing a similar size normal 
distribution across each array, thus removing outliers but keeping statistical 
variation. Quantile normalization was used, which ranks the intensity values 
for each array from lowest to highest, then calculates the mean value for 
each rank position across all arrays. Each probeset intensity value is then 
scaled to the mean value relevant to its rank.  
Probe effect describes the increased range of intensities within a probeset in 
an array, compared to the same probeset across arrays. After log 
transformation, the probe effect was removed from intensity values using 
median polish. This produces one intensity value per probeset per array, by 
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combining values and normalizing each array and each probeset to its 
median, until all array and probeset medians are identical. All above 
background correction and normalization was performed in Partek Suite v6.6.  
2.3.1.2 Identification of differentially expressed 
genes via ANOVA 
ANOVA was performed on values adjusted as in Section 2.3.1.1 above, with 
independent variables of RIN, time, treatment, and (time x treatment). 
Calculation was performed in Partek and genes were further selected based 
on p-value and fold-change (FC). (Partek bases FC on ratio, when ratio is 
calculated from the least-squares mean. FC = ratio unless ratio is less than 
1, in which case FC = -1/ratio). Genes differentially expressed from baseline 
at each timepoint by each treatment, with a fold change ≥±2 and p-
value≤0.05, were selected for further analysis. The null hypothesis was one 
of no difference between baseline (0 hour) and later timepoints.  
2.3.1.3 False discovery rate 
False Discovery Rate (FDR) correction is used in microarray analysis to 
correct for false positives produced as a result of multiple testing. An ANOVA 
using a p-value of ≤0.05 would expect to generate 5% false positives simply 
as a result of multiple testing. Several different tests exist; Benjamini-
Hochberg is a less stringent test commonly used in microarray analysis [103]. 
It involves ranking p-values for each gene from smallest to largest. The 
largest p-value is multiplied by the number of genes to produce a new p-
value; then the 2nd largest is multiplied by (number of genes / rank) again to 
produce a new p-value and so on until all p-values have been adjusted. A p-
value cut-off is then chosen as normal below which genes are considered 
significant. In this case, FDR-adjusted p-values ≤0.05 were used. 
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2.3.1.4 RINs / fluorescing intensity correlation 
As most samples had RINs below 10 (Chapter 3), they were correlated with 
fluorescing intensity using Pearson correlation, to examine if degraded RNA 
(represented by a lower RIN) influenced intensity. Correlation was performed 
for all transcripts in Mor0-2 group (genes deregulated at 2 hour by morphine), 
Mor0-6 group (genes deregulated at 6 hour by morphine), Oxy0-6 group 
(genes deregulated at 6 hour by oxycodone) and Bup0-6 group (genes 
deregulated at 6 hour by bupivacaine). Although correlating RIN with 
intensity could have been done prior to ANOVA, due to time constraints and 
likelihood of user-introduced errors inherent in correlating 47,000 probesets, 
it was performed as a post-hoc test. Transcripts with r values ≥±0.7 
demonstrated a correlation between RNA degradation and intensity and were 
discarded from the lists.  
2.3.1.5 Pathway enrichment 
Gene lists were entered into DAVID Ontology Software. DAVID is an acronym 
for Database for Annotation, Visualisation and Integrated Discovery. It was 
developed by the Laboratory of Immunopathogenesis and Bioinformatics in 
2003 and contains gene annotation information from a range of public 
genomic sources, representing over tens of millions of identifiers from over 
65, 000 species. These are grouped into 1.5 million gene records, allowing 
for the enrichment of information available for any gene. DAVID was used to 
classify genes by biological function, pathway and cellular function using 
over-representation analysis (ORA).  
DAVID generates a list at random containing the same number of genes as 
the list of genes imported, then classifies both lists by biological function, 
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pathway or cellular function. It uses the Fisher test (which calculates the 
deviation of each list from the null hypothesis) to calculate if pathways or 
functions are overrepresented in the list of imported genes. 
2.3.1.6 Hierarchical clustering 
Hierarchical clustering can be used to find similarities between genes and 
arrays. Clustering was performed in Cluster 3.0. Data was filtered to remove 
genes that did not have at least 1 observation with absolute value ≥ 5 and 
those whose maximum – minimum values were less than 2. Genes were 
centred to the median then both genes and arrays were clustered using 
Euclidean distance. Average linkage was used to calculate the difference 
between values, and data produced was visualized in TreeView.  
2.3.1.7 Binomial logistic regression 
Binomial logistic regression (LR) aims to predict the most likely one of two 
possible outcomes for a dependent variable, when the independent variable 
is known. In this case, the outcome / dependent variable (treatment or not, 
with a specific analgesic) was already known, and the aim was to predict 
which variables were most strongly correlated with it, using binomial logistic 
regression. The independent variables used were the genes in each group, 
with the pertinent values being logged and normalized intensity values. The 
dependent variable was the use or otherwise of morphine / oxycodone.  
LR was performed in SPSS v22 using a forward conditional stepwise method. 
In this method, the equation begins with no variables, then they are added 
one by one starting with that most strongly correlated to outcome. Once no 
further improvements can be made to the R-value, no further variables are 
added. Each opioid group underwent LR, using the relevant treatment as the 
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dependent factor. This was done four times per group (once per timepoint) 
for Mor0-2, Mor0-6 and Oxy0-6 groups.  
2.3.1.8 Receiver operating characteristic 
Receiver operating characteristic (ROC) curves are used to represent the 
accuracy of prognostic testing, and show false positives versus true positives. 
Traditionally used in prognostic testing, drawing a ROC curve involves ranking 
numerical values from low to high then plotting the fraction of true positives 
v false positives for each result. In this case, ROC was used to represent the 
accuracy of genes found to be predictive through LR and to investigate the 
importance of those that were highly up- or down-regulated in each group.  
Logged and normalized intensity values were the ranked numerical results, 
subjects given morphine were generally patients, and subjects given 
oxycodone or bupivacaine were generally controls. (If ROC was calculated for 
a gene deregulated only by oxycodone, then oxycodone was the patient group 
and the other treatments the controls). ROC curves were generated in 
GraphPad Prism for all genes significant through LR in Mor0-2, Mor0-6 and 
Oxy0-6 groups, and all top 10 up- and down-regulated genes in these groups 
and Bup0-6. Separate curves were generated at each timepoint.  
2.3.2 Cortisol ELISA analysis 
Mean optical density (OD) was calculated for the two non-specific binding 
wells then subtracted from each standard / sample value. Adjusted standard 
values were used to draw a 4-parameter logistic (4-PL) dose-response curve 
in GraphPad Prism, where x = cortisol concentration and y = optical density. 
4PL curves use four parameters; the response at 0 concentration; the 
steepest gradient of the curve; the inflexion point at which the gradient slows 
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to change from concave upwards to concave downwards and the response at 
infinite concentration. The minimum y-value was also constrained to a value 
of 0 as all values had been blanked by subtracting the mean NSB. 
Sample ODs were interpolated from the curve, the mean of duplicate samples 
was calculated, inverse logged and multiplied by 20 (to take account of initial 
serum dilution). Data was imported into SPSS v22; 0 and 6 hour samples for 
each subject were paired and dependent-samples T tests performed per 
treatment group. One-way ANOVA was performed at 0 and 6 hour for all 
treatment groups to rule out timepoint differences between treatment 
groups. 
2.3.3 CBA analysis 
Cytokine concentrations were imported into SPSS v22 and dependent-
samples T tests performed between 0 and 6 hour cytokine per treatment 
group. One-way ANOVAs were performed separately at 0 and 6 hour per 
cytokine between treatment groups to rule out timepoint differences between 
treatment groups. T-tests and ANOVAs were performed for each of the 7 
cytokines measured.  
2.3.4 NKCC assay analysis 
Number of events were imported into SPSS v22 and medians and percentage 
changes calculated for all samples. Unstimulated cells were the control and 
stimulated cells were the test group; the most important test was comparing 
differences between treatments in stimulated cells at 6 hour, for which 
Kruskall Wallis, a non-parametric test suitable for small datasets and 
unpaired data, was used. It was also used to investigate initial differences at 
baseline, and for the same tests in unstimulated cells.  
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Non-parametric Wilcoxon signed ranks tests were used to compare changes 
between 2 datasets. Using this test, changes were compared between 
unstimulated and stimulated cells for each treatment at each timepoint, 
between unstimulated cells for each treatment between timepoints and 
between stimulated cells for each treatment between timepoints. 
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 Chapter 3 
Gene expression analysis 
3.1 Introduction 
The history of the use of morphine is long and fascinating; morphine was 
probably used even in the stone age [7]. Experimental evidence of the 
immunosuppressive nature of morphine has existed since 1897, when 
Coronedi et al published work showing that high doses of morphine made 
dogs unusually susceptible to Diplococcus lanceolatus [7]. Research in guinea 
pigs demonstrated that animals given morphine showed reduced leukocyte 
trafficking and phagocytosis in vitro [9] and a higher fatality rate following 
TB infection than controls (Tedeschi, 1899; Oppel, 1902; [7]). However, 
evidence in humans may have been published as early as the mid 16th century 
following the death of a probable malaria patient after an experimental opium 
dose [7]. By the end of the 19th century, several physicians (Thomas 
Whipham 1875, Osler et al 1880, Isham 1882, Petit 1879) described 
complications of infections linked to morphine use [7].  
More recently, in vivo animal experiments have shown that morphine reduces 
phagocyte count and killing properties in mice and rabbits [44], alters gene 
expression of MCHII molecules and lymphocyte proliferation in rats [104], 
increases bacterial growth in mice and rats [40, 55] and increases viral load 
in HIV-infected monkeys [56]. In mice with a bacterial burden from infection, 
morphine increases cytokine levels of IL-6 and IL-10 in plasma [40], although 
it has also been shown to decrease IL-6 in mice [65]. Morphine also induced 
a five-fold increase in TRegs of monkeys following a 12-week program of 
morphine administration [105].  
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Human studies show the suppression of lymphocyte proliferation in surgical 
cancer patients following morphine administration [48] and, in healthy 
volunteers, both the suppression of NK cell cytotoxicity (NKCC) [29] and 
possible early activation of membrane-associated signalling proteins [49]. In 
vitro addition of opioids to PBMCs showed oxycodone and diamorphine, but 
not morphine, decreased IL-6 production from IL-2 stimulated cells. Morphine 
showed a trend for suppression of phagocytosis and oxidative burst responses 
to E coli, in monocytes and neutrophils [30]. Morphine also inhibited 
production of IL-2 mRNA from T cells in vitro compared to other opioids, 
reversed by CTAP (a MOR antagonist). This was accompanied by increased 
intracellular cAMP levels [64], which activated protein kinase A with a 
subsequent enhancement of the inhibition of LCK, blocking TCR signalling.  
Receptor genotype may play a part in the human response to the 
immunosuppressive effects of morphine. A11G, a SNP present in the MOR 
gene, results in reduced receptor transcription and reduced response to 
receptor binding and analgesic response when the G allele is present; the AA 
allele showed the greatest breast cancer specific mortality [106].  
Clinical research has so far been mainly retrospective. A study comparing 
opioid prescriptions until death / cancer recurrence at the 10-year mark in 
breast cancer patients found recurrence to be lower in patients receiving 
highly immunosuppressive opioids; the authors suggest this may have been 
because other patients were deceased by this point [107]. A study of 
advanced cancer patients taking morphine but no other opioids showed 
reduced T cell proliferation with increasing morphine, seen only in those who 
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were not taking morphine at study enrolment [12], indicating that tolerance 
may develop to morphine-induced immunosuppression.  
Prospectively, the large scale MASTER study in Australasia found no 
advantage of epidural anaesthesia / analgesia over general anaesthesia (GA) 
and opioid-induced analgesia, using clinical outcomes as an endpoint [37, 66, 
67]. However, the epidural group received pethidine and fentanyl (only 5.6% 
of patients had a pure epidural infusion) and the opioid group received 
morphine, pethidine and fentanyl: fentanyl has been shown to induce NKCC 
suppression (Section 1.7.1 [68]). In patients undergoing TURP, an increase 
in TH1 percentage was seen with spinal anaesthesia compared to the propofol 
and morphine treatment group [62]; as propofol has been shown to be non-
immunomodulatory [77], this effect is more likely to be attributable to 
morphine.  
The design of this study aimed to compare two controls groups to a morphine 
group in a non-cancer patient cohort to remove confounding immune-
modulating disease processes. Neither control group contained patients who 
received morphine and the epidural bupivacaine group contained only 
patients who received no opioid. All patients were given a propofol-only 
anaesthesia during surgery, as other anaesthetic agents including fentanyl 
[68] have been shown to be immunosuppressive, whereas propofol has not 
[77].  
3.2 Aims 
The main objective of this Results chapter was to identify unique patterns of 
lymphocyte gene expression following different intra- and postoperative 
analgesia.  
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3.3 Methods 
3.3.1 Subject recruitment 
Subjects were recruited as described in Chapter 2. Sixty patients were 
recruited in total to the study; patient withdrawals are summarised in Section 
3.4.  
3.3.2 Cell separation and RNA microarray 
Whole blood was taken from patients at timepoints of 0 hour (pre-treatment), 
and 2, 6 and 24 hour (post-treatment). Mononuclear cells were removed 
using the Ficoll-Hypaque technique then CD4+, CD8+ and NK cells separated 
via positive (CD4+, CD8+) and negative (NK) magnetic separation (Miltenyi 
Biotec). RNA was extracted using Qiagen RNeasy kits and frozen (-80°C) for 
array hybridisation. At least 3 samples were needed for a patient’s samples 
to be analysed, as the 6 hour timepoint was chosen for serum assays. 
150ng of mRNA for each of 40 patients was used at each timepoint for gene 
expression, with the exception of 24 hour as only 36 patients had a 24 hour 
sample. Microarray data is susceptible to experimental variation due to the 
large numbers of samples processed, caused by experimental design, 
pipetting errors, inconsistent reagent use, varying operators or scanning 
machine temperature. To minimize variation, the same operator (MD) always 
prepared RNA for hybridisation to arrays; RNA was then passed to the 
Affymetrix processing core facility at QMUL for hybridisation to arrays. To 
control for the effects of machine temperature on hybridisation, samples were 
grouped into as few batches as practically possible, and treatment groups 
were evenly stratified across batches, in a 2:2:1 ratio as below. Although 
slightly more than 40 patients had RNA from at least three timepoints, in 
order to maintain an even stratification, only 40 patients were used. Patients 
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were allocated to a processing batch numerically from subject 1; if blood clots 
had been noted on receipt of samples, RNA was not used. The 156 samples 
from 40 patients were therefore divided into 8 batches, giving a maximum of 
20 samples per batch.  
3.3.3 Statistical analysis 
3.3.3.1 Data normalization 
Array data was imported as CEL files to Partek Genomics Suite v6.6 (Partek 
Incorporated, Missouri USA). Data was corrected and normalised using full 
RMA (robust multi-array average) normalisation, which includes correction 
for background noise, quantile normalization, log to base 2 transformations 
and probe set summarisation using median polish.  
3.3.3.2 Identification of differentially expressed 
genes 
ANOVA was performed on logged and normalized intensity values in Partek, 
with independent variables of RIN, time, treatment, and time x treatment. 
Post ANOVA, p-values were adjusted for False Discovery Rate using the 
Benjamini-Hochberg step-up method, and differentially expressed genes 
were identified. Those genes taken to be significant were those with an 
adjusted fold change ≥ ±2 and p-value ≤ 0.05.  
Genes that were differentially expressed from baseline in each treatment 
group were recorded, with the focus of further analysis on the timepoint that 
showed the maximal effect on gene expression: morphine at 2 hour and 
oxycodone at 6 hour.  The null hypothesis was therefore one of no difference 
between baseline and later timepoints, in all treatments.  
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3.3.3.3 Quality control 
All samples were measured for quality using the Nanodrop spectrophotometer 
at 3 points - following RNA extraction, prior to amplification then again prior 
to fragmentation. 260/280 ratios and RNA quantity were recorded for all 
samples. About 70% of samples had 260/280 ratios above 1.7, indicating 
good quality; those with lower 260/280 ratios tended to also have lower RNA 
concentrations (below 26ng/μl). As there is a lot of variability in nanodrop 
measurements at RNA concentrations below 50ng/μl, the lower ratio was 
assumed to be due to the lower RNA concentration and samples were 
processed regardless. Nanodrop data can be found in Appendix B.  
3.3.3.4 RIN and effect on fluorescing intensity 
The Agilent Bioanalyzer was used to measure the RNA Integrity Number (RIN) 
- a measurement of the integrity of RNA. It measures the 18S and 28S 
ribosomal subunits in RNA and displays their abundance via 2 peaks in an 
electropherogram; smaller RNA fragments are also represented. RIN is 
calculated using the total area under the graph; electropherograms showing 
examples of RNA integrity in our sample cohort are shown in 
Figure 3.1. The lack of statistically significant differences in RIN across 
treatment groups and timepoints is shown in Section 3.5.2. (All data can be 
seen in Appendix B).  
RIN of samples hybridised to arrays ranged from 0 to 9.4 (degraded to intact 
RNA); due to this data spread, RIN was correlated with fluorescing intensity 
using Pearson correlation (Excel) for all samples, to examine if degraded RNA 
was correlated with intensity. This was performed for all deregulated probes 
in Mor0-2 group (genes deregulated at 2 hour by morphine), Mor0-6 group 
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(genes deregulated at 6 hour by morphine), Oxy0-6 group (genes 
deregulated at 6 hour by oxycodone) and Bup0-6 group (genes deregulated 
at 6 hour by bupivacaine). Groups were compared separately using only 
relevant samples; for example intensity values for the 583 probes in Mor0-2 
group were correlated with RIN for 32 samples only - 16 from morphine 0 
hour and 16 from morphine 2 hour. Probes with r-values ≥±0.7 demonstrated 
correlation between RNA degradation and intensity, and were discarded from 
future analysis. Examples of a correlated versus a non-correlated gene are 
shown in  
Figure 3.2.   
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Electropherograms of unamplified RNA 
 
 
 
Figure 3.1: electropherograms showing A: unamplified RNA with a perfect 
RIN, B: degraded RNA. 
 
 
Correlation of RIN to fluorescing intensity  
 
 
 
Figure 3.2: Normalised intensity versus RIN for all 0 and 2 hour arrays in 
the morphine group for two genes showing A (SLC11A1): no correlation and 
B (SLC25A43) correlation (Pearson correlation coefficient of 0.72).  
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3.3.4  Analysis of differentially expressed genes 
Each group of differentially expressed genes was analysed separately, using 
several different methods.  
Genes were ordered by fold change, and the most highly up- and down-
regulated genes were annotated to investigate their relevance to the clinical 
question of morphine-induced versus oxycodone-induced changes.  
Over-representation analysis (ORA) was performed in DAVID v6.7 to identify 
biological pathways that were enriched. DAVID generates a gene list at 
random containing the same number of genes as the list of probes imported 
into the software. It classifies both lists by biological pathway, cellular 
component or molecular function and uses the Fisher test (which calculates 
the deviation of each list from the null hypothesis) to calculate which 
pathways / functions are overrepresented in the list of imported genes.  
Clustering of data was performed in Cluster 3.0 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/index.html). Data was 
filtered to include at least 1 observation with absolute value ≥ 5.0 and 
maximum value – minimum value ≥ 2.0. Filters were applied in all groups. 
Genes were centred on the median and both genes and arrays were clustered 
using Euclidean distance. Average linkage was used to draw dendrograms 
then data was visualized in Treeview v1.6 
(http://www.eisenlab.org/eisen/?page_id=42).  
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3.4 Clinical results  
3.4.1 Patient recruitment 
The pathway of patients from consent to completion is shown in Figure 3.3. 
The high level of patient withdrawal necessitated a mid-study increase in 
patient recruitment targets, to achieve sufficient completed patients. Of 57 
patients enrolled, 53 received study drug and 42 completed the study, with 
47 patients providing at least 3 blood samples (Figure 3.3).  
3.4.2 Sample processing 
As discussed in Section 3.3.2, not all patients enrolled were included in the 
Affymetrix analysis. The numbers of patients initially enrolled to each 
treatment group compared to those whose RNA was subsequently analysed 
with Affymetrix arrays can be seen in Table 1. Patient samples were grouped 
into batches, with all samples for 5 patients in 1 batch. The allocation of 
patients to batches is shown in Table 3.2.   
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Patient enrollment and progress pathway 
 
Figure 3.3: The pathway of patients from consent to withdrawal / 
completion   
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Table 3.1: Number of patients enrolled per treatment group whose RNA was 
subsequently analysed by microarray, showing that not all subjects enrolled 
were used, mainly due to early withdrawals. 
Treatment 
Patients 
enrolled 
(No) 
Patients with 
at least 3 
samples taken 
(No) 
Patients 
completed (No) 
Analysed by 
microarray 
(No) 
Morphine 22 18 17 16 
Oxycodone 19 17 17 16 
Epidural 12 12 7 8 
 
 
Table 3.2: Subjects allocated to each microarray group. Patient samples 
from each analgesic treatment were spread evenly across groups to avoid 
batch effect. 
Group Scan date Morphine Oxycodone Bupivacaine 
1 4-Sep-12 48, 50 44, 49 51 
2 7-Sep-12 31, 35 23, 26 39 
3 28-Sep-12 40, 47 9, 34 41 
4 23/24-Oct-12 52, 53 55, 56 54 
5 30-Oct-12 21, 22 18, 19 36 
6 8-Nov-12 45, 57 30, 33 46 
7 15/16-Nov-12 1, 2 3, 6 24 
8 20-Nov-12 13, 14 15, 29 32 
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3.4.3 Clinical characteristics of patient cohort used 
for microarray analysis 
Clinical characteristics of those patients allocated to the Affymetrix group 
were analysed and are displayed in Figure 3.4 and Figure 3.5. (The full set of 
clinical and statistical data can be found in Appendix A). BMI, age and 
operation duration were compared between all 3 treatment groups using one-
way ANOVA and Kruskal Wallis; no statistically significant differences were 
seen.  
Data was collected for any evidence of varying postoperative infection rates 
between groups; of 41 sets of patients notes read, 1 bupivacaine and 1 
oxycodone patient had postoperative infections that needed treatment with 
antibiotics.  
The modal operation type was open myomectomy (23/40 microarray 
patients) although this was not represented equally across treatment groups 
(Figure 3.5); just 1/8 bupivacaine patients underwent open myomectomy 
compared to 9/16 morphine and 13/16 oxycodone group patients. 
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Clinical characteristics for microarray patient cohort 
 
 
 
Figure 3.4 showing A: mean BMI, B: mean age and C: mean operation duration for all 3 treatment groups. No statistically 
significant differences were found between treatment groups for any measurement. Error bars given are SEM.  
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Operation types for microarray patient cohort 
 
 
Figure 3.5: Operation types for microarray patient cohort, for all patients 
and treatment groups, showing the uneven spread of open myomectomy 
across treatment groups.   
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3.4.4 Pain scores of microarray patient cohort 
Pain scores were recorded for all patients at each timepoint, using the 11-
point Numerical Rating Scale (NRS), except where patients were unconscious 
(frequently the case at 2 hours). Pain scores were compared across treatment 
groups at each timepoint, using one-way ANOVA and Kruskal Wallis (SPSS 
v22) for the microarray patient cohort only. No significant difference was 
found in pain scores between different treatment groups at any timepoint. 
Data is shown in Appendix A. 
The median pain score was 0 in all treatment groups at both baseline and 2 
hours with some outliers. As the pre-operative timepoint, no pain was 
expected at baseline; the pain reported by subject 24 was likely due to their 
underlying condition or an adverse event. At 2 hours most patients remained 
unconscious and did not report pain; those six who did report pain were 
therefore displayed as outliers. Although the number of outliers varied across 
treatment groups, no statistically significant difference was found at 2 hours 
between treatment groups. At 6 and 24 hours, the spread of pain scores was 
more normal, with no outliers and still no statistically significant differences 
between treatment groups.   
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Pain scores for microarray patient cohort 
 
 
Figure 3.6: Pain scores from the Numerical Rating Scale (NRS) at each 
timepoint for all 3 treatment groups. The interquartile range is shown; box 
whiskers show the highest and lowest values not defined as outliers (> 1.5 
box lengths outside the box).  
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3.4.5 Opioid use for microarray patient cohort 
Opioid use was recorded in both patient CRFs and hospital notes. In CRFs, 
cumulative opioid given was recorded at each timepoint. In hospital notes, 
opioid use was recorded in nursing observational notes with variable 
frequency. To investigate differences in total opioid use between groups, CRF 
data was used except where incomplete, when hospital notes were used. 
Means of cumulative opioid use were compared between the morphine and 
oxycodone groups at each timepoint, using an independent samples 2-tailed 
t-test, for the microarray patient cohort only. No statistically significant 
difference was found in opioid use between opioids at any timepoint, as 
expected due to their equianalgesic nature on intravenous use. Non-
cumulative opioid doses were also calculated and independent samples t-
tests performed to compare any difference between treatment groups; again 
no statistically significant difference was found. Data can be seen in Appendix 
A.  
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Mean cumulative opioid doses for microarray patient cohort 
 
 
Figure 3.7: Means of cumulative opioid doses of morphine and oxycodone for the microarray patient cohort. Error bars 
given are SD.  
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3.5 Affymetrix Results 
3.5.1 Normalising and batch effect 
Raw intensity values were normalized and summarized in Partek prior to 
analysis. Pre- and post-normalisation intensities can be seen in Figure 3.8 
and Figure 3.9. It can be seen that, post-normalisation, arrays have a similar 
distribution around the median compared to pre-normalisation; however 
outliers are now aligned more closely with the main data. Distribution of data 
is now more consistent across the samples with the median of each sample 
being equivalent.  
A principal component analysis (Figure 3.10) was also performed, confirming 
that scan date did not import a difference to intensity values.  
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Fluorescing intensity values pre-normalisation 
 
Figure 3.8: Pre-normalisation fluorescing intensity values for all 156 samples that underwent Affymetrix analysis. Figure 
generated using Partek software. Only 156 samples underwent Affymetrix analysis as 4 subjects did not have a 24 hour 
sample.   
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Fluorescing intensity values post-normalisation 
 
Figure 3.9: Post-normalisation fluorescing intensity values for all 156 samples that underwent Affymetrix analysis. 
Arrays have undergone RMA; figure generated using Partek software. Only 156 samples underwent Affymetrix analysis 
as 4 subjects did not have a 24 hour sample.  
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Principal components analysis showing lack of batch effect 
 
Figure 3.10: Principal components analysis showing absence of batch effect 
in sample processing.  
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3.5.2 Variance in RIN 
Although somewhat degraded, RNA was not disproportionately degraded in 
any 1 treatment group or timepoint. One-way ANOVA was performed in SPSS 
and no statistically significant difference in RINs was found at any timepoint 
between treatment groups, or between timepoints in any treatment group 
(see Figure 3.11 and Figure 3.12, and Appendix B for data).  
However, lower RINs indicate degraded RNA, which can produce poor 
hybridisation to arrays, reduced fluorescing intensity and abnormally high 3’ 
5’ ratio in housekeeping genes. cDNA is synthesised from the 3’ end of RNA, 
terminating at the 5’ end, so degraded RNA will be underrepresented at the 
5’ end. Degraded RNA (defined as RNA with a low RIN) also produces more 
deregulated transcripts following microarray analysis [108]. The removal of 
probes whose RIN correlated with intensity values (Section 3.3.3.4) was 
designed to correct for the variable levels of RNA degradation seen across 
samples. Seven probes were removed from Mor0-2 group and 2 from Bup0-
6 group - the resulting numbers of differentially expressed genes for each 
group are shown in Table 3.3. Numbers given indicate total genes for each 
treatment group, and therefore include any that were also differentially 
expressed by other treatments or at other timepoints.  
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Variance in RIN across treatments and timepoints for 
microarray patient cohort 
 
 
Figure 3.11: The spread of RIN values across treatments. The interquartile 
range is shown; box whiskers show the highest and lowest values not 
defined as outliers (> 1.5 box lengths outside the box). 
 
 
 
Figure 3.12: The spread of RINS across timepoints. The interquartile range 
is shown; box whiskers show the highest and lowest values not defined as 
outliers (> 1.5 lengths outside the box).  
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3.5.3 Identification of differentially expressed 
genes 
Following ANOVA and removal of probes whose intensity could be correlated 
with RIN, differentially expressed genes with FC≥2 and FDR-adjusted p-
value≤0.05 were identified. Genes were found in most, but not all groups. 
(For example, no genes were found in Bup0-2 and Bup0-24). Both the 
numbers of probes and the numbers of genes found in each group are given 
in Table 3.3 below.  
Table 3.3: Numbers of genes identified per group with criteria of FC≥2 and 
p-value≤0.05.  
   
Probes deregulated from baseline 
(Gene totals in parentheses) 
Time-
point Treatment Group 
Up-
regulated 
Down-
regulated Total 
2 hr 
Morphine Mor0-2 101 475 576 (520)
Oxycodone Oxy0-2 3 0 3 (3) 
Bupivacaine Bup0-2 0 0 0 
6 hr 
Morphine Mor0-6 156 2 158 (113)
Oxycodone Oxy0-6 790 20 810 (559)
Bupivacaine Bup0-6 19 30 49 (44) 
24 hr 
Morphine Mor0-24 1 0 1 
Oxycodone Oxy0-24 1 0 1 
Bupivacaine Bup0-24 0 0 0 
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3.5.4 Volcano plots 
Volcano plots, generated to visualise genes identified following ANOVA, 
clearly showed that the maximal effect in gene expression for morphine and 
oxycodone, at 2 and 6 hours respectively, had opposite directions of change. 
In both plots (Figure 3.13 and Figure 3.14), all genes with p-value<1 are 
shown; those genes of significance (FC≥±2; p≤0.05) are in the marked outer 
sections.   
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Volcano plot for all deregulated Mor0-2 genes 
 
Figure 3.13: Volcano plot of fold-change against p-value for Mor0-2. This is 
the comparison with the maximal lymphocyte gene expression effect for 
morphine. All genes are shown; the 583 probes (including the 7 removed 
after correlation of intensity with RIN) with FC≥±2 and p≤0.05 are in the 
two outer sections.   
Mary Elizabeth Demopoulos  Chapter 3 Results 
© Mary Demopoulos 2010–2017 120
Volcano plot for all deregulated Oxy0-6 genes 
 
Figure 3.14: Volcano plot of fold-change against p-value for Oxy0-6. This is 
the comparison with the maximal lymphocyte gene expression effect for 
oxycodone. All genes are shown; the 810 probes with FC≥±2 and p≤0.05 
are in the two outer sections.   
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3.5.5 Top 10 up- and down-regulated probes 
Lists of top up- and down-regulated probes were generated for each group 
(Table 3.4 - Table 3.7). It can be seen that there is much commonality in 
highly perturbed genes between treatment groups, as illustrated in the Venn 
diagram (Figure 3.15). Those genes commonly deregulated always have the 
same vector of change from baseline, regardless of treatment group. 
Demonstrating the unique down-regulation of Mor0-2, of all 421 down-
regulated genes, only 13 are also deregulated by another treatment, 9 by 
oxycodone and 4 by bupivacaine. Genes strongly deregulated between all 
treatment groups are up-regulated.  
Genes were not deregulated by each treatment at all timepoints; the key 
groups of deregulated genes, by number of genes perturbed, were Mor0-2 
and Oxy0-6, with 520 and 559 genes respectively. These timepoints define 
the maximal effect of each method of analgesia on lymphocyte gene 
expression; analysis therefore focused on these groups.   
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Table 3.4: top 10 up- and down-regulated probes for Mor0-2 gene group. 
Mor0-2 
Down-regulated Up-regulated 
Gene FC Gene FC 
RCAN3 -4.0978 ARG1 8.9415 
AQP3 -3.962 IL1R2 8.4209 
CX3CR1 -3.7204 MMP9 7.2341 
CREBL2 -3.6165 IL1R2 7.0614 
TRAC -3.5703 CRISP3 5.7943 
KLF10 -3.5147 FOXC1 5.6606 
BCL11B -3.3616 ANKRD22 5.242 
CD28 -3.3541 SAMSN1 5.0094 
NDUFA12 -3.3449 VNN1 4.8867 
229629_at -3.3249 CLEC4E 4.131 
 
Table 3.5: top up- and down-regulated probes for Mor0-6 gene group.  
Mor0-6 
Down-regulated Up-regulated 
Gene FC Gene FC 
FCER1A -4.0447 IL1R2 30.1622 
FLT3LG -3.086 IL1R2 26.6013 
 CD163 14.5325 
 CD163 13.1387 
 THBS1 12.0647 
 C19orf59 9.0895 
 THBS1 8.6255 
 MS4A4A 7.4467 
 CYP1B1 7.4457 
 ACSL1 7.1703 
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Table 3.6: top 10 up- and down-regulated probes for Oxy0-6 gene group.  
Oxy0-6 
Down-regulated Up-regulated 
Gene FC Gene FC 
LRRN3 -3.0412 ARG1 26.515 
NOG -2.9491 IL1R2 25.3851 
GLYR1 / SEPT6 -2.7426 IL1R2 24.439 
NMT2 -2.5123 MMP9 17.9477 
GATA3 -2.3973 ANXA3 16.8648 
GATA3 -2.3751 CLEC4D 13.9846 
VSIG1 -2.3062 CD163 13.8383 
TCEA3 -2.259 CD163 13.1508 
LFNG -2.2309 ACSL1 12.4768 
BACH2 -2.2279 ACSL1 12.1932 
 
Table 3.7: top 10 up- and down-regulated probes for Bup0-6 gene group.  
Bup0-6 
Down-regulated Up-regulated 
Gene FC Gene FC 
UBASH3A -5.2889 IL1R2 32.1056 
NOG -4.4101 IL1R2 28.2915 
TCEA3 -4.3265 CD163 17.0523 
FLT3LG -4.1917 CD163 16.7398 
SIRPG -4.0381 C19orf59 9.6065 
LMF1 -3.8517 CYP1B1 7.7916 
AXIN2 -3.1435 CYP1B1 7.0159 
MDS2 -2.8258 IRAK3 6.5001 
LOC10050 -2.7875 SLC1A3 5.7867 
KLHL3 -2.63 CD163 5.3203 
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Venn demonstrating similarities in highly perturbed genes 
between treatment groups  
 
Figure 3.15: Venn showing similarities in top 10 up- and down-regulated 
genes between treatment groups.   
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3.5.6 Lymphocyte gene expression perturbed by 
morphine at 2 hours post treatment initiation 
All genes were passed through DAVID ontological software, showing that 56 
GO biological processes (p-value ≤ 0.01) were enriched, roughly divided into 
categories of RNA translation (particularly splicing of pre-mRNA), apoptosis, 
cell respiration, lymphocyte activation, cell division and enzyme activity (see 
Appendix B).  
Removing probes also deregulated by either oxycodone or bupivacaine 
removes the general confounding effect of surgery and leaves 494 probes, 
32 up-regulated; ORA was also performed on this group. The comparison of 
processes shown to be enriched following ORA of these 494 probes with those 
enriched following ORA of Oxy0-6 probes only (633 probes - Table 3.8) 
demonstrates that the enrichment of pathways related to RNA translation is 
unique to morphine treatment.  
Hierarchical clustering was used to visualise the deregulated genes across 
156 arrays (all timepoints and all treatments) in Figure 3.16. Logged and 
normalized intensity values were clustered in Cluster 3.0, and the results 
visualized in TreeView. Three gene clusters were seen, with the two end 
clusters containing up-regulated genes and the middle cluster containing all 
down-regulated genes. ORA of up-regulated genes produced 21 enriched 
processes, mostly related to apoptosis (12 similar processes were found in 
Mor0-2 only). ORA of down-regulated genes only produced enriched 
processes mainly relating to RNA translation and transcription, and cell 
respiration.  
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3.5.7 Lymphocyte gene expression perturbed by 
oxycodone at 6 hours post treatment initiation 
Classification of genes by DAVID ontological software showed 104 processes 
(p-value ≤ 0.01) to be enriched, which could be divided into response to 
wounding, apoptosis, lymphocyte activation and cytokine production 
(Appendix B). Removing genes also deregulated by another treatment 
removes the general confounding effect of surgery and gives 633 probes, 10 
down-regulated. ORA of these probes showed 55 enriched processes (p-value 
≤ 0.01). In contrast to Mor0-2, no processes related to RNA translation / 
transcription were found (see Table 3.8).  
A supervised cluster analysis was performed on logged and normalised 
intensity values for the 810 probes deregulated at 6 hours by oxycodone 
(Figure 3.17). Arrays are partially separated into treatment groups but do not 
fully resolve with clustering.  
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Supervised hierarchical clustering of all genes deregulated by morphine at 2 hours (gene list 
Mor0-2: 576 probes) for all 156 samples across all 3 treatment groups 
 
Figure 3.16: Supervised hierarchical cluster analysis for all 576 probes deregulated by morphine at 2 hours for all 156 
arrays. 2 hours is the timepoint at which morphine induces its maximal effect on lymphocyte gene expression. Data was 
correlated by Euclidean distance and average linkage was used to create the linkage tree. Green pixels denote low mRNA 
expression and red pixels denote high mRNA expression. The key highlights the separation of arrays by treatment group 
and the separation of morphine 2 hour arrays from morphine arrays at all other timepoints.   
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Supervised hierarchical clustering of all genes deregulated by oxycodone at 6 hours (gene list 
Oxy0-6: 810 probes) for all 156 samples across all 3 treatment groups 
 
Figure 3.17: Supervised hierarchical cluster analysis for all 810 probes deregulated by oxycodone at 6 hours for all 156 
arrays. 6 hours is the timepoint at which oxycodone induces its maximal effect on lymphocyte gene expression. Data 
was correlated by Euclidean distance and average linkage was used to create the linkage tree. Green pixels denote low 
mRNA expression and red pixels denote high mRNA expression. The key highlights the separation of arrays by treatment 
group and the separation of oxycodone 6 hour arrays from oxycodone arrays at all other timepoints.
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Table 3.8: Summary of overrepresentation analysis highlighting biological processes enriched in genes significantly 
deregulated by A: morphine at 2 hours (450 genes / 494 probes) and B: oxycodone at 6 hours (460 genes / 633 probes). 
Top 20 processes by p-value are shown.  
A:  Biological processes – Mor0-2 (494 probes) Genes 
% of 
total 
input 
p-value B:  Biological processes – Oxy0-6 (633 probes) Genes 
% of 
total 
input 
p-value 
translation 28 6.5 4.90E-08 response to wounding  42 10.3 1.10E-11 
ribonucleoprotein complex biogenesis 18 4.1 2.20E-06 defense response  43 10.5 3.20E-10 
RNA processing 32 7.4 1.40E-05 inflammatory response  30 7.4 5.50E-10 
cellular macromolecular complex assembly 22 5.1 4.10E-05 positive regulation of cytokine production  12 2.9 7.40E-06 
cellular macromolecular complex subunit organization 23 5.3 7.60E-05 immune response  36 8.8 1.20E-05 
mRNA metabolic process 22 5.1 3.40E-04 detection of biotic stimulus  6 1.5 4.40E-05 
RNA splicing, via transesterification reactions 13 3 4.00E-04 
adaptive immune response based on somatic recombination of 
immune receptors built from immunoglobulin superfamily domains  10 2.5 7.20E-05 
RNA splicing, via transesterification reactions with bulged 
adenosine as nucleophile 13 3 4.00E-04 adaptive immune response  10 2.5 7.20E-05 
nuclear mRNA splicing, via spliceosome 13 3 4.00E-04 regulation of cytokine production  15 3.7 8.70E-05 
macromolecular complex assembly 32 7.4 4.90E-04 innate immune response  13 3.2 9.10E-05 
ncRNA metabolic process 16 3.7 5.80E-04 positive regulation of immune system process  17 4.2 1.50E-04 
macromolecular complex subunit organization 33 7.6 7.00E-04 protein kinase cascade  22 5.4 1.60E-04 
regulation of apoptosis 36 8.3 7.50E-04 leukocyte mediated immunity  10 2.5 1.70E-04 
ribosome biogenesis 11 2.5 8.60E-04 response to bacterium  15 3.7 1.70E-04 
regulation of programmed cell death 36 8.3 8.80E-04 positive regulation of multicellular organismal process  17 4.2 1.90E-04 
regulation of cell death 36 8.3 9.20E-04 immune effector process  12 2.9 3.00E-04 
generation of precursor metabolites and energy 18 4.1 2.00E-03 positive regulation of response to stimulus  16 3.9 4.30E-04 
electron transport chain 10 2.3 2.00E-03 positive regulation of immune response  12 2.9 5.80E-04 
activation of caspase activity 7 1.6 2.00E-03 regulation of interferon-gamma production  6 1.5 5.90E-04 
mitotic cell cycle 20 4.6 2.10E-03 regulation of erythrocyte differentiation 5 1.2 6.80E-04 
 
Key:            Key: 
 
RNA translation Response to wounding
Apoptosis Lymphocyte activation
Cell respiration 
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3.5.8 Control group – epidural bupivacaine 
Patients given epidural bupivacaine were viewed as the control group as they 
received a non-opioid analgesic not expected to be immune-modulating. Of 
the 44 genes deregulated by bupivacaine, 21 were down-regulated and 23 
up-regulated. Classification of genes by DAVID ontological software showed 
3 enriched processes (p-value<0.01; Appendix B) in this group. Removing 
those genes also deregulated by another treatment removed the general 
confounding effect of surgery and left 20 genes; ORA of these showed no 
statistically significant enriched processes (p-value<0.01).  
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3.6 Discussion 
This chapter aimed to determine if morphine influenced lymphocyte gene 
expression differently to oxycodone or epidural bupivacaine, when given 
during open gynaecological surgery. RNA was extracted from CD4+, CD8+ 
and NK cells at 0, 2, 6 and 24 hours following initiation of analgesic treatment.  
Non-cancer open gynaecological surgery was chosen as a surgical model 
providing sufficient pain to warrant opioid use, but for which an epidural was 
also suitable. This type of surgery is normally a myomectomy, performed in 
women up to middle age; this younger age group tends to be healthy with 
few co-morbidities. The study design therefore tended to remove possible 
confounding factors of co-morbidities and age, while avoiding hindering 
patient recruitment by restricting eligible surgery. The exclusion of patients 
with cancer from the study removed the confounding immune-modulating 
disease processes which have been consistently identified in many cancer 
types, for example changes in T cell gene expression [109] and features of T 
cell exhaustion [110].  
Importantly, the 3 analgesics were successfully separated, with patients who 
received more than 1 analgesic due to clinical need withdrawn (Figure 3.3,  
 
Table 3.1). The equal distribution of treatment groups across microarray 
hybridisation batches avoided batch effect (Figure 3.10). Normalisation was 
successful, distributing data consistently across samples and aligning outliers, 
while maintaining the array distribution around the median (Figure 3.8 and 
Figure 3.9). Although some samples showed degraded RIN, probes whose 
fluorescing intensity correlated with RIN were removed from the analysis, and 
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no statistically significant difference in RIN was seen between treatments or 
timepoints (Figure 3.11 and Figure 3.12).  
Clinical characteristics were successfully removed as confounding factors. 
BMI, age, operation duration, pain and opioid use were not significantly 
different between treatment groups (Figure 3.4, 
Figure 3.6 and Figure 3.7; Sections 3.4.3, 3.4.4 and 3.4.5). Opioid doses 
given were below those seen previously in similar operations, with 70mg 
reported as the mean morphine dose over 24 hours [111] compared to 49mg 
in this study. This difference may be due to variance in operation type, with 
TAH producing increased tissue damage and pain when compared to the 
predominantly open myomectomies of this study. In addition, this study used 
the less invasive Pfannenstiel incision, whereas incision type is not discussed 
by Stanley et al [111] and may not have been uniform.  
Operation type varied across treatment groups: the modal operation across 
the study was open myomectomy (23/40 microarray patient cohort) but this 
included only 1/8 bupivacaine patients compared to 9/16 morphine patients 
and 13/16 oxycodone patients. Protocol required that patients were randomly 
assigned to analgesic, but clinical need could outweigh this. It is likely that 
bupivacaine patients both had a more complex presentation (confirmed by 
the greater range of surgical procedures) and tended to be heavier, although 
BMI was not significantly increased in this group (Figure 3.4). These patients 
might therefore have been considered to benefit clinically from an epidural 
analgesia and its attendant stepped-up care. Although bupivacaine patients 
were potentially less well and heavier, the scarcity of statistically significant 
deregulated genes (Table 3.3) and enriched processes induced by 
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bupivacaine suggests that operation type and clinical presentation did not 
influence lymphocyte gene deregulation in this study.  
Rationale for focusing on genes exclusively deregulated by a treatment can 
be given by looking at genes deregulated by all treatments. The genes most 
highly up-regulated in Mor0-2 were also induced by other treatments (Table 
3.4, Figure 3.15); 16 of 27 most highly perturbed genes at 2 or 6 hour were 
also deregulated by other treatments. Two genes, CD163 and IL1R2, were 
highly up-regulated in all treatment groups at six hours. Both the similar 
degree of fold change (13-14 mean FC for CD163; 25-30 mean FC for IL1R2) 
and the genes’ function suggest a surgery-induced response.  
CD163 is an acute phase receptor found on monocytes and macrophages that 
scavenges haptoglobin / haemoglobin complexes, is shed upon macrophage 
activation [112] and has been shown to be up-regulated following coronary 
artery bypass graft surgery [113] and by IL-10 [114]. Its up-regulation could 
be linked to an increase in cortisol; it was up-regulated in monocytes 
following high-dose cortisol infusion in healthy volunteers [115]. IL1R2 is a 
decoy receptor for IL-1, found on immune cells; IL1R1, IL1’s functional 
receptor, is found on almost all cell types [116], suggesting that IL1R2 may 
protect immune cells against IL1 and modulate inflammation. IRAK3, also up-
regulated in all groups, prevents the dissociation of IRAK1 from IRAK4 and 
its subsequent association with myD88 and TRAF6. This negatively regulates 
TLR / IL1R signalling, regulating the pro-inflammatory downstream actions 
of TLR [117], and providing immune homeostasis and further evidence of 
surgery-induced change.  
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As well as the deregulation of surgery-induced genes by all treatments, the 
incomplete clustering of arrays by treatment (Figure 3.16) confirms the 
importance of focusing on those genes exclusively deregulated by a 
treatment, and of further investigating genes deregulated by more than 1 
treatment.  
3.6.1 Morphine genes 
The greatest deregulation of lymphocyte gene expression by morphine was 
identified at two hours, so the focus of analysis for morphine-modulated 
genes was at this timepoint. This effect is clinically important as almost all 
patients were still in surgery; mean operation duration was approximately 2-
2.5 hours in the 3 treatment groups, with the longest surgery lasting just 
under 4 hours and only seven less than 2 hours. A meta-analysis of rectal 
cancer clinical trials across 6 publications found mean operation duration 
ranged from approximately 2-4.5 hours in laparoscopic surgery and 1.75-3.5 
hours in open surgery [118], giving our 2 hour timepoint considerable 
translational relevance in cancer resection surgery, regardless of surgical 
approach.  
Supervised clustering of Mor0-2 genes (Figure 3.16) sees their separation 
into down-regulated genes involved with RNA transcription and translation 
and up-regulated genes involved with apoptosis. The ordering of arrays 
shows that the analysis does not fully resolve morphine 2 hour arrays, 
confirming the importance of focusing on the 450 uniquely deregulated 
genes. Bupivacaine arrays are spread throughout the array group, in keeping 
with their relative lack of gene deregulation. Enrichment analysis of Mor0-2 
450 genes suggests a down-regulation of cell proliferation and T cell 
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expansion, reduced cytotoxicity killing ability of NK and CD8+ cells and 
generalised reduced cellular activity.  
421 of 434 down-regulated Mor0-2 genes are unique to morphine; those of 
particular interest include CD28, LCK, TRAC, MICB, HLA-DMB, BCL11B, 
RCAN3, AQP3, CX3CR1 and KLF10. CD28 (FC -3.4) is a constitutively 
expressed receptor and co-stimulant for T cell activation found on both CD4+ 
and CD8+ cells; it has been suggested that the initial signalling scaffold 
induced by ligand binding forms a structure that intracellular CD28 elements 
bind to, enhancing TCR effects [119]. CD28-/- mice showed a lack of T cell 
expansion upon antigen stimulation, reduced TH cell differentiation and 
increased expression of TH2 cytokines [120]. Blockade of CD28 in CD8+ cells 
prevented clonal expansion, degranulation and IFN-γ production during the 
primary and secondary immune response [121, 122]. At levels to mimic 
physiological cortisol, hydrocortisone inhibited the production of TH1 
cytokines in naïve CD4+ cells, but prevented a concurrent TH2 shift by also 
inhibiting the production of IL-4 during TH2 differentiation; importantly, this 
was CD28-dependent [123]. Morphine-induced CD28 down-regulation may 
therefore reduce T cell activation and shift cells to a TH2 profile; a change 
that could be augmented by the presence of increased cortisol. It would be 
ideal to investigate any variance in cortisol concentration across treatment 
groups, to consider its impact on gene deregulation.  
LCK and TRAC were also down-regulated by morphine. LCK is a tyrosine 
kinase that phosphorylates tyrosine in the CD28 cytoplasmic tail [124] and is 
localised with TCR in the immune synapse [125]. TRAC (T cell receptor α 
constant) codes for the constant part of TCR’s α subunit, an essential part of 
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the TCR; patients with an inherited immunodeficiency disorder have a 
mutation impairing TRAC splicing to produce reduced αβ TCR chain 
expression and immune dysregulation [126]. The down-regulation of CD28, 
LCK and TRAC by morphine suggests a potential morphine-induced T cell 
immune synapse dysfunction and a shift to a TH2 profile.  
MICB (MHC class 1 polypeptide-related seq B) is an induced self-antigen and 
transmembrane protein normally expressed only at low levels, but up-
regulated in virus-infected and tumour cells [127]. It is a ligand for the 
NKG2D receptor, found on CD8+, γδ+ and NK cells, whose activation 
phosphorylates DAP10 and recruits PI3K, inducing target cell killing [128]. 
The NKG2D receptor is needed for NKCC; MICB down-regulation in mice in 
vivo resulted in a reduced killing ability of NKG2D [129]. The morphine-
induced down-regulation in this study suggests a reduced cytotoxic killing 
ability of CD8+ and NK cells in the morphine group. HLA-DMB (major 
histocompatibility complex, class 2 DMB) was also down-regulated by 
morphine and is the β chain of a membrane-bound heterodimer found in 
intracellular vesicles. In APCs it is involved in peptide loading to MHCII by 
catalysing the exchange of invariant to pathogenic peptide [130]. A similar 
role in T cells, a possibility as they can have a role as APCs, suggests that the 
down-regulation of HLA-DMB by morphine could reduce CD4+ response to 
pathogen.  
BCL11B, down-regulated by morphine, is a zinc finger transcription factor 
[131] and T cell gene up-regulated during T cell transitioning from precursor 
to double negative state, along with TCF12 [132]. Overexpression of BCL11B 
induces T helper cell differentiation in mice [133] whereas down-regulation 
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has been shown to reprogram cells to a NK-like non-specific cell [134]. Both 
BCL11B and TCF12 were down-regulated, suggesting that morphine may 
induce a reduced pathogenic response via CD8+ cells and a decrease in cell 
differentiation in CD4+ cells.  
RCAN3 (regulator of calcineurin 3) is the most strongly down-regulated gene 
by morphine. It inhibits calcineurin, a Ca2+- and calmodulin-dependent serine 
/ threonine phosphatase in the cytoplasm, which activates signalling 
pathways via activation of NFAT transcription factors and subsequent 
cytokine gene expression [135, 136]. Calcineurin has been implicated in T 
cell anergy through prolonged activation of NFAT without its activation 
partner AP-1, up-regulation of genes including E3 ubiquitin ligases and 
proteases in murine CD4+ cells (mRNA and protein) and degradation of 
signalling proteins [137]. Morphine deregulated 2 E3 ubiquitins: HECW2 was 
up-regulated and WWP1 was down-regulated. The down-regulation of RCAN3 
suggests a potential increase in calcineurin activity induced by morphine and 
possible subsequent T cell anergy. 
Aquaporin 3 (AQP3), also strongly down-regulated, is a transmembrane 
protein involved in the transport of water and glycerol across the cell 
membrane. Higher levels (mRNA and protein) were shown in TH17 but not 
TH1 cells following differentiation [138] and AQP3 was expressed in activated 
but not inactivated T cells from healthy PBMCs [139]. AQP3-mediated H2O2 
transport is needed for activation of CDC42 in mice, which is essential for T 
cell migration towards chemokines [140]. The down-regulation of AQP3 by 
morphine therefore has the potential to disrupt T cell migration and activation 
and indicates a shift to a TH2 profile.  
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CX3CR1, aka fractalkine receptor, is a G-protein coupled receptor found on 
lymphocytes, which binds the chemokine fractalkine. It was up-regulated in 
human lymphocytes following administration of cortisol to mimic a stressful 
event [141] and probably caused the adrenalin-induced increase in circulating 
CD8+ effector cells in humans, opposite to the cortisol-induced, CXCR4-
mediated decrease in circulating naïve CD4+ and CD8+ cells [142]. The 
down-regulation of CX3CR1 by morphine suggests a reduction in circulating 
CD8+ cells, possibly mediated by a decrease in serum cortisol levels.  
Kruppel-like factor 10 (KLF10), down-regulated by morphine, is a zinc finger 
transcription factor which is pro-apoptotic in association with the down-
regulation of oncogene BCL2 [143]. It represses FOXP3, the transcription 
factor responsible for initiating and maintaining TReg differentiation. Neither 
FOXP3 nor BCL2 were deregulated, but BNIP3, which antagonises BCL2’s 
actions, was down-regulated. The down-regulation of KLF10 and BNIP3 
suggest that cells of the morphine group may display decreased levels of 
apoptosis and increased TReg differentiation [144].  
29 of 86 up-regulated genes are unique to morphine, including DAPK2, 
PGLYRP1, srGAP2 and srGAP2C. Those present in more than 1 treatment will 
be discussed in Chapter 6. DAPK2 is a Ca2+-bound calmodulin dependent 
serine / threonine protein kinase involved in apoptosis and autophagy 
pathways [145], activating TRAIL-induced apoptosis pathways upon 
knockdown in vitro [146]. Its up-regulation suggests a tendency for 
decreased apoptosis of T cells by morphine. DAPK2 also appeared in many 
enriched apoptosis pathways. PGLYRP1 (peptidoglycan recognition protein 1) 
is a GN / GP bacteria pattern receptor involved in the development of allergic 
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asthma. PGLYRP1 (-/-) mice showed fewer TH2 and TH17 cells in the lungs 
following house dust mite sensitisation [147, 148]; a similar effect in human 
T cells suggests a possible shift to a TH2 profile.  
Two probes each for Slit-Robo GTPase-activating protein 2 (srGAP2) and its 
paralog srGAP2C were up-regulated; these proteins are members of the FBAR 
protein family involved in actin dynamics and membrane trafficking [149]. 
Overexpression of srGAP2 in neuronal cells induces membrane protrusions 
rather than the invaginations, decreasing migration [150] with knockdown 
increasing migration [151]. Again in neuronal cells, srGAP2 couples GTPase 
signalling to postsynaptic scaffolding proteins Homer and Gephyrin, 
producing spine morphogenesis, inhibitory synapse formation and the 
accumulation of GABA and AMPA receptors; all effects were inhibited by 
srGAP2C [152]. In NIH 3T3 (murine fibroblast) cells, srGAP2 is needed for 
contact inhibition of locomotion, a repulsion between two fibroblasts [153]. 
The up-regulation of srGAP proteins by morphine suggests an influence of 
morphine on immune synapse formation, if the proteins have a similar 
function in T cells. 
3.6.2 Oxycodone genes 
The greatest deregulation of lymphocyte gene expression by oxycodone was 
at six hours, where 559 genes were differentially expressed, 19 down-
regulated. As with morphine, clustering of arrays did not fully resolve the 
treatment group (Figure 3.17) underlining the importance of focusing on the 
460 genes uniquely deregulated by oxycodone, rather than the whole 
dataset. The 460 unique genes were comprised of 450 up-regulated and 10 
down-regulated genes.  
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Several up-regulated genes were of interest including ANXA3, S100A12, 
S100P, GCA and STAT3. The most highly up-regulated gene was ANXA3 
(annexin 3), which binds via phosphatidylserine to dying fibroblast cells; the 
authors suggest that ANXA3 (and other annexins) may tag dying cells 
similarly to opsonin [154]. It was expressed more highly in TH1 compared to 
TH2 cells [155]; its up-regulation by oxycodone therefore suggests that 
oxycodone may have the potential to shift T cells to a TH1 profile and increase 
the clearance of apoptotic cells. S100A12 and S100P are Ca2+-binding S100 
proteins with a role in cell migration. S100A12 is found in monocytes and 
lymphocytes and induces migration of monocytes and neutrophils in vitro 
when found outside the cell; its injection into mouse peritoneum induces 
leucocyte recruitment. S100P induces cellular migration in diseased states 
[156]. The up-regulation of these genes by oxycodone suggests a possible 
increase in lymphocyte trafficking.  
Grancalcin (GCA) is a Ca2+-binding protein found in neutrophils and 
macrophages, with a theoretical role in degranulation due to its association 
with both membrane and granule upon cell activation. Higher levels were 
found in LPS-stimulated leucocytes [157] although deficient mice did not 
show a decreased resistance to infection [158]. Its up-regulation by 
oxycodone may be supportive of increased NK cell degranulation in this 
group, if its role in NK cells is similar to its role in macrophages.  
Signal transducer and activator of transcription 3 (STAT3) is phosphorylated 
by members of the JAK family following cytokine receptor activation; 
activated STAT then dimerizes and moves to the nucleus to activate 
transcription [159]. It is required for TH17 differentiation [160], and ablation 
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of STAT3 in murine NK cells and dominant negative STAT3 mutations in 
human NK cells both produced reduced NKG2D expression and reduced 
responses to IL-10 [161]. The up-regulation of STAT3 by oxycodone suggests 
a possible increase in TH17 differentiation and an increased killing ability of 
NK cells.  
Only 10 genes were down-regulated uniquely by oxycodone, including NMT2 
and BACH2. NMT2 is an enzyme involved in the N-myristoylation (addition of 
fatty acid myristate) of proteins, resulting in altered protein-protein 
interactions, enhanced protein / membrane binding and changes in protein 
stability [162]. Its depletion in murine T cells impaired the TCR signalling 
cascade; conversely it was expressed more highly in colon cancer tissue than 
healthy tissue [163]. Its down-regulation by oxycodone suggests a possible 
impaired T cell signalling, contrary to the general hypothesis of oxycodone-
mediated gene deregulation.  
BACH2 is a transcriptional regulator that both activates and suppresses 
transcription: BACH2 -/- mice showed positively regulated TReg development 
and repressed conventional T cells [164, 165], and repressed lineage-specific 
genes, including GATA3 [165]. GATA3 was down-regulated by oxycodone and 
morphine and is a transcription factor needed for notch-mediated 
differentiation of TH2 murine cells [166]. It has also been called the master 
driver of TH2 differentiation and its mRNA, protein and activity were 
repressed by glucocorticoid administration via inhibition of p38MAPK-induced 
phosphorylation [167]. The down-regulation of BACH2 and GATA3 by 
oxycodone may increase TReg or TH1 cells; the down-regulation of GATA3 by 
morphine may increase TH1 cells intraoperatively, opposite to the general 
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shift hypothesized, and possibly influenced by reduced cortisol. Any variance 
in cortisol concentration across treatment groups could be investigated, to 
consider the impact on gene deregulation as discussed in relation to CD28.  
3.6.3 Bupivacaine genes 
Only 44 genes were differentially expressed at 6 hours by bupivacaine, 21 
down-regulated. 20 genes were deregulated uniquely by bupivacaine; those 
expressed in all treatment groups are discussed in Chapter 6.  
3.6.4 Over Representation Analysis (ORA) 
ORA was performed in DAVID ontological software to give an overview of the 
analgesic-induced changes. Processes highlighted were classified into several 
groups, including RNA transcription and translation, apoptosis, lymphocyte 
activation, cell respiration, signal transduction and response to wounding. 
Those genes seen repeatedly in groups of pathways were noted as possibly 
significant. No statistically significant processes were enriched in genes 
unique to bupivacaine treatment. This reinforces the merit of using 
bupivacaine as a control group, as the lymphocyte genes that did experience 
altered expression from baseline did not seem to function in a coherent 
manner. 
RNA transcription and translation processes were only enriched following 
morphine treatment: 23 processes, represented by 92 genes (1 up-
regulated) were seen, suggesting a global down-regulation of RNA 
transcription, translation and splicing of pre-mRNA processes. This down-
regulation may be due to a reduction in T cell proliferation, seen previously 
following morphine administration [48]; reduced cellular activity would then 
result in decreased protein translation [168, 169]. Alternatively, it could be a 
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direct response to morphine, or an indication of apoptosis, although the 
down-regulation of apoptosis processes suggests that this is not the case.  
Several small nuclear ribonucleoprotein polypeptides (SNRPs D1, E, F and G) 
appeared repeatedly in these pathways. They form part of the core structural 
spliceosome ring and are essential for splicing pre-mRNA transcripts [170]; 
their down-regulation either prevents protein translation or reflects a down-
regulation already occurring.  
The process grouping apoptosis was enriched by morphine and oxycodone. 
Morphine showed 12 processes, with 40 of 44 genes down-regulated. In 
comparison, no processes were enriched by oxycodone at 2 hours, but by 6 
hours 3 processes were enriched, represented by 35 up-regulated genes. No 
apoptosis processes were enriched by bupivacaine. It appears that apoptosis 
is up-regulated by oxycodone and down-regulated by morphine; the 
implications of this with regard to T cell anergy will be addressed in Chapter 
7.  
Several genes were frequently repeated in morphine’s enriched apoptosis 
pathways including DAPK2 and DYRK2. DAPK2’s up-regulation may result in 
decreased apoptosis (see above). DYRK2 is a serine/threonine protein kinase 
which increased cell proliferation via post-translational modification of c-Jun 
and c-Myc following knockdown in human osteosarcoma cells, preventing 
their degradation and shortening the G1 phase of cell cycle [171]. The down-
regulation of DYRK2 by morphine suggests a tendency to decreased T cell 
proliferation.  
PTEN and BCL6 were frequently repeated genes in oxycodone’s enriched 
apoptosis pathways. PTEN is a tumour suppressor with a phosphatase 
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function, through which it inactivates substrate and suppresses tumours 
[172]. It is involved in T cell differentiation, and was suppressed upon T 
helper but not TReg induction, in murine CD4+ cells [173]. Its up-regulation 
by oxycodone is supportive of the hypothesis of oxycodone-induced 
immunomodulation; the increase in TReg differentiation highlighted in the 
gene expression data could be the result of a normal resolution of a previous 
active immune response.  
BCL6 is a zinc finger transcription factor repressor and master regulator of T 
follicular cells (TFH) [174]. Increased expression of TH1, TH2 and TH17 
cytokines were seen in BCL knock-out mice, and upon BCL over-expression, 
TFH gene expression is induced to the detriment of TH1, TH2 or TH17 
cytokines [175]. The up-regulation of BCL6 by oxycodone could favour the 
development of TFH over other T helper cell types and the subsequent 
formation of germinal centres [174] and B cell memory. Interestingly, the 
BCL6 corepressor BCOR, thought to repress transcription of BCL6, is down-
regulated in morphine, although BCL6 deregulation is not seen.   
Although apoptosis processes were enriched by oxycodone, the two groups 
of processes in the top 20 list by p-value (Table 3.8) were lymphocyte 
activation and response to wounding. Lymphocyte activation showed 19 
processes for oxycodone; 100 genes were represented by 70 different probes, 
suggesting a reliable response. Only LRRN3 and LY9 were down-regulated. 
No lymphocyte activation processes were enriched by the 450 genes uniquely 
deregulated by morphine at 2 hour; 12 processes (19 genes, 14 down-
regulated) were enriched in the whole 520-gene group at 2 hours. This 
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breakdown suggests that processes relating to lymphocyte activation were 
up-regulated and particularly prevalent in the oxycodone group at 6 hr.  
Several genes were found repeatedly in lymphocyte activation pathways in 
oxycodone, including TLR4 and TLR8. TLR4 is fundamental to innate immunity 
and recognises LPS in gram-negative bacteria, triggering NF-κB and MAPK 
signalling pathways and inducing inflammation [176]. Its up-regulation by 
oxycodone suggests that these patients are able to induce inflammation 
normally. Likewise TLR8 is involved in recognising pathogens as part of innate 
immunity and its up-regulation is supportive of effective inflammation and a 
functioning innate immune response in the oxycodone group.  
Twenty-two response to wounding processes were enriched by oxycodone – 
103 genes (148 probes), with only 2 down-regulated (GATA3 and LY9). This 
process grouping was not enriched by morphine until 6 hours, with 14 
processes represented by 48 genes (67 probes), just 1 down-regulated. This 
suggests that response to wounding processes were up-regulated by both 
oxycodone and morphine at six hours, but, as before, oxycodone had a 
stronger response, based on the higher number of up-regulated processes 
and probes.   
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3.7 Conclusion 
The study design successfully kept the 3 study analgesics distinct, and 
removed all confounding factors bar operation type, differently to similar 
previously published clinical research. Morphine induces deregulation of 450 
unique genes which suggest an intraoperative reduction in immune function. 
The deregulation of 460 unique genes by oxycodone occurs postoperatively 
and suggests a possible improvement to the immune response. The scarcity 
of gene deregulation and statistically significant enriched biological processes 
by epidural bupivacaine confirms its suitability as a control group.  
The main change in gene expression for morphine patients was the 2 hour 
down-regulation seen in genes involved in RNA transcription and translation, 
apoptosis and cell respiration. The down-regulation of RNA transcription- and 
translation-related genes implies a lower level of protein translation, 
concurring with the previously known suppression of lymphocyte proliferation 
and NKCC following morphine administration. Down-regulation of apoptosis 
and cell respiration pathways may reflect increased T cell anergy (see Chapter 
7).  
In contrast, oxycodone’s effect, limited to the 6 hour timepoint, suggests a 
heightened immune response, based on specific gene deregulation and the 
enrichment of processes related to response to wounding, lymphocyte 
activation and apoptosis. In immunocompromised patients, oxycodone or 
epidural bupivacaine may therefore be considered preferable analgesics to 
morphine for use during the surgical period.  
The deregulation of specific genes suggests suitable functional assays that 
may confirm the results of gene expression analysis. CD28, LCK, TRAC, AQP3 
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and PGLYRP1 were all uniquely deregulated by morphine and suggestive of a 
morphine-induced TH2 shift. ANXA3 and BACH2 were deregulated by 
oxycodone and suggest a TH1 shift. These potential T helper cell shifts could 
be confirmed by serum cytokine analysis. The down-regulations of MICB by 
morphine and up-regulation of STAT3 by oxycodone are consistent with 
morphine-induced impaired NKCC, which could be confirmed using a 
degranulation or 51chromium-release assay. Finally, several genes 
deregulated in this study – GATA3, CD28 and CD163 – have been shown 
previously to be deregulated following cortisol administration. Measurement 
of serum cortisol may suggest if cortisol influenced gene deregulation in this 
study.  
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 Chapter 4 
Functional assays 
4.1 Introduction 
The analysis of gene expression data in Chapter 3 suggested that while 
morphine induces potentially immunosuppressive gene deregulation in 
lymphocytes within the intraoperative timeframe, oxycodone induces gene 
deregulation that may improve the immune response, postoperatively. Based 
on this data, we wanted to determine if the effector functions of lymphocytes 
were altered following analgesic administration.  
Gene deregulation analysis suggested that morphine could induce a shift 
towards a TH2 profile whereas oxycodone could induce a shift towards a cell-
mediated TH1 response. This was based on the deregulation of genes such 
as CD28 and AQP3 by morphine and ANXA3 and BACH2 by oxycodone, and 
supported by previous data [62]. Serum levels of seven TH1/2/17 cytokines 
were therefore compared across treatment groups using a cytometric bead 
array.  
Cortisol is a glucocorticoid that works through the glucocorticoid receptor to 
coordinate inflammation, stress and immune responses, amongst other 
functions [177]. Cortisol levels are altered by morphine administration [178-
182] and by surgery [50, 183]. Glucocorticoid receptor signalling exerts its 
effects in part by acting as a transcriptional regulator [184], therefore a 
variation in cortisol concentration may influence gene deregulation. Several 
deregulated genes of this study have also been shown to be deregulated by 
cortisol; serum cortisol levels were therefore investigated via ELISA.  
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Morphine is known to induce reduced NK cell cytotoxicity (NKCC), in contrast 
to oxycodone [29-31]; this finding is supported by gene deregulation in this 
study. MICB, a ligand for the NKG2D receptor needed for NKCC, was down-
regulated by morphine, while STAT3 was up-regulated by oxycodone; its 
ablation decreases NKG2D receptor expression [161]. NKCC was therefore 
investigated via NK cell degranulation.  
 
4.2 Aims 
The aims of this chapter were to corroborate the gene expression analysis 
described in Chapter 3 using the functional assays described above. 
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4.3 Methods 
4.3.1 Cytometric bead array 
Samples were taken from non-cancer open gynaecological surgery patients 
recruited to this study as described in Chapters 2 and 3. Serum 
concentrations of 7 major cytokines expressed by TH1, TH2 and TH17 cells 
were assayed via cytometric bead array (CBA): IL-2, IL-4, IL-6, IL-10, IL-
17a, TNFα and IFN-γ. Samples from 0 (pre-treatment) and 6 hour 
(postoperative) timepoints were compared across all treatment groups, using 
BD Biosciences kit 560484, as per protocol. The key difference from a simple 
ELISA is that a CBA allows simultaneous quantification of several cytokines, 
removing experimental variation and reducing sample volume needed. It 
uses different fluorescing intensities of the fluorochrome phycoerythrin (PE), 
attached to beads specific for each cytokine’s antibody in varying intensities. 
Samples were run through LSR Fortessa and mean fluorescing intensities for 
the nine standards inputted to FCAP Array software v3, generating a dose-
response curve. Sample concentrations were interpolated from the curve and 
averaged to take account of duplication.  
Dependent-samples t-tests were performed in each treatment group, 
comparing changes from baseline to 6 hour for each cytokine. One-way 
ANOVAs were performed between treatment groups at each timepoint for 
each cytokine to rule out pre-existing differences. Patient samples were 
selected for assay based on a high sample volume in order to leave sample 
for future assays if needed. The number of samples assayed was limited by 
cost.   
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Table 4.1: Subject numbers of patients providing serum samples for 
cytometric bead array   
 
4.3.2 NK cell degranulation assay 
Samples were taken from non-cancer open gynaecological surgery patients 
recruited to this study as described in Chapters 2 and 3. NK cell cytotoxicity 
was measured indirectly via degranulation using CD107a, a marker of 
cytoplasmic granules released on cell degranulation. NK cells selected using 
negative magnetic separation were used for this assay. Half of each patient 
sample was stimulated with Staphylococcal enterotoxin B (SEB) and half was 
unstimulated; CD107a was captured with anti-human CD107a. NK cells were 
selected with anti-human antibodies for CD56 and CD3 and healthy donor 
PBMCs (National Blood Service) were used as compensation; three aliquots 
each received either PE-conjugated anti-CD56, FITC-conjugated anti-CD3 or 
APC-conjugated anti-CD107a antibodies. Following incubation, events were 
acquired through LSR Fortessa then data analysed with FloJo software.  
Median and percentage change were calculated for all samples. Wilcoxon 
signed ranks tests were performed in each treatment group, both comparing 
changes from baseline to 6 hour for unstimulated and stimulated cells, and 
comparing within-timepoint differences for unstimulated and stimulated cells. 
Kruskall Wallis tests were performed between treatment groups separately at 
baseline and 6 hour for both unstimulated and stimulated cells. Samples were 
Treatment Subjects N 
Morphine 31 40 43 47 48 50 52 53 8 
Oxycodone 33 34 44 54 56 5 
Bupivacaine 32 38 39 41 46 51 57 7 
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selected for assay based on the presence of sufficient viable cells. The number 
of samples assayed was limited by cell viability. 
 
Table 4.2: Subject numbers of patients providing NK cells for the NK 
degranulation assay  
  
Treatment Subjects No per group 
Morphine 1 13 45 48 50 52 53  7 
Oxycodone 6 9 29 33 34 44 49 7 
Bupivacaine 32 36 41 46  4 
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4.3.3 Cortisol ELISA 
Samples were taken from non-cancer open gynaecological surgery patients 
recruited to this study as described in Chapters 2 and 3. Serum cortisol 
concentrations for samples from all treatment groups at 0 hour (pre-
treatment) and 6 hour (postoperative) were assayed via ELISA using R&D 
Systems kit KGE008. ELISA was performed as per protocol working on the 
principle of competitive binding. Optical densities (ODs) were obtained using 
a BMG Labtech plate reader and blanked by subtracting values from non-
specific binding cells. Adjusted duplicate values for standards were imported 
into GraphPad Prism to prepare a dose-response curve. Sample 
concentrations were interpolated from the curve, the mean of duplicate 
samples was calculated and scaled up to give serum cortisol concentration. 
Dependent-samples t-tests were performed in each treatment group, 
comparing changes from baseline to 6 hour. One-way ANOVAs were 
performed between treatment groups at each timepoint to rule out pre-
existing differences. Samples were chosen numerically and selected for assay 
based on a high sample volume, in order to leave sample for future assays if 
needed.  
Table 4.3: Subject numbers of patients providing serum samples for cortisol 
ELISA 
Treatment Subjects N 
Morphine 13 14 22 31 35 40 43 47 50 52 57 11 
Oxycodone 5 19 23 26 29 30 33 34 44 49 56 11 
Bupivacaine 24 25 32 38 39 41 46 51 54 9 
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Dose-response curves for each serum cortisol ELISA 
 
 
Figure 4.1: Dose-response curves were plotted for all cortisol standards 
separately for each ELISA. Optical densities were adjusted for non-specific 
binding cells and cortisol concentrations were logged.   
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4.4 Results 
4.4.1 Cytometric bead array 
The cytokine theoretical level of detection, determined from the standard 
curve during kit manufacture [185], provides a benchmark below which 
cytokine concentrations may not be accurate. Sample values for cytokines 
IL-2, IL-4, IFN-γ, TNFα and IL-17a were below or almost all below this level 
so are discounted from the analysis.  
Although most baseline samples for IL-6 and IL-10 were below the level of 
detection, most samples at 6 hour were above, so data for these cytokines 
was analysed. Means were generated for IL-6 and IL-10 at both timepoints 
(Figure 4.2) and dependent samples t-tests were performed between 
timepoints for both cytokines per treatment group (SPSS v22). To investigate 
pre-existing differences between treatment groups at baseline or later at 6 
hour, one-way ANOVA was performed at each timepoint for each cytokine.  
Statistically significant increases from 0 to 6 hour were seen in IL-6 for all 
treatment groups. The greatest increase from baseline was seen in morphine, 
with mean levels increasing from 1.1 ± 0.3 to 52.9 ± 15.1pg/ml (p=0.011) 
compared to 6 hour levels of 19.4 ± 5.6pg/ml for oxycodone (p=0.028) and 
23.0 ± 5.3pg/ml for bupivacaine (p=0.006). However, one-way ANOVA 
showed no significant difference between treatment groups at either 
timepoint.  
Statistically significant differences between 0 and 6 hour for IL-10 were only 
seen in the morphine group. Mean increased from 1.0 ± 0.2 to 14.6 ± 
2.6pg/ml (p=0.001); in oxycodone, the 6 hour mean was 12.4 ± 5.6pg/ml 
and in bupivacaine, 9.6 ± 4.0pg/ml, neither significant (Figure 4.2). No 
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difference was found in IL-10 concentration between treatment groups at 
either timepoint using one-way ANOVA.   
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Mean serum cytokine concentrations at baseline (0 hour) 
and 6 hour for all treatment groups 
 
 
Figure 4.2: Mean serum concentrations of IL-6 and IL-10 at baseline and 6 
hour for A: morphine, B: oxycodone and C: bupivacaine groups. Error bars 
are SEM. 
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4.4.2 NK degranulation assay 
Box plots, median and percentage change were generated at baseline and 6 
hour for unstimulated and stimulated samples in each treatment group 
(Figure 4.3 and Figure 4.4). Median rather than mean was used due to the 
small sample size and non-Gaussian distribution. Individual data is shown in 
Figure 4.5. 
Wilcoxon signed ranks tests, suitable for small sample size or non-Gaussian 
distribution, were used to compare paired samples. Unstimulated versus 
stimulated cells at each timepoint, unstimulated cells between timepoints and 
stimulated cells between timepoints were compared across treatment groups. 
The only statistically significant change was at 6 hour in oxycodone, where 
median number of events increased from 392 in unstimulated cells to 2306 
in stimulated cells (Z=-1.992; p=0.046). However, no statistically significant 
difference was found between treatment groups for any combination of 
datasets using Kruskal Wallis, including at 6 hour between stimulated cells.  
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NK cell degranulation events at baseline (0 hour) and 6 hour for both unstimulated and 
stimulated cells for all treatment groups
 
Figure 4.3: Box plots for degranulation events in all treatment groups, for A: unstimulated cells at baseline, B: stimulated 
cells at baseline, C: unstimulated cells at 6 hour, D: stimulated cells at 6 hour. Box plots show interquartile range with 
whiskers denoting largest and smallest values (excluding outliers>1.5 box lengths outside box, marked separately). 
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Median number of degranulation events in NK cells 
 
 
 
Figure 4.4: Median number of events at baseline and 6 hour in unstimulated and stimulated cells, for A: morphine, B: 
oxycodone and C: bupivacaine. Error bar is standard deviation.  
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NK degranulation events for individual patients 
 
Figure 4.5: Number of degranulation events displayed for individual patients 
at baseline and 6 hour in A: morphine, B: oxycodone and C: bupivacaine 
patients   
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4.4.3 Cortisol ELISA 
Box plots and means were generated at baseline and 6 hour for each 
treatment group (Figure 4.6 and Figure 4.7). Bupivacaine shows the greatest 
difference in mean cortisol concentration between timepoints, from 50.0 ± 
8.7 to 180.4 ± 87.7 ng/ml (p=0.185), followed by morphine, from 46.9 ± 
7.3 to 105.5 ± 39.6 ng/ml (p-value 0.123; Figure 4.7) and oxycodone (41.7 
± 7.7ng/ml to 50.6 ± 15.5mg/ml (p=0.607)). However, changes were not 
statistically significant.  
To investigate pre-existing differences between treatment groups at baseline 
or later at 6 hour, one-way ANOVA was performed at each timepoint; again 
no statistically significant differences were seen. Levene’s test for equality of 
variances showed statistically significant differences at 6 hour between 
morphine and oxycodone (F = 5.21; p=0.03) and bupivacaine and oxycodone 
(F = 6.18; p = 0.02; Figure 4.6). Individual serum cortisol concentration data 
and statistical results can be seen in Appendix B. 
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Serum cortisol concentrations at baseline (0 hour) and 6 hour for all treatment groups 
 
Figure 4.6: Box plots at 0 and 6 hour for serum cortisol concentrations in A: morphine, B: oxycodone and C: bupivacaine 
groups. Interquartile range and largest and smallest values (excluding outliers>1.5 box lengths outside box, marked 
separately) are shown.  
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Mean serum cortisol concentrations at baseline (0 hour) 
and 6 hour for all treatment groups 
 
 
 
Figure 4.7: Mean cortisol concentrations for A: morphine, B: oxycodone and 
C: bupivacaine with SEM marked.  
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4.5 Discussion 
This chapter aimed to use functional assays to corroborate the gene 
expression analysis described in Chapter 3, and to investigate a possible role 
for serum cortisol in influencing deregulation. A cytometric bead array (CBA) 
for TH1, TH2 and TH17 cytokines, an NK cell degranulation assay and a serum 
cortisol ELISA were all performed across treatment groups at baseline and 6 
hour.  
Of seven cytokines assayed with CBA, 5 (IL-2, -4, -17a, IFN-γ and TNFα) 
were below the detection threshold and therefore not analysed. The detection 
threshold for CBA is generally higher for each cytokine than for individual 
ELISAs; however even using a lower threshold, the samples would have 
remained below theoretical detection levels. Repletion of this assay in a larger 
sample cohort would have been desirable, however sample volume, time and 
cost prohibited it.  
IL-6 increased significantly in all treatment groups from baseline to 6 hour, 
likely an effect of surgery [186, 187]. Morphine induced the greatest increase, 
from 1.1 to 52.9 pg/ml, compared to increases of 1.2 to 19.4 pg/ml by 
oxycodone and 2.0 to 23.0 pg/ml by bupivacaine. Increased IL1R2 in the 
blood has been associated with higher IL-6 levels in an epidemiological 
cardiac risk factor study [188]; IL1R2 transcript levels were increased by all 
analgesics at 6 hr. IL1R2 is a decoy receptor that antagonizes IL-1. Morphine 
induced a greater up-regulation in IL1R2 levels than oxycodone (morphine: 
28.38 FC, oxycodone: 24.91 FC, bupivacaine: 30.20 FC) similarly to IL-6 
levels.  
Mary Elizabeth Demopoulos  Chapter 4 Results 
© Mary Demopoulos 2010-2017 166
However, an increase in IL-6 levels lasting over 2 hours following morphine 
administration in rats has also been shown, prevented by adrenal cortex 
removal [189], suggesting that the greater increase in IL-6 by morphine in 
this study may have been partially induced by morphine rather than being 
simply surgery-related. IL-6 shifts cells to a TH2 profile [190], as suggested 
by gene expression analysis in this study. Morphine has also been shown to 
reduce lymphocyte proliferation in rats, blocked by the MOR antagonist 
naltrexone [191]; as reduced lymphocyte proliferation is also seen with a TH2 
shift, the morphine-induced reduced proliferation could be a result of a TH2 
shift mediated through MOR.  
IL-10 levels showed a statistically significant increase in response to 
morphine, increasing from 1.0 to 14.6 pg/ml. Levels increased from 0.9 to 
12.4 pg/ml in oxycodone and 1.0 to 9.6 pg/ml in bupivacaine, neither 
statistically significant. IL-10 is an anti-inflammatory cytokine produced by 
TH2 cells and needed for a normal inflammatory response [192]. It negatively 
regulates the production of TH1 cytokines [193-195], consistent with a 
hypothesized morphine-induced shift to a TH2 profile. IL-10 also increases 
levels of CD163 expressed on monocytes [114]; shed CD163 can reduce T 
cell proliferation [196]. It has been shown to be increased 2-fold in mice 
following morphine administration [197] but has also been shown to be 
decreased [198]. As the maximal effect of morphine on lymphocyte gene 
deregulation was at 2 hour, it would be interesting to investigate IL-6 and IL-
10 concentrations at this timepoint.  
CD28, down-regulated by morphine, prevented a cortisol-induced shift to a 
TH2 profile following a reduction in TH1 cytokine production in naïve T cells 
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[123]. The down-regulation of CD28 seen in this study would therefore fail to 
prevent this TH2 shift, also suggested by the increases in IL-6 and IL-10 
concentrations and deregulated genes. Conversely, GATA3, a transcription 
factor needed for notch-mediated differentiation of TH2 murine cells [166], 
was down-regulated by both opioids. It is a driver of TH2 differentiation and 
its activity, mRNA and protein levels were all repressed following 
glucocorticoid administration [167]. Down-regulation of GATA3 suggests a 
shift to a TH1 profile in both opioid groups, opposite to that suggested for the 
morphine group, and possibly induced by an increase in cortisol 
concentration.  
The increase in mean serum cortisol concentration from baseline to 6 hour 
was not statistically significant in any treatment group. Greater increases 
were seen in morphine and bupivacaine groups, from 46.9 to 105.5 ng/ml 
and 50.0 to 180.4 ng/ml respectively, compared to that of oxycodone (41.7 
to 50.6 mg/ml). However, morphine and bupivacaine had higher SEMs and 
statistically significant differences with oxycodone at 6 hour using Levene’s 
test for equality of variances, suggesting greater sample spread. 
Bupivacaine’s low sample size (n=9) contributed to this, and together these 
indicate that the increased (non-significant) serum cortisol concentration 
induced by morphine and bupivacaine at 6 hour may not translate to the 
whole population.  
Any effect of cortisol on genes deregulated by both morphine and bupivacaine 
was nevertheless considered. LPL was up-regulated by both analgesics at 6 
hour and has been shown to be increased by cortisol production [199]; 
however previous publications do not link it to morphine-induced enriched 
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processes such as lymphocyte activation or cell respiration. FLT3LG is down-
regulated by both morphine and bupivacaine and has been shown to be up-
regulated with cortisol following heavy exercise [200] but also up-regulated 
in PBMCs of patients with Graves’ disease [201], a condition in which low 
cortisol can be found [202]. The down-regulation of FLT3LG in this study may 
be related to the small increase in cortisol level identified. FLT3LG is an 
essential cytokine needed for expansion of lymphoid lineages [203] therefore 
the gene down-regulation induced by cortisol could contribute to suppression 
of lymphocyte activation, also induced by cortisol in CD4+ and CD8+ 
lymphocytes [204] and hypothesized for morphine, although not bupivacaine.  
In contrast, FLT3, the receptor for FLT3LG, was up-regulated by both 
analgesics; it has tyrosine kinase functions and has been shown to inhibit 
apoptosis and drive cellular proliferation. More importantly, it is a ligand for 
the glucocorticoid receptor so its up-regulation would reduce inflammation 
[205, 206] and suppress NKCC [207]. Cortisol is up-regulated by the HPA 
axis [206]; it is possible that FLT3 is similarly up-regulated, although no 
evidence exists for this.   
NKCC was assayed indirectly via measurement of CD107a following cell 
degranulation. Non-stimulated and stimulated NK cells at baseline and 6 hour 
for all treatments were assayed. Both baseline opioid groups showed a higher 
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median number of events in non-stimulated compared to stimulated cells (
 
Figure 4.4) showing that stimulation unexpectedly produced reduced levels 
of CD107a and thus reduced degranulation. At baseline, 3/5 morphine 
samples and 4/6 oxycodone samples showed a lower count following 
stimulation. In contrast, 3/4 bupivacaine samples were successfully 
stimulated at baseline, shown by a 23% increase in median number of events 
from non-stimulated to stimulated cells. The failure to stimulate cells from 
opioid samples may have been due to a high number of non-viable NK cells 
or degraded or insufficient Staphylococcal enterotoxin B (SEB), although a 
problem with SEB is unlikely as bupivacaine samples were stimulated 
successfully. A difference in clinical characteristics of patients between 
treatment groups could be responsible and will be discussed in Chapter 7. 
Although degranulation appeared to be unsuccessful for the baseline opioid 
groups, this does not invalidate the 6 hour experiment; it can be viewed 
separately and comparisons made within the timepoint between non-
stimulated and stimulated cells, and analgesic groups.  
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At 6 hour, median number of events was higher when stimulated were 
compared to non-stimulated samples, for all analgesics; 4/5 morphine 
samples, 5/6 oxycodone samples and 3/4 bupivacaine samples were 
successfully stimulated. Successful stimulation is unlikely to be due to a 
recovery in surgery-induced suppressed NKCC as this is thought to last for 
up to 28 days post-surgery [208]. Only oxycodone showed a statistically 
significant increase, with median events increasing from 392 to 2306 
following stimulation. Although this may support the findings of the gene 
expression study, Figure 4.5 suggests that the significant increase is strongly 
influenced by 1 sample and is therefore unlikely to be representative of the 
whole population. When this sample is removed, the comparison is no longer 
statistically significant. Sample size was small (n=15 across all treatments) 
and the results need further validation; the degranulation assay should be 
repeated with more samples.  
The NK cell functional degranulation assay used only NK cells, in contrast to 
the gene expression analysis for which mRNA from both T and NK cells were 
used. The data discrepancy of morphine-induced altered cell cytotoxicity 
suggested by gene expression analysis but not confirmed by the functional 
degranulation assay could be explained by the presence of cytotoxic CD8+ 
cells. These cells have an important role in cancer cell removal and defects in 
this population have been widely documented [209, 210]; CD8+ mRNA was 
present for the gene expression analysis but CD8 + cells were not used for 
the degranulation assay.  
MMPs, specifically MMP1, MMP2 and MMP9, [211] mediate CD16 shedding 
from the NK cell surface resulting in the refractory period. MMP9 was up-
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regulated by morphine at 2 hour (FC 7.2) and MMP9 and MMP25 by 
oxycodone at 6 hour (FCs of 17.9 and 4.4 respectively). The morphine-
induced MMP9 deregulation is unlikely to have been induced by previous NK 
degranulation as cells failed to degranulate in vitro at baseline (Figure 4.4). 
It is more likely to have been directly induced by morphine as shown 
previously in humans [29] and mice [212]. Up-regulated MMP9 could then 
stimulate CD16 shedding, which would produce a refractory period and 
subsequently the expected reduced degranulation. CD16 is also present on 
the surface of some CD8+ cytotoxic T cells [213]; the hypothesized increased 
shedding could therefore also occur on CD8+ cells. It would be interesting to 
repeat the degranulation assay additionally using CD8+ cells.  
CD16 shedding is also induced by ADAM17, a metalloprotease expressed by 
NK cells [214] and up-regulated, with ADAM9 and ADAM19, by oxycodone 
(FCs of 2.2, 3.4 and 2.8 respectively). The ADAM17 up-regulation seen may 
be a response to degranulation, assuming that the baseline in vitro 
degranulation was also seen in vivo and that the increase in degranulation in 
the oxycodone group is repeatable with a larger sample size. ADAM9 was up-
regulated following stimulation of PBMCs with IL-10 [215] and was also up-
regulated in this study by morphine at 6 hour (FC 3.4). It is a 
metalloproteinase disintegrin involved in leukocyte migration in inflammatory 
muscle conditions [215]. If it also has a role in T cell migration in healthy 
individuals, up-regulation of ADAM9 at 6 hour would be consistent with 
oxycodone’s increased lymphocyte activation and morphine’s recovering 
lymphocyte activation suggested by gene expression analysis at this 
timepoint. It is possible that ADAM9 up-regulation was induced by IL-10, 
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increased at 6 hour in all groups, and as a refractory response to NK cell 
degranulation.  
Due to the small sample size and equivocal result, the degranulation assay 
should be repeated. In addition, as some publications suggest that increased 
degranulation exists with impaired cytotoxicity [216], direct cellular 
cytotoxicity could be investigated using the 51chromium-release assay to 
further validate these findings.   
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4.6 Conclusion 
In conclusion, all patients showed a TH2 shift, with morphine patients 
showing the greatest TH2 shift as demonstrated by the greatest increases in 
IL-6 and IL-10. The increase in IL-6 by all treatments is likely to be a surgery-
induced, and, additionally in the morphine group, a morphine-induced 
increase. Only morphine patients showed a statistically significant increase in 
IL-10, strengthening the TH2 profile and possibly up-regulating ADAM9, 
which may be involved in CD16 shedding from NK and T cells. MMP9 was also 
up-regulated and has been implicated in CD16 shedding; shedding precedes 
the NK cell refractory period. Further work could investigate ADAM9 and 
MMP9 up-regulation and CD16 shedding from both NK and cytotoxic CD8+ 
cells in morphine and oxycodone-treated groups.  
The effect of the analgesics on NK cell degranulation was equivocal and 
should be repeated with more samples. A 51chromium-release assay could be 
performed to determine if target cell killing is reduced by morphine. No 
treatments showed a statistically significant increase in levels of serum 
cortisol concentration at 6 hour, suggesting that cortisol levels did not affect 
gene deregulation significantly. A possible influence of increased serum 
cortisol on deregulation of specific genes such as FLT3, FLT3LG and CD28 
could be further investigated.  
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 Chapter 5 
Gene identification through statistical 
methods 
5.1 Introduction 
The analysis of gene expression data in Chapter 3 and the functional assays 
of Chapter 4 suggested that morphine may be immunosuppressive during the 
intraoperative period, while oxycodone may improve the immune response 
postoperatively. Morphine predominately down-regulated genes enriched in 
processes related to RNA transcription and translation, apoptosis and cell 
respiration at 2 hours. Oxycodone deregulated only 3 genes at this timepoint 
but induced expression of genes enriched in processes related to apoptosis 
and lymphocyte activation at 6 hours, suggestive of a heightened immune 
response.  
Given that morphine is cheap and widely used for intra- and postoperative 
analgesia, it is not realistic or desirable to curtail its use as analgesic, 
particularly as pain itself is immunosuppressive [87, 89-91]. However, the 
identification of key genes involved in mediating the effects of analgesia on 
lymphocyte gene deregulation is essential to understanding the mechanisms 
of immunosuppression. In addition, the identification of genes indicating a 
baseline susceptibility to opioid-induced gene deregulation would enable 
analgesia to be selected appropriately in vulnerable patients.  
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5.2 Aims 
The aims of this chapter are to use statistical methods to identify individual 
genes both key in mediating the effects of analgesia on gene deregulation, 
and those that may indicate individual susceptibility to immune modulation 
by opioids.   
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5.3 Methods 
Eligible non-cancer open gynaecological patients were recruited to the study 
as described in Chapters 2 and 3. Following venepuncture, mononuclear cells 
were removed from blood samples using Ficoll-Hypaque technique then 
CD4+, CD8+ and NK cells separated via magnetic separation. Extracted RNA 
(Qiagen RNeasy kit) was hybridised to Affymetrix arrays and analysed using 
Partek software. ANOVA was used to generate gene lists at different time / 
treatment combinations which were used for the statistical analysis of this 
chapter.  
5.3.1 Logistic regression 
Binary logistic regression (LR) was performed to find genes most strongly 
predictive of a particular treatment. Normalised intensity values for all 40 
patients for all genes deregulated by a treatment were inputted separately at 
each timepoint, to establish if values could predict treatment. LR was 
performed in SPSS v22 using forward conditional stepwise as the data entry 
method. Predictive genes were those with p-value ≤0.05.  
5.3.2 Receiver operating characteristic (ROC) 
curve 
ROC curves are normally used to show the accuracy of clinical prognostic 
testing and in this case were used to confirm LR results where possible and 
to evaluate the significance of genes most highly deregulated by morphine 
and oxycodone. Again, logged and normalised intensity values were inputted 
separately for each timepoint and values for all 40 patients were used. 
Morphine values were patient values with other treatments acting as controls, 
unless a gene was solely deregulated by oxycodone. ROC curves were 
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generated in GraphPad Prism and results were taken to be positive if AUC ≥ 
0.7.  
ROC curves were not generated for genes highly deregulated by bupivacaine 
as the low sample size of this group (n=8) compared to morphine and 
oxycodone groups (n=16 per group) would have conferred an inaccuracy to 
the test.   
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5.4 Results 
5.4.1 Logistic regression 
Genes found to be predictive of a treatment through logistic regression (LR) 
are shown in Table 5.1. Eight genes predicted morphine treatment and 13 (5 
unannotated) predicted oxycodone treatment. Six genes predicted 
bupivacaine treatment and 3 predicted morphine treatment using those 
genes deregulated at 6 hours only. Heatmaps were drawn to show the relative 
position of predictive genes within the datasets with maximal effect for 
morphine (2 hour) and oxycodone (6 hour) (Figure 5.1 and Figure 5.2).  
 
Table 5.1: Genes found to be predictive of analgesic use following logistic 
regression. 
Gene group 
Timepoint 
0 hr 2 hr 6 hr 24 hr 
 HSPH1 CH25H 
Mor0-2 only No genes found TIAM1 DAPK2 No genes found 
494 probes TPK1 RFX7 
 AGPAT3 SLC26A11 
Mor0-6 only No genes found LDLRAD3 AMPH No genes found 25 probes CH25H 
 OSCAR 1559573_at 234196_at MCL1
Oxy0-6 only IL13RA1 C13orf18 HIP1 ORM1/ORM2 
633 probes USP15 229879_at 237618_at ZNF608 
 234196_at 232958_at  
 234196_at  
 C1QB  
Bup0-6 only EPHA1 STEAP3 MS4A4A ARHGAP29 
20 probes  NUDT16   
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Supervised hierarchical clustering of probes deregulated at 2 hours exclusively by morphine 
(gene list Mor0-2: 450 genes / 494 probes) for all 156 samples across all 3 treatment groups. 
 
Figure 5.1: Supervised hierarchical clustering generated for all 494 probes (450 genes) deregulated by morphine only 
at 2 hour, for all 156 arrays. 2 hours is the timepoint at which morphine induces its maximal effect on lymphocyte gene 
expression. Data was correlated by Euclidean distance and average linkage was used to create the linkage tree. Genes 
predictive of morphine treatment following LR of this group are marked. Green pixels denote low mRNA expression and 
red pixels denote high mRNA expression. The key highlights samples by dataset. 
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Supervised hierarchical clustering of probes deregulated at 6 hours exclusively by oxycodone 
(gene list Oxy0-6: 460 genes / 633 probes) for all 156 samples across all 3 treatment groups.  
 
Figure 5.2: Supervised hierarchical clustering generated for all 633 probes (460 genes) deregulated by oxycodone only 
at 6 hour for all 156 arrays. 6 hours is the timepoint at which oxycodone induces its maximal effect on lymphocyte gene 
expression. Data was correlated by Euclidean distance and average linkage was used to create the linkage tree. Genes 
and unannotated probes predictive of oxycodone treatment following LR of this group are marked. Green pixels denote 
low mRNA expression and red pixels denote high mRNA expression. The key highlights samples by dataset. 
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5.4.2 ROC curves 
ROC curves were generated for genes identified through two separate routes: 
those that predicted treatment through LR and those that were highly 
deregulated (top 10 up- and down-regulated) by morphine or oxycodone. 69 
genes underwent ROC analysis in total, 10 of which had AUC values ≥ 0.7 
and were therefore taken to be significant. ROC curves are shown in Figure 
5.3 and Appendix B.  
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Table 5.2: Genes found to be significant through ROC analysis, taken from an initial pool of all genes found to predict 
treatment through LR and the most highly up- and down-regulated 10 genes deregulated by morphine and oxycodone. 
Genes were significant if AUC value ≥ 0.7. Varying patient / control numbers reflects the different group sizes and 
absence of some 24 hour samples.  
Gene Time-point 
Group 
comparison AUC 
Std. 
Error 95% CI P value Controls Patients 
AGPAT3 2 hr M v O+B 0.7083 0.08405 0.5436 to 0.8731 0.0272 24 16 
LDLRAD3 2 hr M v O+B 0.7552 0.07739 0.6035 to 0.9069 0.006842 24 16 
TPK1 2 hr M v O+B 0.737 0.08104 0.5781 to 0.8958 0.012 24 16 
AMPH 6 hr  M v O+B 0.7266 0.0812 0.5674 to 0.8858 0.01635 24 16 
CH25H 6 hr  M v O+B 0.75 0.07869 0.5957 to 0.9043 0.008066 24 16 
MGST1 6 hr  M v O+B 0.724 0.08492 0.5575 to 0.8904 0.01762 24 16 
229879_at 2 hr O v M+B 0.7083 0.08697 0.5378 to 0.8788 0.02725 24 16 
1559573_at 6 hr  O v M+B 0.7109 0.08965 0.5352 to 0.8867 0.02538 24 16 
234196_at 6 hr  O v M+B 0.7995 0.07559 0.6513 to 0.9477 0.001508 24 16 
237618_at 6 hr  O v M+B 0.8464 0.06512 0.7187 to 0.974 0.0002 24 16 
C13orf18 6 hr  O v M+B 0.763 0.07591 0.6142 to 0.9118 0.005317 24 16 
MCL1 6 hr  O v M+B 0.7656 0.07772 0.6133 to 0.918 0.0049 24 16 
ORM1/ORM2 6 hr  O v M+B 0.7031 0.086 0.5346 to 0.8717 0.0313 24 16 
SLC25A37 6 hr  O v M+B 0.7292 0.0844 0.5637 to 0.8946 0.01515 24 16 
BACH2 24 hr O v M+B 0.7563 0.08039 0.5986 to 0.9139 0.009067 20 16 
GATA3 24 hr O v M+B 0.7063 0.08869 0.5324 to 0.8801 0.03568 20 16 
ORM1/ORM2 24 hr O v M+B 0.7375 0.0821 0.5766 to 0.8984 0.0155 20 16 
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ROC curves for 4 of 16 genes significant for morphine and 
oxycodone patients following ROC analysis 
 
 
 
Figure 5.3: ROC curves for 4 genes found to be significant following ROC 
analysis. A and B are significant for morphine patients; C and D are 
significant for oxycodone patients. All other ROC curves are shown in 
Appendix B.   
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5.5 Discussion 
5.5.1 Overview 
Chapter 3 defined the general effects of the 3 study analgesics on lymphocyte 
gene expression, while Chapter 4 confirmed a greater TH2 shift induced by 
morphine and a possible reduction in NKCC. This chapter aimed to use 
statistical methods to both define genes that could be driving these changes, 
and those that could indicate individual susceptibility to the changes. Logistic 
regression (LR) and receiver operating characteristic (ROC) curves were 
used. Generally, genes predictive of a treatment at baseline might indicate a 
susceptibility to later opioid-induced gene deregulation, whereas genes 
predictive subsequently may be involved in mediating these changes.  
LR of genes deregulated by morphine at 2 hour found 8 to be predictive of 
treatment, 5 also significant through ROC. MGST1 was highly deregulated by 
morphine at 6 hour and significant through ROC. Thirteen genes were found 
to be predictive of oxycodone treatment, 7 also significant through ROC, with 
a further 3 highly deregulated genes significant through ROC. Epidural 
bupivacaine deregulated only 20 genes exclusively at 6 hour and was 
predicted by 6 genes through LR.  
5.5.2 Morphine 
Logistic regression of the genes deregulated by morphine at 2 hour produced 
predictor genes that clustered together in pairs in the supervised cluster 
analysis (Figure 5.1). Four genes predicted morphine using 2 hour values and 
4 using 6 hour values; at 2 hour all predictive genes were down-regulated. 
The 4 genes predictive of treatment following LR of 2 hour values were 
AGPAT3, HSPH1, TIAM1 and TPK1; AGPAT3 and TPK1 were also significant 
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through ROC. AGPAT3 is an acyltransferase involved in the phospholipid 
biosynthetic pathway, converting lysophosphatidic acid (LPA) to phosphatidic 
acid (PA): PA is needed for lymphocyte proliferation [217]. The down-
regulation of AGPAT3 would reduce levels of PA and thus T cell proliferation, 
in keeping with the pathway down-regulations seen. If increased LPA in turn 
increased levels of its precursor lysophosphatidylcholine, the suppressive 
qualities of TRegs could be enhanced, via increased TGF-β production [218]. 
TPK1 (thiamin pyrophosphokinase 1) exists as a homodimer and catalyses 
the conversion of thiamine to thiamine pyrophosphate (TPP). TPP is a cofactor 
in essential processes including oxidative degradation of sugars and 
mitochondrial synthesis of ATP [219]. The likely reduction of TPP following 
TPK1 down-regulation is in keeping with the general down-regulation of 
genes related to cell respiration, as discussed in Chapter 3.  
HSPH1 is a heat shock protein and member of the HSP105 family [220], 
required for Wnt signalling and β-catenin stabilisation. Without HSP105, β-
catenin is degraded and gene transcription impaired [221]; β-catenin also 
binds to cadherins, which influence cell adhesion and migration [222]. If 
HSPH1 has similar effects, its down-regulation by morphine could prevent 
gene transcription, influence cell adhesion and decrease IFN-β expression 
[223], all downstream effects of β-catenin. IFN-β has been linked with 
macrophage-mediated priming of NK cells, producing increased 
degranulation [224]; its reduction would therefore be consistent with the 
reduced NKCC previously induced by morphine [29-31]. TIAM1 is needed for 
T cell adhesion and migration [225] and was found repeatedly in pathways 
related to apoptosis. In T lymphocytes, it is involved in protrusion formation 
in the leading edge during PMA-stimulated migration [226]; knockout 
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produced increased tumour migration in pancreatic cancer cells [227]. The 
morphine-induced down-regulation is consistent with the down-regulation of 
processes related to lymphocyte activation and apoptosis. As a predictor 
gene, it may be important in mediating these changes.  
Using 6 hour values, 2 up-regulated (CH25H and DAPK2) and 2 down-
regulated genes (RFX7 and SLC26A11) predicted morphine treatment. 
CH25H (deregulated at 2 and 6 hour) is an interferon-stimulated ER-
associated protein catalysing cholesterol oxidation, with antiviral effects 
through its 25HC production [228, 229]. It was up-regulated in LPS-
stimulated murine macrophages [230], so may have a role in inflammation. 
If stimulation of T cells also results in CH25H up-regulation, the sustained up-
regulation induced by morphine could be a sign of a normal immune 
response. CH25H was also significant through ROC. DAPK2 is a serine 
threonine protein kinase present in mitochondria and involved in apoptotic 
and receptor-induced cell death. Its depletion both increases intracellular 
reactive oxygen species (ROS), impairing mitochondrial metabolism 
downstream [231] and activates NF-kB by reducing the threshold for TCR 
activation, leading to a defect in cell survival [232]. The up-regulation of 
DAPK2 by morphine could produce an anti-apoptotic response and increased 
mitochondrial metabolism. The anti-apoptotic effect is in keeping with 
enriched processes seen at 2 hour, whereas increased mitochondrial 
metabolism is not and suggests a pro-inflammatory response.  
SLC26A11 is a sulphate transporter based in the cell membrane of high 
endothelial venule cells; lymphocytes emigrating from blood to secondary 
lymphoid organs do so through these venules, whose cells contain high 
Mary Elizabeth Demopoulos  Chapter 5 Results 
© Mary Demopoulos 2010-2017 187
sulphate levels [233]. Down-regulation by morphine could disrupt sulphate 
transport and subsequently lymphocyte trafficking.  
LDLRAD3 was up-regulated by morphine at 6 hour but predicted morphine 
treatment and was significant through ROC at 2 hr. It is part of a lipoprotein 
receptor involved in APP processing and has a similar structure to LRP1, a 
protein related to the lipoprotein receptor and needed for TCR and CD28 
activation [234]. The intracellular domain of LDLRAD3 has been shown to 
interact with several members of the NEDD4 family of E3 ubiquitin ligases, 
including Itch, to activate the inactive ligase via autoubiquitination; 
interaction subsequently increases its degradation [235]. The morphine-
induced up-regulation of LDLRAD3 and initial increase in E3 ubiquitin ligase 
activity prior to degradation could effect regulation of immune function and 
cell signalling.  
5.5.3 Oxycodone 
Thirteen genes predicted oxycodone treatment following LR, all up-regulated 
in common with the majority of the group. Seven were also significant 
through ROC analysis. SLC25A37, BACH2 and GATA3 were highly deregulated 
genes significant through ROC.  
OSCAR, IL13RA1 and USP15 are annotated genes that predict oxycodone 
response pre-treatment. OSCAR is an osteoclast-associated receptor 
expressed on myeloid cells, which associates with FcRγ to promote cellular 
activation [236] and phagocytosis of opsonised cells and microbes. A similar 
effect of OSCAR in T cells could increase cell activation; up-regulation of 
OSCAR may predict those patients more likely to experience increased 
lymphocyte activation or a smaller TH2 shift. IL13RA1, again a predictor gene 
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pre-treatment, is a subunit of IL13R, which complexes with IL4Rα to bind the 
TH2 cytokines IL-4 and IL-13. Up-regulation of IL13RA1 by oxycodone may 
increase cytokine activity and subsequent transcription and cellular immune 
responses via activated JAK1, STAT3 and STAT6. Its presence pre-treatment 
suggests a subsequent increased TH2 response. 
USP15 deubiquitinates MDM2, preventing its degradation and allowing it to 
suppress the transcriptional activity of p53, the tumour suppressor [237] 
[238]. USP15 was up-regulated by oxycodone as was TP53I3, induced by P53 
and thought to be involved in p53-mediated cell death. USP15 was also up-
regulated following treatment of human T cells with morphine [239]; up-
regulation in this study could therefore be opioid-receptor induced and part 
of a p53 homeostatic mechanism. However, the up-regulation of USP15 and 
TP5313 suggests a reduction rather than increase in p53 activity, opposite to 
the overall influence hypothesized for oxycodone.  
Only 1 annotated gene, HIP1 (Huntingtin interacting protein 1), predicted 
oxycodone treatment at 6 hour. Its paralog HIP1R interacts with clathrin light 
chains (CLC), components of clathrin-coated vesicles, so HIP1 may be 
relevant for endosomal trafficking. Knockdown of CLC in HeLa cells prevented 
HIP1R localising correctly and caused an actin build-up [240]; if HIP1 
behaved in a similar manner in lymphocytes, up-regulation by oxycodone 
would promote intracellular trafficking. HIP1 was predictive of oxycodone at 
6 hour, the timepoint at which oxycodone exerted its maximal effect on gene 
deregulation. 
MCL1 and ORM1/ORM2 predict oxycodone treatment at 24 hour. MCL1 was 
also significant through ROC and is an anti-apoptotic regulator, induced after 
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TCR stimulation in murine T cells [241]. Its overexpression in CD8+ cells of 
virally-infected mice increased differentiation of terminal effector and effector 
memory cells while decreasing differentiation of central memory cells [242]. 
Up-regulated MCL1 indicates increased TCR stimulation and an increased 
ability of CD8+ cells to respond quickly to antigen. ORM1/ORM2 are proteins 
up-regulated in the acute phase of inflammation [243] and have been shown 
to inhibit neutrophil migration in rats in vivo [244]; the up-regulation of these 
genes may impair T cell migration but may also be part of the inflammatory 
response.  
BACH2 and GATA3 were highly down-regulated and significant through ROC 
analysis. BACH2 is a transcriptional regulator that both activates and 
suppresses transcription; BACH2 -/- mice showed positively regulated TReg 
development, repressed conventional T cells [164] and repressed lineage-
specific genes, including GATA3 [165] (also down-regulated by morphine). 
GATA3 is a transcription factor required for notch-mediated differentiation of 
TH2 murine cells [166], has been called the master driver of TH2 
differentiation and was repressed by glucocorticoid administration [167]. 
Cortisol is a glucocorticoid induced by surgery [50, 183] and morphine [178-
182] which coordinates inflammation and a normal immune response [177]. 
An effect on cortisol levels could therefore alter the immune response. The 
down-regulation of BACH2 and GATA3 by oxycodone suggests T cell ratios 
biased towards TH1 or TRegs, possibly influenced by cortisol. The down-
regulation of GATA3 by morphine suggests a TH1 rather than TH2 shift, not 
in keeping with functional changes hypothesized generally.  
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5.6 Conclusion 
This chapter aimed to use statistical methods to elucidate genes key in 
mediating or predicting the immunomodulatory effects of morphine and 
oxycodone. Eight genes predicted morphine treatment and 13 predicted 
oxycodone treatment through logistic regression. Of these, 5 morphine and 
7 oxycodone genes were also significant through ROC analysis. BACH2 and 
GATA3 were highly deregulated by oxycodone and also significant through 
ROC.  
Of the genes predictive of morphine treatment, AGPAT3, TPK1 and TIAM1 
have roles in lymphocytes and could be investigated further as biomarkers. 
AGPAT3 and TPK1 were also significant through ROC. Through altered 
phospholipid levels, down-regulated AGPAT3 may be key in mediating 
reduced T cell proliferation and increased TReg activity, while TPK1 may be 
important in mediating suppressed cell respiration by reducing levels of 
thiamine pyrophosphate, essential for ATP synthesis. TIAM1 may mediate 
reduced T cell trafficking by faulty leading edge formation during lymphocyte 
migration. LDLRAD3 is interesting as its deregulation at 6 hour, predictive 
ability and significance through ROC may be important in recovering 
lymphocyte activation.  
OSCAR, BACH2 and MCL1 are relevant predictive genes induced by 
oxycodone. OSCAR promotes cellular activation and phagocytosis of 
opsonised cells, the down-regulation of BACH2 may induce a shift to a TH1 
profile, and MCL1 indicates previous T cell stimulation. The deregulation of 
OSCAR and BACH2 are potential biomarkers for those patients who respond 
to oxycodone with increased lymphocyte activation or a reduced TH2 shift.  
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Further assays such as qRT-PCR or Western blot would be appropriate to 
confirm that these genes and proteins are indeed overexpressed in the 
relevant patient groups, with a view to considering them as biomarkers for 
opioid-induced lymphocyte gene deregulation. Validation in an independent 
cohort would be desirable to confirm the findings of this study.  
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 Chapter 6 
Dynamic changes in gene expression 
6.1 Introduction  
Chapter 3 reported the contrasting lymphocyte gene deregulation induced by 
morphine and oxycodone. Morphine induces deregulation primarily at 2 hours 
that, based on process enrichment, may be phenotypically 
immunosuppressive. The maximal effect of oxycodone on gene deregulation 
is at 6 hours and may be supportive of normal immune function, again based 
on process enrichment. The timecourse of these gene expression changes 
was investigated further in this chapter. Although the number of genes 
deregulated by each treatment at each timepoint indicates that all 
perturbations were brief, timepoint and treatment group overlaps were seen 
on supervised hierarchical clustering (Figures 16 and 17 of Chapter 3), 
indicating that some gene deregulation is sustained and induced by more 
than 1 treatment. Continued immunomodulation may produce a different 
phenotype to brief perturbations.  
6.2 Aims 
This chapter aims to investigate the duration of gene deregulation by the 3 
treatment groups, and the clinical relevance of genes continually deregulated 
across timepoints and treatment groups.   
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6.3 Methods 
Eligible non-cancer open gynaecological patients were recruited to the study 
as described in Chapters 2 and 3. Following venepuncture, mononuclear cells 
were removed from blood samples using Ficoll-Hypaque technique then 
CD4+, CD8+ and NK cells separated via magnetic separation. Extracted RNA 
(Qiagen RNeasy kit) was hybridised to Affymetrix arrays and analysed using 
Partek software. ANOVA was used to generate gene lists from different time 
/ treatment combinations for the statistical analysis of this chapter.  
6.3.1 Dynamic changes 
Gene lists were compared across treatments and timepoints using Partek 
software and Excel, to investigate genes showing sustained versus short-lived 
perturbation across treatments and timepoints. Cluster 3.0, TreeView (see 
Chapter 2) and Excel were used to compare separation of arrays by treatment 
or timepoint. DAVID ontological software (Chapter 2) was used to compare 
process enrichment in different groups of genes.   
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6.4 Results 
6.4.1 Overview of timepoint changes 
The pattern of change by timepoint is distinctive (Figure 6.1); at 2 hours 
post-baseline, genes were almost exclusively deregulated by morphine, with 
only three (ADORA3, ANKRD22 and CHKA) induced by oxycodone treatment, 
and none by epidural bupivacaine. Most morphine genes (434 of 520 – those 
in processes relating to RNA transcription and translation, cell respiration and 
apoptosis as discussed in Chapter 3) were down-regulated. Genes up-
regulated by morphine treatment included the three up-regulated by 
oxycodone.  
By 6 hours, all treatments induced lymphocyte gene deregulation, but in 
contrast to 2 hours, oxycodone deregulated more genes than any other 
treatment, and almost all (540 genes) were up-regulated. These deregulated 
genes were represented by 810 probes, contrasting with the 520 genes 
deregulated by morphine at 2 hours, which were represented by only 576 
probes. This may demonstrate the greater reproducibility of the oxycodone 
response. By 24 hours, only CCR2 was up-regulated by oxycodone and 
RNASE2 by morphine; neither gene was deregulated at a previous timepoint. 
Supervised hierarchical clustering of all deregulated genes (Figure 6.2) shows 
the pattern of change through the timepoints studied; the key highlights the 
clustering of 0 and 24 hour arrays versus 2 and 24 hour.   
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Dynamic gene expression changes following initiation of 
analgesia 
 
 
 
 
Figure 6.1: Number of probes deregulated by each treatment from 2 hour to 
24 hour. 
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Supervised hierarchical clustering of probes deregulated by all treatments 
 
Figure 6.2: Supervised hierarchical clustering for all probes deregulated by the 3 study analgesics at 2 and 6 hour (gene 
groups Mor0-2, Mor0-6, Oxy0-6 and Bup0-6 – total 1485 genes) for all 156 arrays. Data was correlated by Euclidean 
distance and average linkage used to create the linkage tree. Green pixels denote low mRNA expression and red pixels 
denote high mRNA expression. The key highlights the separation of arrays by timepoint.  
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6.4.2 Sustained deregulation across timepoints 
Within each treatment group, genes were mainly perturbed transiently 
(Figure 6.1 and Figure 6.3). Only small similarities were found between 2 and 
6 hour gene groups deregulated by morphine and oxycodone. (No genes were 
differentially expressed by bupivacaine at 2 or 24 hour so the parallel 
comparison was not performed).  
6.4.2.1 Morphine sustained response genes 
In the morphine group, 495 genes deregulated at 2 hours (Mor0-2) were no 
longer deregulated at 6 hours (Mor0-6; Figure 6.3). The 25 genes 
continuously deregulated were classified as sustained response genes and 
considered separately, as they were continuously deregulated and mainly up-
regulated (24 genes) counter to the general trend of morphine-induced 
genes. Sustained response (SR) genes are therefore defined as those genes 
deregulated by morphine at both 2 and 6 hours. They include 24 of the 86 
genes up-regulated by morphine at 2 hour and just 1 down-regulated gene, 
FLT3LG. All SR genes have the same direction of change from baseline at 
both 2 and 6 hours. The only SR gene uniquely induced by morphine was 
CH25H.  
Fold changes were compared between treatment groups for all SR genes 
(Figure 6.4); the most highly up-regulated gene at 6 hours for all groups was 
IL1R2 (28.38 FC in morphine; 24.91 FC in oxycodone; 30.20 FC in 
bupivacaine). In morphine and oxycodone, CLEC4D (FCs of 6.23 / 12.97 
respectively) and SAMSN1 (FCs of 6.61 / 7.34 respectively) were the next 
highest up-regulated genes. 
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Supervised clustering of the 86 genes up-regulated by morphine at 2 hour 
(including 24 SR genes) was performed (Figure 6.5); SR genes are seen to 
mainly group together in the right-hand half of the heatmap, suggesting that 
of all up-regulated genes, SR genes resolve the array clustering by timepoint 
most successfully. The fold changes over time shown for SR genes in all 
treatment groups (Figure 6.4) demonstrates their earlier up-regulation by 
morphine followed by an up-regulation induced by all treatments at 6 hours, 
before decreasing to an insignificant FC<±2 at 24 hours. Process enrichment 
of SR genes only identified significant overrepresentation of processes 
involved in lymphocyte activation, compared to the 113-gene whole Mor0-6 
group (Table 6.1).  
6.4.2.2 Oxycodone early responder genes 
The two genes deregulated by oxycodone at both 2 and 6 hour (Figure 6.3) 
were ADORA3 and ANKRD22, both up-regulated. These were defined as 
oxycodone early responder genes: those genes that are deregulated by 
oxycodone at both 2 and 6 hours. With the same pattern of sustained 
deregulation, ADORA3 was also a morphine SR gene (Section 6.4.2.1). 
Neither gene was deregulated by bupivacaine treatment.   
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Sustained opioid-induced gene deregulation across 
timepoints  
 
 
Figure 6.3: The number of genes persistently deregulated following both 
morphine and oxycodone treatment at 2 and 6 hour. The 25 genes in the 
central morphine segment are defined as sustained response genes; the 2 
genes in the central oxycodone segment are defined as oxycodone early 
responder genes.  
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Dynamic fold changes for morphine sustained response genes 
 
 
Figure 6.4: Fold changes at 2, 6 and 24 hour for morphine sustained response (SR) genes (genes deregulated by 
morphine at both 2 and 6 hour). The most highly up-regulated gene by all treatments is IL1R2 at 6 hour. Only one SR 
gene is perturbed at 2 hour by another treatment - ADORA3 by oxycodone. At 6 hour, 23 SR genes are perturbed by 
oxycodone and 6 SR genes by bupivacaine. FLT3LG is the only continuously down-regulated sustained response gene; 
this gene is also down-regulated at 6 hour by bupivacaine.   
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Supervised clustering of 86 genes up-regulated at 2 hour by morphine 
 
Figure 6.5: Supervised hierarchical clustering of all 86 genes up-regulated by morphine at 2 hour, for all 156 arrays. 
Data was correlated by Euclidean distance and average linkage used to create the linkage tree. Green pixels denote low 
mRNA expression and red pixels denote high mRNA expression. SR genes are annotated and the key highlights the 
separation of arrays by treatment.  
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Table 6.1: Summary of overrepresentation analysis highlighting biological processes enriched in genes significantly 
deregulated by A: morphine at 6 hour (113 genes / 158 probes) and B: selective enrichment for genes with sustained 
deregulation at 2 and 6 hour (25 SR genes / 31 SR probes). Top 20 processes by p-value are shown.  
 
A: Biological processes - Mor0-6 (113 
genes) Genes 
% of 
total 
input
p-value B: Biological processes – SR genes (25 genes) Genes 
% of 
total 
input 
p-value 
response to wounding 21 19.6 2.00E-10 positive regulation of immune system process 5 20 4.40E-04 
response to organic substance 19 17.8 9.90E-07 immune response 7 28 4.80E-04 
inflammatory response 13 12.1 1.50E-06 response to wounding 6 24 1.10E-03 
defense response 17 15.9 2.60E-06 inflammatory response 5 20 1.40E-03 
innate immune response 9 8.4 3.70E-06 negative regulation of cytokine production 3 12 1.60E-03 
negative regulation of cytokine production 6 5.6 4.90E-06 positive regulation of molecular function 6 24 1.70E-03 
immune response 7 6.5 1.20E-05 regulation of kinase activity 5 20 2.00E-03 
response to lipopolysaccharide 17 15.9 1.10E-05 defense response 6 24 2.10E-03 
response to molecule of bacterial origin 7 6.5 2.20E-05 regulation of transferase activity 5 20 2.30E-03 
response to insulin stimulus 7 6.5 5.30E-05 regulation of antigen processing and presentation 2 8 3.10E-03 
organic acid biosynthetic process 8 7.5 7.60E-05 regulation of dendritic cell antigen processing and presentation 2 8 3.10E-03 
carboxylic acid biosynthetic process 8 7.5 7.60E-05 positive regulation of kinase activity 4 16 5.20E-03 
positive regulation of developmental process 10 9.3 9.50E-05 regulation of phosphorylation 5 20 5.20E-03 
positive regulation of molecular function 14 13.1 1.30E-04 positive regulation of transferase activity 4 16 5.80E-03 
fatty acid biosynthetic process 9 8.4 1.80E-04 regulation of phosphorus metabolic process 5 20 6.00E-03 
positive regulation of immune system process 8 7.5 2.00E-04 regulation of phosphate metabolic process 5 20 6.00E-03 
regulation of cytokine production 6 5.6 1.80E-04 negative regulation of immune system process 3 12 7.20E-03 
regulation of phosphorylation 12 11.2 2.60E-04 positive regulation of catalytic activity 5 20 7.70E-03 
response to endogenous stimulus 12 11.2 3.60E-04 negative regulation of interleukin-12 production 2 8 7.70E-03 
regulation of phosphate metabolic process 12 11.2 3.60E-04 chronic inflammatory response 2 8 9.30E-03 
Key:
Response to wounding 
Lymphocyte activation 
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6.4.3 Sustained deregulation across treatment 
groups 
6.4.3.1 All treatments at 6 hours 
A number of genes were deregulated across treatments. Similarities in 
numbers of deregulated genes induced by treatment groups, regardless of 
timepoint then grouped by timepoint, are shown (Figure 6.6).  
Ten genes (14 probes) were up-regulated by all treatments at 6 hour (Figure 
6.6C); these genes included C19orf59/MCEMP1, CD163, CYP1B1, IL1R2, 
IRAK3, NUDT16, SLC1A3, SORT1 and ST6GALNAC3. The most highly up-
regulated genes were IL1R2, C19orf59/MCEMP1 and CD163 (Figure 6.7); 
deregulation of these genes is likely to be surgery-related. The 78 genes (112 
probes) deregulated by both morphine and oxycodone at 6 hours showed the 
same direction of change from baseline regardless of opioid and included 17 
SR genes.   
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Numbers of genes consistently deregulated across 
treatment groups  
 
 
 
Figure 6.6: Similarities in deregulated genes A: between treatment groups, 
regardless of timepoint; B: between all treatment groups at 2 hours, and C: 
between all treatment groups at 6 hours.  
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Dynamic fold changes for genes deregulated by all treatments at 6 hours 
 
 
 
 
Figure 6.7: Fold changes at 2, 6 and 24 hour for the 10 genes deregulated at 6 hours by all treatments. 
Mary Elizabeth Demopoulos  Chapter 6 Results 
© Mary Demopoulos 2010-2017 206
6.4.4 Sustained deregulation across timepoints 
and treatment groups 
6.4.4.1 Morphine (2 hours) and oxycodone (6 hours) 
66 genes (77 probes) were deregulated by both morphine at 2 hour and 
oxycodone at 6 hour, the timepoints where the maximal change in gene 
expression for these treatments was observed. All genes had the same vector 
of change regardless of treatment; 9 were down-regulated and 57 up-
regulated. Deregulated genes were enriched in 25 processes (p-value≤0.01) 
related to lymphocyte activation, apoptosis and response to wounding (Table 
6.2). No processes relating to RNA translation or transcription were present.  
Fold changes were compared between all treatment groups for these 66 
genes (Figure 6.8); the most strongly down-regulated gene in all treatment 
groups was NOG. The remaining 8 down-regulated genes were ADA, GATA3, 
IFFO2, LFNG, STRBP, TCEA3, VSIG1 and ZNF395. One of the most highly up-
regulated genes in all groups was IL1R2, also deregulated by all treatments 
at 6 hour (Figure 6.6C). In the opioid groups, ARG1 and MMP9 were also 
highly up-regulated, with higher fold changes induced by oxycodone, in 
common with the majority of genes in this group (Figure 6.8).  
Supervised hierarchical cluster analysis (Figure 6.9) highlights the separation 
of up- from down-regulated genes, and the clustering of morphine 2 hour and 
oxycodone 6 hour arrays together.   
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Table 6.2: Summary of overrepresentation analysis highlighting biological 
processes enriched in genes significantly deregulated by both morphine at 
2 hour (Mor0-2) and oxycodone at 6 hour (Oxy0-6).  
Biological processes – 66 genes Genes % of total input p-value 
positive regulation of immune system process 6 10.5 1.00E-03 
immune response 9 15.8 1.50E-03 
negative regulation of multicellular organismal process 5 8.8 1.90E-03 
negative regulation of immune system process 4 7 2.50E-03 
defense response 8 14 3.40E-03 
regulation of apoptosis  9 15.8 4.00E-03 
regulation of programmed cell death  9 15.8 4.20E-03 
regulation of organ growth  3 5.3 4.20E-03 
regulation of cell death  9 15.8 4.30E-03 
positive regulation of T cell differentiation 3 5.3 4.80E-03 
positive regulation of leukocyte activation 4 7 4.90E-03 
positive regulation of cell activation  4 7 5.60E-03 
negative regulation of signal transduction 5 8.8 5.60E-03 
positive regulation of lymphocyte differentiation 3 5.3 5.70E-03 
regulation of kinase activity  6 10.5 5.80E-03 
regulation of dendritic cell antigen processing and presentation 2 3.5 6.50E-03 
regulation of antigen processing and presentation 2 3.5 6.50E-03 
negative regulation of cytokine production 3 5.3 6.70E-03 
regulation of transferase activity  6 10.5 6.90E-03 
response to wounding  7 12.3 7.00E-03 
negative regulation of cell communication 5 8.8 8.40E-03 
response to glucose stimulus  3 5.3 9.40E-03 
reproductive developmental process  5 8.8 1.00E-02 
response to hexose stimulus  3 5.3 1.00E-02 
response to monosaccharide stimulus 3 5.3 1.00E-02 
Key: 
Response to wounding  
Lymphocyte activation 
Apoptosis 
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Dynamic fold changes for genes deregulated by both morphine at 2 hour (Mor0-2) and 
oxycodone at 6 hour (Oxy0-6) 
 
 
Figure 6.8: Fold changes at 2, 6 and 24 hour for the 66 genes deregulated by both morphine at 2 hour (Mor0-2) and 
oxycodone at 6 hour (Oxy0-6). Fold changes are shown for all treatment groups.   
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Supervised hierarchical clustering of all 66 genes deregulated by both morphine at 2 hour 
(Mor0-2) and oxycodone at 6 hour (Oxy0-6)  
Figure 6.9: Supervised hierarchical clustering of the 66 genes deregulated by morphine at 2 hour (Mor0-2) and 
oxycodone at 6 hour (Oxy0-6) for all 156 arrays. Data was correlated by Euclidean distance and average linkage used 
to create the linkage tree. Green pixels denote low mRNA expression and red pixels denote high mRNA expression. The 
key highlights the separation of arrays by treatment and timepoint. 
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6.5  Discussion 
This chapter aimed to investigate the dynamic changes in gene expression 
induced by all treatments, especially for the gene groups with maximal effect: 
those genes induced by morphine at 2 hours and oxycodone at 6 hours. It 
also aimed to investigate other genes deregulated by more than 1 treatment 
and the clinical relevance of transiently expressed genes versus those with a 
more sustained perturbation.  
The transient nature of lymphocyte gene deregulation following initiation of 
analgesia can be clearly seen by the variance in numbers of probes 
deregulated by each treatment across timepoints (Figure 6.1). Supervised 
hierarchical clustering of all deregulated genes shows clear array clustering 
by timepoint, with 2 and 6 hour arrays clustering together, reflecting their 
deregulation from baseline versus the lack of deregulation seen in 0 and 24 
hour arrays (Figure 6.2). Arrays that do not fit this pattern may reflect the 
genes deregulated from baseline at more than 1 timepoint.  
The dynamics of process enrichment across timepoints also indicates that the 
gene deregulation seen was transient. In morphine-induced genes, processes 
relating to RNA transcription and translation, apoptosis and cell respiration 
were enriched at 2 hours, but by 6 hours only apoptosis remained enriched. 
The down-regulation of apoptosis processes at 2 hour may be indicative of T 
cell anergy [245, 246], a functional inactivation of T cells often induced by 
persistent antigen exposure, which leaves cells in a hyporesponsive state 
[247]. This is discussed further in Chapter 7. Genes in enriched processes at 
2 hours were almost all down-regulated, but by 6 hours all genes bar one 
(FCER1A) were up-regulated.  
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The enrichment of processes related to lymphocyte activation, response to 
wounding and apoptosis by genes up-regulated by morphine at 6 hours did 
not seem to be immunosuppressive. However, their response was more 
moderate than that of oxycodone, with fewer genes present in lymphocyte 
activation and apoptosis processes. 28 morphine genes, 103 oxycodone 
genes and 13 bupivacaine genes were present in lymphocyte activation 
processes, suggesting that oxycodone induced lymphocyte activation more 
strongly than morphine, and that it did not induce anergy at any time.  
Two new sub-groups of genes: Morphine sustained response (SR) and 
Oxycodone early responder, were introduced in this chapter based on the 
extended deregulation of genes across timepoints. The scarcity of genes 
found in each sub-group reflects the relative lack of sustained deregulation 
by each treatment; most deregulation was transient. 23 of the morphine SR 
genes were also deregulated by oxycodone, with the exception of CH25H and 
FLT3LG. SR genes were generally up-regulated in contrast to most Mor0-2 
genes. Compared to enrichment of the full dataset of genes deregulated by 
morphine at 6 hours, more highly statistically significant lymphocyte 
activation-related processes are enriched in SR genes (Table 6.1), confirming 
that the SR group is well represented with lymphocyte activation-related 
genes. However, although 8 up-regulated SR genes were present in these 
processes at 2 hour, enrichment of the full dataset of Mor0-2 genes produced 
19 genes, just 5 up-regulated, in lymphocyte activation processes. Without 
further functional assays, it is not possible to determine the lymphocyte 
activation phenotype induced by morphine at 2 hour.  
Mary Elizabeth Demopoulos Chapter 6 Results 
© Mary Demopoulos 2010-2017 212
The biological process: positive regulation of immune system process was 
represented in Mor0-2 by 5 up- and 11 down-regulated genes; by 6 hours, 
only the up-regulated probes remained deregulated, suggesting that 
lymphocyte activation was recovering. The enrichment by Mor0-2 genes of 
16 processes involved in RNA transcription and translation (90 genes present, 
2 up-regulated) not enriched by 6 hour genes also supports this. T cell 
activation increases protein translation [168, 169]; the reduced protein 
translation induced by morphine at 2 hours, evidenced by process down-
regulation, may be caused by reduced T cell activation. TRAC, LCK and CD28 
were all down-regulated by morphine at 2 hour and all could result in reduced 
T cell activation [119, 120, 124, 126].  
As mentioned above, the SR genes uniquely deregulated by morphine are 
CH25H and FLT3LG. CH25H (cholesterol 25-hydroxylase) is an interferon-
stimulated ER-associated protein catalysing the oxidation of cholesterol, and 
produces 25HC in human cells in vitro, preventing infection and replication of 
Hepatitis C virus [228]. It was up-regulated in murine macrophages following 
LPS stimulation in a TLR4-dependent manner [230]. Its sustained up-
regulation by morphine is therefore counter to the general 
immunosuppression hypothesis. FLT3LG is the only down-regulated SR gene 
and acts on receptor FLT3 to activate pathways promoting proliferation of 
haematopoietic progenitor cells and inhibiting apoptosis. It is an essential 
cytokine needed for expansion of lymphoid lineages which reduced T cell 
dysfunction in a murine model of burn wound sepsis [203]. It primes CD8+ 
T cells via mobilisation of dendritic cells and subsequent production of TBet 
by CD8+ cells which then show increased antigen sensitivity and cytolytic 
ability [248, 249]. mRNA deregulation in Mor0-2 and Bup0-6 indicated ligand 
Mary Elizabeth Demopoulos Chapter 6 Results 
© Mary Demopoulos 2010-2017 213
down-regulation and receptor up-regulation, suggesting CD8+ cells may have 
lower antigen sensitivity and cytolytic ability.   
Other SR genes include CLEC4D, CLEC4E and SAMSN1. CLEC4D is a 
constitutively expressed C-type lectin receptor up-regulated by microbial 
stimulation via the MyD88 pathway, which forms a trimeric receptor with 
CLEC4E and FCER1-γ (IgE receptor chain) to bind pathogenic ligands [250]. 
Binding suppresses murine TLR-4 responses in vitro and in vivo, evidenced 
by increased pro-inflammatory cytokines (IL-6, IFN-γ, TNF-α) in knock-out 
splenocytes / mice [251]. CLEC4E also transduced the loss of the 
transcription factor IRF1 and IL-12 following fungus binding to human 
dendritic cells [252]; IL-12 inhibits IL-4 synthesis and thus TH2 differentiation 
in T cells [183]. Up-regulation of both CLECs would therefore shift T cells 
away from a TH1 profile; up-regulation by oxycodone is later at 6 hour. TLR-
4 was also up-regulated by both opioids at 6 hour, indicating a possible 
compensatory response.  
SAMSN1 is an adaptor protein increased following stimulation of human 
CD19+ B cells with IL-4, CD40L and anti-IgM. Cluster analysis showed 
SAMSN1 clustering with signalling genes such as TRAF1 [253]; KO mice 
showed enhanced TH1 and TH2 humoural responses and increased B cell 
proliferation on BCR stimulation. The early up-regulation of SAMSN1 by 
morphine and later by oxycodone may therefore inhibit TH humoural immune 
responses. It is possible that the up-regulation of SR genes is an early 
response to counter a morphine-induced immunosuppression. This is 
supported by the prevalence of enrichment of lymphocyte activation-related 
processes in SR genes.  
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At 6 hour in the morphine group, enriched processes suggested that 
lymphocyte activation was no longer suppressed, despite continuous 
morphine administration via Patient-Controlled Analgesia (PCA). Patients 
initially received a morphine bolus in surgery at anaesthetic induction; some 
patients then had a second small bolus before the end of surgery 
(intraoperative morphine dose ranged from 10-20mg). Postoperatively, 
patients self-administered morphine via a PCA. The non-cumulative means of 
opioid dosing (Appendix A) show that no morphine patients received 
morphine between the intraoperative dose(s) and 2 hour timepoint, and that 
the mean dose at 6 hours was double that at 2 hours. Postoperatively, dosing 
was at maximum 1mg per 6 minutes. The half-life of morphine is 2.2 hours 
[254] so between 2 and 6 hours, morphine serum levels may be decreasing.  
It is likely that the transient nature of the morphine-induced gene 
deregulation is due to the initial morphine bolus followed by slower PCA 
dosing. It is possible that the initial morphine (but not oxycodone) bolus 
induced MOR desensitisation and consequent reduced gene transcription, as 
seen in mice brain slices using tagged MOR [255]. Due to the timepoint 
spacing, the morphine-induced gene deregulation is known to be transient in 
nature as far fewer genes are deregulated at 6 hours. In contrast, duration 
of the oxycodone-induced gene deregulation is less well defined as it begins 
sometime between 2 and 6 hours but may last until shortly before the 24 
hour timepoint.  
The two oxycodone early responder genes were ADORA3 and ANKRD22. 
ADORA3 (adenosine A3 receptor) is coupled to a Gi receptor so inhibits 
adenylate cyclase; it was up-regulated in PBMCs of rheumatoid arthritis 
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patients [256]. In cancer, it both induced cell proliferation in a glioblastoma 
cell line via down-regulation of ERK1/2 [257] and inhibited colon carcinoma 
growth via modulation of NF-kB and GSK-3β in mice in vivo [258]. These 
divergent effects may depend on agonist concentration, with low 
concentrations producing proliferation in normal cells, and high 
concentrations producing apoptosis in normal or tumour cells [259]. 
Adenosine may show a surgery-induced increase in this study caused by the 
degradation of extracellular ATP [260] which may have caused ADORA3 up-
regulation. However, adenosine levels were not measured during this study 
so it is not possible to ascertain the effects of increased ADORA3, up-
regulated in this study by both morphine and oxycodone.  
ANKRD22 (ankyrin repeat domain 22) is a transcription factor up-regulated 
both in pancreatic cancer [261] and following ZEB1 silencing in murine 
prostate tumour models. ZEB1 is a zinc finger transcription repressor critical 
to early T cell development [262] but was not deregulated by oxycodone. It 
is unlikely that the early deregulation of ANKRD22 is relevant to any putative 
oxycodone-induced immunomodulation.  
Ten genes are perturbed by all treatments at 6 hours (Figure 6.6C); these 
genes are likely to represent those induced by surgery, anaesthetic or the 
underlying gynaecological condition. They include IL1R2, C19orf59 / MCEMP1 
and CD163. IL1R2, also an SR gene, is a decoy receptor antagonising IL-1; 
its up-regulation would antagonise the surgery-induced increase in IL-1. It is 
found on immune cells only, in comparison to the ubiquitous presence of 
IL1R1 [116], suggesting a protective function of IL1R2 for immune cells 
against IL-1. IL-1 mediates inflammation in many diseases and is a key 
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immunosuppressive cytokine. Other genes linked to the downstream 
activation of IL-1 were up-regulated (IRAK3) and down-regulated (TRAF3 – 
morphine only); both these perturbations are in keeping with the down-
regulation of IL-1 activity. IRAK3 prevents IRAK1 dissociating from IRAK4 
and associating with myD88 and TRAF6 to enact TLR / IL1R signalling and 
pro-inflammatory response [117], providing immune homeostasis. TRAF3 
was down-regulated in morphine only; it suppresses TRAF2-induced NFκB 
activity, associates with IRAK-1 to produce a TLR response [263] and its 
deficiency has been found to be present with a defective TLR3 response and 
HSV encephalitis [264].  The perturbation of IL1R2 and associated genes 
suggests a surgery-induced inflammation-modifying response, induced early 
in morphine.  
CD163 is an acute-phase regulated receptor involved in clearance of 
haemoglobin complexes by macrophages, found in plasma immediately 
following CABG surgery [113]. It was also up-regulated (mRNA and protein) 
in monocytes of healthy volunteers following in vivo high-dose cortisol 
infusion [115]. Shed CD163 inhibits proliferation of T cells, possibly via 
cellular myosin [196] and its cell surface expression in monocytes is increased 
by IL-10 [114]. Its deregulation by all treatments is indicative of its role as 
an anti-inflammatory scavenger protein; its early up-regulation by morphine 
could be related to increased cortisol or IL-10 in this group. C19orf59 / 
MCEMP1 is a transmembrane protein expressed by mast cells [265] and 
macrophages [266], whose precise function is unknown, but may be involved 
in regulation of mast cell differentiation [266] and immune responses, due to 
the presence of binding motifs similar to those found in immune receptor 
genes in its promoter region [265].  
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Differentially expressed epidural bupivacaine genes (Bup0-6) were enriched 
in processes related to signal transduction and cell proliferation. No 
statistically significant processes were enriched when interrogating genes 
deregulated by bupivacaine only at 6 hours (23 probes). Both the 
deregulation of surgery- or anaesthesia-induced genes by all treatments at 6 
hour, and the relative lack of an immunomodulatory effect induced by 
bupivacaine, are supportive of a successful study design.  
One of the largest groups of genes differentially expressed across treatments 
was the 66-gene group consistently deregulated by morphine and oxycodone 
at the time of their maximal response (Mor0-2 and Oxy0-6). IL1R2, ARG1 
and MMP9 were the top 3 up-regulated genes in this group, as well as the 3 
most highly up-regulated genes in Mor0-2. ARG1 (Arginase 1) competes with 
inducible nitrous oxide (induced by IFN-γ [267]) to metabolise L-arginine, 
hydrolysing it to L-ornithine and urea. ARG1 was present with reduced 
arginine in PBMCs following injury [268] and L-arginine deficiency was linked 
to down-regulation of the TCR ξ chain in PBMCs and myeloid cells [268, 269]. 
Reduced L-arginine, increased ARG1 activity and protein expression and 
increased IL-10 were also seen in trauma patients [268]. ARG1 up-regulation 
suggests decreased T cell activation as a result of TCR ξ chain down-
regulation and a shift to a TH2 profile, occurring at the earlier intraoperative 
timepoint in the morphine group. 
MMP9 is a matrix metalloproteinase that degrades the extracellular matrix, 
positively contributing to wound healing as part of the surgical response. It 
was up-regulated in mice peripheral glial cells following morphine 
administration, together with glial fibrillary acidic protein and IL-1β 
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activation, indicating a glial cell response; these effects were blocked by 
naloxone, the MOR antagonist [212]. In liver cells, MMP9 is up-regulated by 
injury and activates TGF-β, increasing Treg numbers [270]. MMP9 also 
antagonised the analgesic properties of morphine in mice, shown by the 
increased analgesia seen in MMP9 KO mice [271]. The MMP9 up-regulation 
by morphine and oxycodone may therefore have been mediated through 
MOR, and could increase Treg numbers and patients’ need for morphine 
during the intraoperative period.  
Down-regulated genes present in both Mor0-2 and Oxy0-6 included GATA3 
and NOG. GATA3 is a transcription factor pivotal in development. Notch-
mediated differentiation of TH2 murine cells has been shown to depend on 
GATA3 [166]; it has been called the master driver of TH2 differentiation and 
its activity, mRNA and protein levels were repressed by glucocorticoid 
administration [167]. The down-regulation of GATA3 could therefore shift T 
cells to a TH1 profile, not in keeping with the suppressed immunity and TH2 
profile hypothesized for morphine, and shown in Chapter 4. The deregulation 
of GATA3 may have been induced by reduced cortisol, which although not 
significantly increased at 6 hour, was not measured at 2 hours (Chapter 4).  
NOG codes for the polypeptide noggin which binds and inactivates members 
of TGF-β family [272] including BMP-4, involved in CD4+ activation and 
proliferation [273]. Down-regulation of NOG would increase activation of 
BMP-4 and proliferation of CD4+ cells, counter to the immunosuppressive 
hypothesis of morphine. No processes involved in RNA translation or 
transcription were enriched in Mor0-2/Oxy0-6 genes; processes were mainly 
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related to lymphocyte activation, response to wounding and apoptosis, 
suggesting that RNA translation processes were unique to Mor0-2.  
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6.6 Conclusion 
In conclusion, based on the consistent deregulation of surgery-related genes 
by all analgesics at 6 hours, the experimental design and microarray analysis 
were successful. This is supported by the scarcity of genes deregulated by 
epidural bupivacaine and the lack of enrichment of statistically significant 
biological processes by this group.  
The morphine-induced gene deregulation discussed in Chapter 3 was 
transient in nature. Enrichment of processes related to RNA translation and 
transcription, apoptosis and cell respiration, suggestive of a morphine-
induced T / NK cell anergy, were present at 2 hours but had disappeared by 
6 hours. The known suppression of lymphocyte proliferation and NKCC 
following morphine administration suggests that the possible anergy leads to 
reduced effector function, as shown by the greater morphine-induced TH2 
shift, and possibly by the reduced morphine-induced NK cell degranulation 
(Chapter 4). However, 25 sustained response genes enriched in processes 
involved in lymphocyte activation were up-regulated at 2 and 6 hours and 
their functional phenotype was not defined.  
Oxycodone shows a limited effect on lymphocyte gene expression at 2 hours, 
and processes enriched in up-regulated genes at six hours - related to 
response to wounding, lymphocyte activation and apoptosis - are suggestive 
of an active immune response. The gene up-regulation and consequent 
process enrichment may be prolonged, possibly starting shortly after 2 hours 
post-induction and ending as late as just before 24 hours. In contrast, the 
timepoint design of the study confirmed that the morphine-induced gene 
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deregulation was mainly transient and possibly induced by receptor 
desensitisation as a result of the intraoperative morphine bolus.
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 Chapter 7 
Discussion and future work 
Evidence of morphine-induced immunosuppression may have been 
accumulating as early as the mid-16th century, following the death of a 
malaria patient given an experimental opium dose [7]. In the 1800s, 
infections linked to recreational opium use were described, while dogs given 
high morphine doses were seen to be susceptible to Diplococcus lanceolatus 
[7]. More recently, a plethora of animal data relating morphine to 
immunosuppression has been published [9, 40, 44, 55, 56, 65, 104]. 
However, the reliability of human in vivo data is limited by the difficulty of 
controlling for confounding factors inherently present in clinical research [37, 
66, 67], which may account for the relative scarcity of prospective human 
clinical research. This study aimed to investigate possible morphine-induced 
immunosuppression by analysing gene expression of lymphocytes taken from 
patients undergoing gynaecological surgery. The study design limited the 
effect of confounding factors and the results of gene expression analysis were 
confirmed with functional assays.  
The initial analysis of gene deregulation following ANOVA identified a maximal 
effect of morphine on lymphocyte gene expression 2 hours after initial 
analgesic administration, whereas oxycodone’s maximal effect was at 6 
hours. Morphine-induced genes were mainly down-regulated but those 
induced by oxycodone were mainly up-regulated. Processes categorised as 
RNA transcription and translation, apoptosis and cell respiration were 
enriched in morphine-induced genes while mitochondria were the most 
commonly seen enriched cellular component. In contrast, processes enriched 
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in oxycodone-induced genes were classified as response to wounding, 
lymphocyte activation and apoptosis; enriched cellular components were 
almost entirely restricted to the plasma-membrane. The process enrichment 
and vector of change of morphine-induced genes suggests reduced cellular 
activity, while the opposite is suggested by oxycodone-enriched processes. 
Reduced activity of CD4+, CD8+ and NK cells intra-operatively following 
morphine administration would reduce cell-based immunity, allowing tumour 
cells to survive, and, in tumour resection surgery, could increase the 
likelihood of metastatic spread due to malignant cell shedding [274].  
Previous research suggests that morphine may induce an immune shift from 
cell-mediated (TH1) to humoural-mediated (TH2): it decreased IL-2 
production and proliferation in splenocytes [31], reduced PHA-stimulated 
proliferation in T cells [48] and IL-2 production in T cells [56]. Several genes 
uniquely deregulated by morphine are indicative of a reduction in cell-based 
immunity: CD28, LCK and TRAC down-regulation suggest a dysfunction of 
the immunological synapse. CD28 is present constitutively on CD4+ and 
CD8+ cells and is a co-stimulant for T cell activation, enhancing TCR effects 
[119]. CD28-/- mice showed a lack of T cell expansion upon antigen 
stimulation, reduced TH cell differentiation and increased TH2 cytokine 
expression [120]; down-regulated CD28 may therefore induce a TH2 shift.  
LCK is a tyrosine kinase that phosphorylates tyrosine in the CD28 cytoplasmic 
tail [124], localising with TCR or CD4+ in the central SMAC of CD8+ or CD4+ 
cells respectively [125, 275]. Phosphorylation initiates protein interactions 
and the downstream signalling cascade that result in CD28’s co-stimulatory 
functions [276]. TRAC (T cell receptor α constant) codes for the constant part 
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of TCR’s α subunit, an essential part of the TCR; a splicing mutation produces 
reduced αβ TCR chain expression causing an inherited immunodeficiency 
disorder [126]. The down-regulation of CD28 and LCK would therefore inhibit 
CD28’s ability to act as a co-stimulant, while TRAC down-regulation would 
prevent TCR function; together these suggest a T cell immune synapse 
dysfunction and a reduction in cell-mediated immunity.  
AQP3, a transmembrane protein transporting water and glycerol, was highly 
down-regulated by morphine and was expressed in activated but not 
inactivated T cells from healthy PBMCs [139]. It mediates H2O2 transport in 
mice, needed for activation of CDC42, essential for T cell migration towards 
chemokines [140]. A similar effect of AQP3 in humans may result in a shift 
from a TH1 profile by disrupting T cell migration and activation. PGLYRP1 
(peptidoglycan recognition protein 1) was uniquely up-regulated by morphine 
and is a bacteria pattern receptor. PGLYRP1 (-/-) mice showed fewer TH2 and 
TH17 cells in the lungs following house dust mite sensitisation [147, 148]; a 
similar effect in human T cells is consistent with a TH2 shift.  
A cytometric bead array, performed to confirm the possible morphine-induced 
TH2 shift, showed an increase from baseline for IL-6 and IL-10 [190]. The IL-
6 increase was statistically significant in all treatments, suggesting a surgery-
induced change [186, 187] but highest in the morphine group. Gene 
deregulation results supported this increase, with IL1R2 mRNA levels also 
increased by all analgesics at 6 hour: increased blood IL1R2 and IL-6 levels 
were associated in an epidemiological cardiac risk factor study [188]. As 
IL1R2 is a decoy receptor antagonizing IL-1 and therefore again indicative of 
a TH2 shift, its deregulation is consistent with the TH2 shift shown by 
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increased IL-6; in addition IL-6 may specifically be involved in a TH2 shift 
[190]. 
The higher IL-6 levels for morphine patients suggest an additional influence 
of morphine on IL-6, seen previously following morphine administration in 
rats [189]. IL-6 is a pleiotropic cytokine induced following infection or injury 
[277]; higher levels are linked to worse outcomes in burn [278] and sepsis 
[279, 280]. Its expression levels are also influenced by genetic diversity 
[281] although this was not investigated. IL-6 induces lymphocyte activation 
and acute phase protein synthesis when appropriately stimulated but is also 
a mediator of the initial systemic inflammatory response syndrome (SIRS) 
that can occur following acute injury or inflammation [278]. It has also been 
shown to increase with VEGF following colon cancer resection [282]; VEGF 
was not assayed but an increase, if it existed, could turn on the angiogenic 
switch in tumour micro-metastases [283], increasing the likelihood of tumour 
microfragments successfully metastasising.  
A systematic review suggested that the mean IL-6 levels of this study were 
similar to mean peak concentrations following other moderate surgery, but 
also that peak levels are reached at 18-24 hours [284]. An additional 
measurement of IL-6 concentration at 24 hours would therefore be useful 
and may show an even greater increase from baseline. The lower levels of 
IL-6 produced following oxycodone and bupivacaine administration indicates 
a lesser TH2 shift, and may reduce the likelihood of patients developing SIRS 
and improve outcomes especially if linked with lower levels of VEGF.  
IL-10 levels significantly increased only in the morphine group, to values 
lower than previously seen following less invasive laparoscopic 
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cholecystectomies [285]. IL-10 is an anti-inflammatory cytokine produced by 
TH2 cells and needed for a normal inflammatory response [192]. It negatively 
regulates the production of TH1 cytokines [193-195], consistent with a shift 
to a TH2 profile. Previous murine data of the effect of morphine on IL-10 both 
supports a morphine-induced increase [197] and is discordant with it [198]. 
Increased IL-10 increases CD8+ cells and their cytolytic ability in vitro, 
increases infiltration and activation of intra-tumour CD8+ cells and increases 
cytolytic activity of NK cells [286]. An increase in IL-10 may therefore not be 
consistent with the hypothesis of morphine-induced immunosuppression, 
although is consistent with a TH2 shift. It may be relevant that IL-10 levels 
were similar in all treatments at 6 hour.  
Downstream, increased IL-10 could up-regulate the metalloprotease ADAM9 
as shown previously in IL-10-stimulated PBMCs [215] and in this study by 
morphine and oxycodone gene expression data. ADAM17 induces CD16 
shedding in NK cells; a similar function of ADAM9 could introduce a refractory 
period in NK cells [214], potentially reducing NKCC as seen previously 
following morphine administration [29-31, 41, 287]. The greater increase in 
mean IL-6 and IL-10 concentrations confirms a larger TH2 shift in morphine 
patients, with associated poorer prognosis due to an increased risk of SIRS 
and metastatic spread. It would be interesting to perform an additional CBA 
at 2 and 24 hours, with the addition of VEGF and other angiogenic factors, to 
investigate timing of the peak TH2 shift. A peak may have occurred at 2 hours 
- the time of morphine’s maximal effect on gene deregulation, or at 24 hours 
as suggested by previous surgical data.  
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The greater morphine-induced TH2 shift would move morphine patients away 
from cell-mediated and towards antibody-mediated immunity. Morphine 
administration has also been shown to reduce NKCC, consistent with the 
reduced IL-2 element of a TH2 shift [288, 289]. Reduced IL-2 was not 
demonstrated in this study, but may have been present at the non-assayed 
2 hour timepoint. Specific gene deregulation also suggests reduced NKCC 
induced by morphine, with the opposite effect induced by oxycodone. MICB, 
a ligand for the NKG2D receptor needed for NKCC, was down-regulated by 
morphine while STAT3, which decreases NKG2D receptor expression when 
ablated / mutated, was up-regulated by oxycodone [161].  
The NK cell degranulation assay performed was inconclusive at baseline: 
opioid samples failed to degranulate effectively, and bupivacaine samples did 
not show a significant increase following degranulation. With the 6 hour 
timepoint viewed as a separate experiment, all samples degranulated 
effectively and oxycodone samples showed a statistically significant increase. 
As removal of the outlier (Figure 4.5) removed oxycodone’s statistical 
significance due to the small sample size, the assay needs further validation 
and should be repeated with more numerous samples. However, the results 
as they stand are not discordant with the hypothesis, with morphine showing 
reduced NKCC compared to oxycodone. The assay could also be repeated at 
2 hour – the timepoint at which morphine exerted its maximal gene 
deregulatory effect – to determine if reduced NK cell cytotoxicity was also 
seen at this timepoint.  
Reduced NKCC can be indicative of anergy in NK cells [290-292]. Anergy is a 
functional inactivation of cells normally induced by persistent antigen 
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exposure, leaving cells hyporesponsive, also occurring in T cells [245-247] 
where it has been defined as the inability of antigen specific T cells to produce 
IL-2 and clonally expand [293]. Reduced IL-2 production, not demonstrated 
in this study, also suppresses NKCC [288, 289] and is consistent with the TH2 
shift suggested here. Enriched processes in morphine-induced genes may 
reflect cell anergy. The down-regulation of RNA transcription and translation 
and cell respiration may reflect reduced T and NK cell clonal expansion; 
reduced cellular activity results in decreased protein translation [168]. A 
concomitant decrease in apoptosis is supported by previous work in which T 
cells activated by CTLA-4 to induce anergy also showed reduced apoptosis 
via the PI 3K-PKB/AKT anti-apoptotic pathway [245]. Mitochondria are the 
most commonly seen enriched cellular components, again supportive of a 
hypothesis of increased anergy. None of the above processes were enriched 
in genes deregulated by oxycodone, but those enriched - response to 
wounding, lymphocyte activation and apoptosis – are suggestive of increased 
cell activation rather than anergy.  
Several deregulated genes are supportive of the theory of anergy. CD28 and 
SOCS1 were uniquely down-regulated by morphine and have previously been 
shown to have lower expression in anergic compared to active murine T cells 
[294]. LCK and TRAC, discussed above, were also uniquely down-regulated 
by morphine and may contribute with CD28 to a dysfunctional T cell immune 
synapse and reduced cellular activity. RCAN3, inhibitor of calcineurin, was 
one of the most strongly down-regulated genes by morphine. Sustained 
calcineurin activation is linked to anergy; in murine T cells, it up-regulated 
ubiquitin ligases and TSG101, a receptor involved in sorting 
monoubiquitinated proteins for degradation and producing unstable synapses 
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[137]. The down-regulation of RCAN3 would encourage the sustained 
activation of calcineurin and subsequent T cell anergy.  
Functionally, increased anergy of lymphocytes in the intraoperative period 
would result in the reduced cytotoxic ability of CD8+ and NK cells, and a 
reduced ability of CD4+ cells to expand into effector cells. In vulnerable 
tumour resection patients, these changes could increase the likelihood of 
dispersed tumour microfragments, known to be disseminated after surgery 
[274], resulting in metastases. The increased lymphocyte activation that may 
be induced by oxycodone post-operatively would have the opposite effect and 
may protect against metastatic spread in tumour resection surgery. This is 
not confirmed by our data; further work could investigate reduced cytotoxic 
ability of CD8+ cells, reduced cytotoxic ability of NK cells in a larger sample, 
and any reduced expansion ability of CD4+ cells. This could be assayed in 
both cancer and non-cancer patients, and the 2 hour timepoint should be 
included.  
Both immune parameter changes induced by morphine - the stronger TH2 
shift and the possible decreased NKCC, are supported by previous data [29-
31, 48, 56] and by pathway down-regulation in enriched morphine genes. All 
changes are suggestive of increased anergy. Statistical analyses, performed 
to evaluate the relative importance of individual genes that may mediate 
these parameter changes, did not find those identified previously through 
gene expression analysis to be predictive of treatment with either opioid. 
However, other relevant genes were predictive of treatment using logistic 
regression (LR).  
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AGPAT3, TIAM1 and TPK1 were predictive of morphine treatment, confirmed 
through ROC analysis. AGPAT3 is an acyltransferase involved in the 
phospholipid biosynthetic pathway. Its down-regulation would increase 
lysophosphatidic acid and decrease its product phosphatidic acid; the latter 
is needed for lymphocyte proliferation [217]. Morphine-induced down-
regulation of AGPAT3 could therefore reduce T cell proliferation, consistent 
with increased T cell anergy and a TH2 shift. Increased 
lysophosphatidylcholine (lysophosphatidic’s precursor) could enhance the 
suppressive qualities of TRegs, via increased TGF-β production, as shown 
previously [218]. Lipid biosynthetic pathways were enriched in unique 
morphine-induced genes at 6 hour so any suppression of fatty acid production 
induced by morphine at 2 hour may be transient.  
TIAM1 is involved in protrusion formation in the leading edge of T cells with 
RAC1 [226]. The down-regulation of TIAM1 could reduce the ability of T cells 
to form a leading edge and subsequently migrate, again suggesting increased 
T cell anergy. TPK1 is an enzyme whose end-product, thiamine 
pyrophosphate, is involved in ATP synthesis; TPK1 down-regulation may 
therefore be involved in mediating the reduced cell respiration suggested 
through enriched pathways, subsequently increasing cell anergy. The down-
regulation of all 3 genes is supportive of increased anergy and reduced cell 
respiration induced by morphine. Their ability to predict morphine treatment 
at 2 hours, the key timepoint for morphine-induced gene deregulation, 
suggests that they may be important in mediating increased anergy.  
OSCAR and MCL1 predicted oxycodone treatment using LR, confirmed 
through ROC analysis. OSCAR is an osteoclast-associated receptor that 
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associates with FcRy to promote cell activation and phagocytosis of opsonized 
cells [236]. A similar effect of OSCAR in lymphocytes could increase T cell 
activation or induce increased phagocytosis by macrophages. MCL1 is an anti-
apoptotic regulator, induced after TCR stimulation in murine T cells [241] 
whose predictive ability at 24 hour suggests successful T cell activation has 
occurred. Its overexpression in CD8+ cells of virally-infected mice increased 
differentiation of terminal effector and effector memory cells [242]; its up-
regulation in this study indicates previous TCR stimulation and suggests an 
increased ability of CD8+ cells to respond to antigen.  
GATA3 and BACH2, highly deregulated, were significant for oxycodone 
treatment following ROC analysis. BACH2 was uniquely down-regulated by 
oxycodone and may mediate a TH1 shift supportive of an improved outcome, 
indirectly via a decrease in GATA3 [167]. BACH2 -/- mice showed repressed 
lineage-specific genes, including GATA3 [165]: GATA3 drives TH2 
differentiation [167] and was down-regulated not only by oxycodone but also 
by morphine, discordantly with the theorized morphine-induced TH2 shift.  
The potential of genes as predictive biomarkers is dictated by the timepoint 
at which they are predictive of treatment; the 24 hour predictive ability of 
MCL1 precludes it as a biomarker whereas the predictive ability of OSCAR at 
baseline suggests it has potential. AGPAT3, TIAM1 and TPK1 are all predictive 
at 2 hour and therefore may not be precluded as biomarkers. OSCAR, 
AGPAT3, TIAM1 and TPK1 could be investigated further as biomarkers of 
opioid-induced gene deregulation and subsequent immunosuppression. 
Cortisol is a glucocorticoid coordinating inflammation, stress and immune 
responses [177], whose levels are altered by morphine administration [178-
Mary Elizabeth Demopoulos Discussion 
© Mary Demopoulos 2010-2017 232
182] and by surgery [50, 183]. The glucocorticoid receptor can act as a 
transcriptional regulator [184]; several deregulated genes of this study 
(GATA3, CD28, CD163, LPL and FLT3LG) have been previously associated 
with changes in cortisol levels. However, the 6 hour increase in cortisol 
concentration seen was not significant and the largest increase was seen in 
bupivacaine patients, followed by morphine. It would be interesting to assay 
cortisol concentrations at 2 hours, as this was the time of morphine’s maximal 
response on gene deregulation. It may also be the time of peak postoperative 
cortisol levels, possibly present between 0 and 4 hours (systematic review: 
[284]) at a higher level than measured in this study. The non-significant 
levels found may therefore be due to assay timing missing the peak 
concentration, which could potentially have influenced gene deregulation.  
FLT3LG was down-regulated by both morphine and bupivacaine and is a 
cytokine needed for expansion of lymphoid lineages [203]. It is up-regulated 
in patients with Graves’ disease [201], a condition in which low cortisol can 
be found; the down-regulation of FLT3LG could be related to the increased 
cortisol levels seen in these treatments. Cortisol shifts CD4+ cells to a TH2 
profile in the absence of CD28 [123]; CD28 was down-regulated by morphine 
in this study, suggesting that cortisol could contribute to the morphine-
induced TH2 shift, especially if it reached statistical significance at the non-
assayed 2 hour timepoint. The degree of influence of cortisol on gene 
deregulation is unknown and an additional 2 hour assay should be performed. 
However, as the largest 6 hour cortisol increase was induced by bupivacaine, 
the group with the fewest deregulated genes, cortisol is unlikely to be highly 
influential on gene deregulation in this study.  
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The design of the study removed most confounding factors. Non-compliant 
patients administered more than 1 analgesic were withdrawn, keeping 
analgesic groups separated; previous studies have not done this [66, 67]. 
The high number of resultant withdrawals meant that mRNA of only 40 
patients underwent microarray analysis. Non-cancer surgery removed 
immune-modulating disease processes consistently identified in many cancer 
types, for example changes in T cell gene expression in follicular lymphoma 
[109], abnormal genotype and immune synapse formation in AML [295] and 
features of T cell exhaustion in CLL patients [110]. All groups were BMI, age, 
operation duration, pain and sex-matched and opioid use was matched 
between opioid groups with no significant difference in mean doses. 
Anaesthetic was propofol-only therefore excluding those anaesthetics 
previously found to alter immune parameters, such as fentanyl or ketamine 
which reduce NKCC [68, 69] or levobupicacaine which has a different cytokine 
profile to sevofluorane and morphine [77].  
The pattern of gene deregulation confirmed a successful study design. Ten 
genes were deregulated by all treatments at 6 hours. CD163 was up-
regulated and is an acute-phase regulated receptor involved in macrophage 
haemoglobin clearance, present in plasma after surgery [113] and up-
regulated in monocytes following cortisol [115] and IL-10 administration 
[114]. IL1R2, a decoy receptor for IL-1, was up-regulated together with 
related gene IRAK3. These genes all suggest an inflammation-modifying 
response, consistent with a surgery-induced response. Epidural bupivacaine 
deregulated only 20 unique genes with no statistically significant enriched 
processes following overrepresentation analysis, suggesting that epidural was 
an effective non-immunomodulatory control analgesic. These gene 
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deregulation changes were all indicative of a study design that successfully 
removed confounding factors.  
However, the small number of patient samples available for gene expression 
limited the microarray analysis. At the time of patient recruitment, 
myomectomies were moving from predominately open to predominantly 
laparoscopic surgery, hindering recruitment. The recombination of mRNA 
from 3 cell sub-types for hybridisation to arrays was caused by financial 
constraints and prevented gene deregulation analysis assigning each 
deregulated gene to a specific cell type. In any future study, mRNA would 
ideally not be recombined, allowing mechanisms to be elucidated more easily. 
qRT-PCR is normally performed on highly deregulated genes to confirm the 
results of gene expression array; this was not performed due to time and cost 
constraints, but could be added in a future study.  
NK cell degranulation was only performed on a small number of samples due 
to time and cost constraints. Some publications suggest that increased 
degranulation exists with impaired cytotoxicity [216] so direct cellular 
cytotoxicity could be investigated using the 51chromium-release assay, not 
degranulation, with more numerous samples. The assay could be repeated 
with 2 and 24 hour as additional timepoints. Enriched pathways suggest that 
CD8+ cytotoxicity may also have been affected by morphine and therefore 
cytotoxicity could be measured in these cells using either the degranulation 
or 51chromium-release assays [296].  
The failure of baseline opioid samples to degranulate successfully following 
stimulation may be related to a difference in patients’ clinical characteristics: 
of patients used for NK degranulation, fewer bupivacaine patients underwent 
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open myomectomy; remaining operation types were (sub)total hysterectomy 
± BSO and debulking. Hysterectomy is usually performed to resect fibroids if 
preservation of fertility is not necessary [297] or if a multifibroid uterus is 
present (although fibroid number / size data was not collected). The higher 
number of TAH in bupivacaine patients therefore suggests possibly more 
patients with multifibroid uteri. Fibroids develop due to an abrogation of 
normal NKCC [298, 299] or an in vivo environment richer in oestrogen and 
therefore more suppressive to NK cells [300]; removal of NK cells from the 
suppressive in vivo environment may result in increased NKCC in vitro. This 
effect may be seen more strongly in those cells initially more strongly 
suppressed, ie those from patients who underwent more radical surgery due 
to multifibroid uteri. The successful baseline degranulation for bupivacaine 
samples may therefore be explained by greater initial suppression of NKCC 
in vitro, and underlines the importance of using as near-identical patients as 
possible for this assay. Patients were matched in all other parameters.  
Five cytokines failed to reach the theoretical level of detection on CBA; an 
ELISA, with slightly lower cytokine detection levels, could be performed as an 
alternative to CBA. The later timepoint of 6 hour was chosen as previous 
research suggested that changes would still be present [86]; however, as 
with NK cell degranulation, 2 and 24 hour timepoints could be added to 
investigate peak TH2 shift. Additional timepoints could also be added to the 
cortisol ELISA to investigate the time of peak concentrations.  
Although it is clear that morphine has an effect on lymphocyte gene 
deregulation, the mechanisms and effects of this are unknown. Morphine 
primarily activates the μ-opioid receptor (MOR): its metabolite morphine-6-
Mary Elizabeth Demopoulos Discussion 
© Mary Demopoulos 2010-2017 236
glucuronide (M6G) is a strong MOR agonist [301] which may be almost wholly 
responsible for the analgesic effects of morphine [302]. M6G may contribute 
to gene deregulation; it induced antinociception and reduced immune 
parameters (T cell proliferation, serum IgM and IgG) in patients with 
advanced cancer [12] and decreased NKCC, lymphocyte proliferation and 
IFN-γ production in rats [303]. M6G levels were not measured in this study.  
The failure of oxycodone to induce immunosuppression is most likely due to 
a different receptor binding profile. Oxycodone, morphine and M6G all showed 
unique analgesia, respiratory depression and constipation activity profiles 
following intracerebroventricular administration in rats [93], radioligand 
binding studies suggest that oxycodone is a κ-opioid receptor (KOR) agonist 
with a weak affinity for MOR [94], and a murine bone cancer model showed 
reduced MOR-agonist but not oxycodone binding, suggesting that oxycodone 
does not bind strongly to MOR [304]. Activation of KOR by oxycodone may 
not cause immunosuppression, but based on the results of this study, could 
increase T cell activation and NKCC. The relationship of KOR versus MOR to 
immunosuppression could be investigated further with the use of selective 
antagonists in a future study.  
Functional selectivity describes the ability of a ligand to induce unique 
intracellular responses through conformational receptor changes [18]. This 
has been described at various levels of activation for the MOR [305] and could 
explain the unique immunomodulatory profile of oxycodone, if it does 
primarily activate MOR. Morphine and M6G induced analgesia in mice that 
was blocked by a JNK inhibitor, suggesting that opioid analgesic tolerance is 
induced via a JNK-dependent pathway; oxycodone-induced analgesia was not 
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blocked in this way [19]. Morphine and fentanyl caused MOR desensitization 
via two separate pathways, activating JNK either without the need for 
arrestin, or arrestin-dependently, respectively [20], another example of 
functional selectivity. These suggest that even if oxycodone primarily 
activates MOR, not KOR, functional selectivity could enable differing 
immunomodulatory effects.  
Opioid receptors exist on T cells [58] and opioids have been shown to induce 
immunomodulatory effects both in vivo [12, 40, 44, 55, 56, 65, 105] and in 
vitro [30] [64]. Immunomodulation could therefore be activated peripherally; 
if this is the case, the superior ability of oxycodone to cross the blood brain 
barrier [1] may produce relatively lower peripheral plasma levels of 
oxycodone, reducing any potential immunosuppression.  
The duration of gene expression changes is relevant to the clinical 
translational relevance of these results. 450 mainly down-regulated unique 
genes were deregulated by morphine at the intraoperative 2 hour timepoint, 
and 113 genes (17 unique) deregulated at 6 hour. Twenty-five genes showed 
a sustained deregulation from 2 to 6 hour, suggestive of an early recovery of 
immunosuppression; 6 hour genes were almost all up-regulated and enriched 
in the same processes as oxycodone at 6 hour: response to wounding, 
lymphocyte activation and apoptosis, all suggesting increased lymphocyte 
activation. The shift from a total of 434 down-regulated genes at 2 hour to 2 
down-regulated genes at 6 hour suggests that morphine-induced 
immunosuppression may be mainly transient. In contrast, the gene 
deregulation induced by oxycodone began at 2 hour with just 3 genes (also 
deregulated by morphine) then increased to deregulation of 460 unique, 
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mainly up-regulated, genes at 6 hour, ending with deregulation of just 1 gene 
at 24 hour. The absence of a venepuncture timepoint between 6 and 24 hours 
means that the duration of the majority of oxycodone-induced gene 
deregulation is unknown, but may begin between 2 and 6 hours and not end 
until just before 24 hours.  
The difference in duration of opioid-induced gene deregulation is surprising 
as their half-lives are similar [1, 97] and all analgesics were administered 
similarly and continuously. The initial intraoperative bolus was followed by 
slower postoperative patient-controlled analgesia (PCA) dosing with a 
maximum dose of 1 mg per 6 min. There was no statistically significant 
difference between the means of total opioid doses. Therefore, the initial 
bolus may account for the morphine-induced gene deregulation at 2 hours; 
bolus ranges were similar but the initial oxycodone bolus induced the 
deregulation of only 3 non-unique genes, compared to the 450 unique genes 
induced by the morphine bolus. It is possible that the bolus produced MOR 
desensitisation and a subsequent reduction of lymphocyte gene transcription. 
MOR desensitisation was seen previously following morphine but not 
oxycodone administration using radiotagged MOR in mice brain slices [255]; 
desensitisation is independent of internalisation and was also seen in AtT20 
tumour cells following morphine administration [306]. It is likely that 
oxycodone primarily activates KOR and that immunosuppression is mediated 
by MOR, as suggested by previous publications.  
The dynamics of the gene deregulation results suggest that it may be possible 
to avoid morphine-induced gene deregulation by replacing the initial 
intraoperative morphine bolus with oxycodone or epidural bupivacaine, and 
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thereafter utilising the cost effectiveness of morphine via PCA. The 
disadvantages of morphine-induced gene deregulation were confirmed 
through the TH2 shift and possible reduced NKCC seen, which should be 
confirmed at more timepoints and, for NKCC, with more samples. A non-
morphine intraoperative bolus would be particularly suitable in vulnerable 
patients, such as those undergoing tumour resection surgery, where reduced 
cell-mediated immunity should be avoided as tumour microfragments are 
known to be dispersed after surgery.  
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7.1 Future work 
Additional experiments could be performed to confirm the gene expression 
analysis and its functional translation relevance. Gene expression analysis 
should initially be confirmed via qRT-PCR of the most highly deregulated 
genes at each timepoint. The duration of oxycodone-induced gene 
deregulation is not known due to venepuncture timepoint spacing, so it would 
be ideal to repeat the gene expression analysis with another timepoint 
between 6 and 24 hour.  
The maximal effect of morphine on lymphocyte gene expression was at 2 
hour post initial analgesia administration: cytokine and cortisol ELISAs should 
be performed at 2 hour to more clearly determine the functional relevance of 
the morphine-induced gene deregulation. Individual ELISAs rather than CBA 
could be performed as these have cytokine-specific theoretical levels of 
detection. In addition, VEGF could be assayed and a 24 hour timepoint added 
for all cytokines, as this may be the time of peak IL-6 concentrations.  
NKCC should be investigated directly by performing a 51chromium-release 
assay, as increased degranulation may exist with impaired NKCC. It should 
be investigated additionally at 2 hour as well as the original timepoints, using 
patients undergoing identical surgery where possible. Cytotoxic CD8+ cells 
were not degranulated but should be also assayed for cytotoxicity using the 
same 51chromium-release assay.  
Several genes may be key to mediating opioid-induced immunomodulation. 
mRNA levels may not reflect protein levels but protein levels produced by 
selected genes could be measured via Western blot to investigate any 
correlation. CD28, AGPAT3, TPK1 and TIAM1 may mediate morphine-induced 
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changes at 2 hour and OSCAR may mediate oxycodone-induced changes at 
6 hour: gene expression results should initially be confirmed with qRT-PCR, 
then protein levels measured via Western blot.  
An effect on the T cell immunological synapse is possible as indicated by the 
deregulation of srGAP2, CD28, LCK and TRAC by morphine and the increase 
in anergy suggested by enriched pathways. Based on the importance of the 
synapse, an assay could be performed to investigate the presence of an 
impaired immunological synapse in CD4+ and CD8+ cells treated with 
morphine. It is also possible that a dysfunction could produce the reduced 
degranulation that may be seen in NK cells treated with morphine. Morphine-
treated and control lymphocytes could be incubated with target cells then live 
cell imaging performed using electron microscopy for 6 hours to detect 
synapse formation. Reduced T cell proliferation or NKCC could then be 
corroborated with faulty synapse formation.  
The role of anergy in morphine-induced immunosuppression could be 
investigated by determining the cellular response of morphine- versus 
oxycodone-treated T cells to anti-CD3 and anti-CD28 stimulation beads, and 
measuring IL-2 production and proliferation using CFSE staining in 
conjunction with flow cytometry.  
It is possible that morphine induces gene deregulation peripherally; the in 
vitro addition of morphine or oxycodone to donor lymphocytes may induce 
deregulation of the genes discussed above and this could be investigated via 
qRT-PCR. Finally, CD8+ and NK cells treated with morphine or oxycodone 
could be analysed via flow cytometry to investigate shedding of cell surface 
CD16 and concomitant deregulation of MMP or ADAM genes via qRT-PCR.  
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 Chapter 8 
Conclusion 
The results of this study support the prior knowledge of morphine-induced 
immunosuppression, demonstrated via the intraoperative deregulation of 450 
unique genes in study patients treated with morphine. In contrast, those 
receiving oxycodone showed a postoperative deregulation of 460 unique 
genes, while patients receiving epidural bupivacaine experienced 
deregulation of only 20 lymphocyte genes. Processes indicating a possible 
increase in lymphocyte anergy were transiently enriched by morphine genes 
at 2 hours. In contrast, processes postoperatively enriched by oxycodone 
genes indicated a prolonged normal inflammatory and immune response to 
surgery, with no change in cell anergy. Genes predictive of morphine or 
oxycodone were linked to decreased or increased anergy respectively and 
should be investigated further as possible predictive biomarkers.  
Functional assays indicated that cortisol is unlikely to have influenced gene 
deregulation as no treatment induced a statistically significant difference in 
cortisol concentration from baseline. However, any influence of cortisol on 
gene deregulation could be further investigated at an additional 2 hour 
timepoint. Morphine showed the greatest increase in serum IL-6 and IL-10 
concentrations from baseline, suggesting a greater morphine-induced TH2 
shift that could be responsible for functional changes seen previously, such 
as reduced lymphocyte proliferation. This was corroborated by gene 
expression analysis with the unique down-regulation of genes including 
CD28, TRAC, LCK and AQP3. Further clarity on the degree of the TH2 shift 
may be obtained by additional cytokine assays at 2 and 24 hours, the 
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respective timepoints of morphine’s maximal effect on lymphocyte gene 
deregulation and the possible peak postoperative IL-6 concentration. The 
degranulation assay of this study did not disprove the hypothesis of 
morphine-induced reduced NKCC but should be repeated with more samples 
for confirmation.  
In this study, morphine induced gene deregulation suggestive of increased 
lymphocyte anergy in the intraoperative period, confirmed functionally via a 
TH2 shift. This may be a result of MOR desensitisation and subsequent 
decreased gene transcription induced by the intraoperative bolus. As similar 
gene down-regulation was not induced by intraoperative oxycodone or 
bupivacaine, it could be removed by using either of these analgesia as an 
intraoperative bolus. A non-morphine bolus would be especially beneficial for 
tumour resection patients, who would be vulnerable to metastatic spread if 
subjected to reduced cell-mediated immunity or increased lymphocyte anergy 
at the time of possible tumour microfragment dispersal.  
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 Appendix A 
Table 9.1: Demographic data for all patients at the time of study enrolment 
Subject 
No BMI Age Ethnicity Treatment 
Surgery 
duration 
(hh:mm) 
Surgery performed 
Opioid 
dose 
(mg) 
1 24 43 Caucasian Morphine 02:15 Open myomectomy 27 
2 24 45 Other Morphine 03:50 Open myomectomy and hysteroscopy 34 
3 25 34 Black Oxycodone 02:35 
Open myomectomy 
+ right partial 
salpingectomy for 
adhesions on tube 
33 
4 19 49 Caucasian Morphine 02:15  25 
5 24 43 Asian Oxycodone 01:50  25 
6 22 32 Oxycodone Open myomectomy 29.2 
7 26 41 Black Morphine 02:50   
8 32 40 Black Oxycodone   
9 25 38 Asian Oxycodone 01:40 
myomectomy and 
laparatomy 21 
10 28 35 Asian 01:55  28 
11 34 33 Black 03:00   
12 34 37 Black   
13 20 36 Black Morphine 03:01 Open myomectomy 21 
14 20 37 Caucasian Morphine 02:40  31 
15 21 37 Black Oxycodone open myomectomy 15 
16 36 58 Black 05:00   
17  29 Asian 02:00   
18 24 41 Black Oxycodone 03:04 open myomectomy 17 
19 22 49 Caucasian Oxycodone 02:50 
Right salpingo-
oophorectomy 20 
20 42 33 Black Bupivacaine 02:15   
21  40 Asian Morphine 02:30 open myomectomy 15 
22 27 35 Black Morphine 03:15 open myomectomy 23 
23 27 45 Black Oxycodone 02:30 open myomectomy 31 
24 32 43 Black Bupivacaine 02:00   
25 24 34 Asian Bupivacaine 02:30   
26  38 Asian Oxycodone 02:20 open myomectomy 23 
27 35 45 Caucasian Morphine 03:10   
28 21 30 Black Bupivacaine 01:30   
29 18 38 Asian Oxycodone 02:10 open myomectomy 14 
30 32 48 Other Oxycodone 02:20 
Total abdominal 
hysterectomy 
(non-Pfannenstiel 
incision) 
23 
31 26 40 Black Morphine 02:15 Total abdominal hysterectomy 66 
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32 40 50 Other Bupivacaine 03:00 
Subtotal 
hysterectomy and 
bilateral salpingo-
oophorectomy 
 
33 40 33 Caucasian Oxycodone 02:00 Open myomectomy 20 
34 27 41 Black Oxycodone Open myomectomy 24 
35 29 41 Caucasian Morphine 02:00 
Total abdominal 
hysterectomy with 
conservation of 
ovaries 
41.4 
36 26 47 Caucasian Bupivacaine 01:25 Open subtotal hysterectomy  
37 30 43 Black Bupivacaine   
38  33 Asian Bupivacaine   
39 23 45 Black Bupivacaine 02:00 Subtotal hysterectomy  
40 26 44 Asian Morphine 02:00 Open myomectomy 10 
41 37 43 Caucasian Bupivacaine 02:25 
Total abdominal 
hysterectomy and 
bilateral salpingo-
oophorectomy 
 
42 21  Morphine   
43 29 34 Black Morphine  24 
44 32 34 Caucasian Oxycodone 02:00 Open myomectomy 18 
45   Morphine   
46 23 40 Bupivacaine 01:50 Open myomectomy  
47 25 72 Asian Morphine  
Total abdominal 
hysterectomy and 
bilateral salpingo-
oophorectomy 
17 
48 31 37 Caucasian Morphine 02:00 Open myomectomy 30 
49 42 44 Black Oxycodone 01:40 Open myomectomy 30 
50 33 70 Caucasian Morphine Hysterectomy 24 
51 30 36 Caucasian Bupivacaine 01:30 
Open salpingo-
oophorectomy and 
appendectomy 
 
52 25 35 Caucasian Morphine 02:30 Open myomectomy 23 
53 32 55 Caucasian Morphine 02:30 
Laparotomy – 
frozen section and 
debulking 
24 
54 36 60 Caucasian Bupivacaine 03:45 
Total abdominal 
hysterectomy, 
bilateral salpingo-
oophorectomy and 
appendectomy 
 
55 22 38 Caucasian Oxycodone 01:35 
Right salpingo-
oophorectomy and 
appendectomy 
27 
56 22 33 Caucasian Oxycodone 02:30 Open myomectomy 20 
57 23 43 Asian Morphine 01:45 Open myomectomy 23 
 
 
Mary Elizabeth Demopoulos Appendices 
© Mary Demopoulos 2010-2017 264
Table 9.2: Consented versus completed microarray cohort patients for each 
surgical procedure. 
Surgery performed Consented patients Completed patients 
Open myomectomy 24 22 
Total abdominal hysterectomy 
+/- bilateral salpingo-
oophorectomy 
6 6 
Subtotal abdominal 
hysterectomy +/- salpingo-
oophorectomy 
4 3 
Open myomectomy + partial 
salpingectomy for tubal 
adhesions 
1 1 
Right salpingo-oophorectomy 1 1 
Laparotomy – frozen section and 
debulking 1 1 
Salpingo-oophorectomy + 
appendectomy 2 2 
Total abdominal hysterectomy + 
appendectomy 1 1 
 
Table 9.3: Mean age, BMI, operation duration and modal ethnicity for each 
treatment group in microarray patient cohort.  
Treatment 
group N 
Mean 
age Mean BMI 
Operation 
duration (min) Modal ethnicity
Morphine 16 44.9 26.1 151 Caucasian 
Oxycodone 16 38.9 26.7 135 Black 
Bupivacaine 8 45.5 31.1 134 Caucasian 
 
Table 9.4: Distribution of ethnicity for each treatment group in microarray 
patient cohort.  
Treatment 
group N Black Caucasian Asian Other Unknown 
Morphine 16 3 7 4 1 1 
Oxycodone 16 6 5 3 1 1 
Bupivacaine 8 2 4 0 1 1 
 
Table 9.5: Ethnicity for all patients enrolled into the study.  
Ethnicity Number of patients 
Caucasian 18 
Black 20 
Asian 12 
Other 3 
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Table 9.6: Age for all patients enrolled in the study.  
Age range Number of patients 
18-29 1 
30-39 24 
40-49 24 
50-59 3 
60-69 1 
70+ 2 
 
Table 9.7: BMI for all patients enrolled in the study. 
BMI range Number of patients 
<20 2 
20-24 17 
25-29 14 
30-34 11 
35-39 4 
40+ 4 
 
Table 9.8: Statistical data for differences in age, BMI and operation duration 
for all treatment groups in microarray patient cohort.  
 Treatment group N Mean SD Median 25 % 75 % ANOVA KW 
Age Morphine 15 44.9 11.8 41.0 37.0 45 0.11 0.09 
 Oxycodone 16 38.9 5.4 38.0 34.0 43.3   Bupivacaine 8 45.5 7.2 44.0 40.8 49.3 
BMI Morphine 15 26.1 4.1 25.4 23.5 29.8 0.15 0.21 
 Oxycodone 16 26.7 7.0 24.7 21.6 31.6   Bupivacaine 8 31.1 6.3 31.1 24.2 36.9 
Op 
duration Morphine 15 150.0 34.9 150.0 120.0 170.0 0.49 0.38 
 Oxycodone 16 134.9 27.5 140.0 110.0 152.5   Bupivacaine 8 134.4 47.5 120.0 95.0 171.3 
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Table 9.9: Pain scores for all patients enrolled in the study. *Where mild was 
recorded in error rather than a numerical rating, a score of 3 was allocated 
to enable statistical analysis. NK = not known.  
Subject No 0 hr 2 hr 6 hr 24 hr Treatment 
1 0 0 4 4 Morphine 
2 0 0 5 4 Morphine 
3 0 0 2 1 Oxycodone 
4 0 0 2 1 Morphine 
5 0 0 2 2 Oxycodone 
6 0 0 1 3 Oxycodone 
7 0 0 WD WD Morphine 
8 0 WD WD WD Oxycodone 
9 0 8 6 4 Oxycodone 
10 0 0 5 2 Morphine 
11 0 0 5 WD Epidural 
12 0 WD WD WD Oxycodone 
13 0 0 8 1 Morphine 
14 0 0 6 3 Morphine 
15 0 0 1 6 Oxycodone 
16 0 WD WD WD  Not treated 
17 0 WD WD WD Oxycodone 
18 0 0 5 2 Oxycodone 
19 0 1 1 1 Oxycodone 
20 0 4 WD WD Epidural 
21 0 0 1 1 Morphine 
22 0 0 0 0 Morphine 
23 0 0 5 5 Oxycodone 
24 2 0 2 WD Epidural 
25 0 0 1 1 Epidural 
26 0 0 3 4 Oxycodone 
27 0 0 WD WD Morphine 
28 0 0 WD WD Epidural 
29 0 0 0 1 Oxycodone 
30 0 0 8 8 Oxycodone 
31 0 0 7 7 Morphine 
32 0 0 3 4 Epidural 
33 0 0 3 1 Oxycodone 
34 0 0 2 2 Oxycodone 
35 0 5 1 0 Morphine 
36 0 5 7 5 Epidural 
37 0 0 9 WD Epidural 
38 0 0 1 5 Epidural 
39 0 0 2 1 Epidural 
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40 0 0 NK 7.5 Morphine 
41 0 0 8 WD Epidural 
42 0 WD WD WD Morphine 
43 0 0 1 1 Morphine 
44 0 0 2 2 Oxycodone 
45 NK NK NK NK Morphine 
46 0 0 0 2 Epidural 
47 0 0 2 0 Morphine 
48 0 0 0 0 Morphine 
49 0 0 5 2 Oxycodone 
50 0 0 Mild* 5 Morphine 
51 0 0 0 4 Epidural 
52 0 0 3 3 Morphine 
53 0 NK 4 3 Morphine 
54 0 0 7 2 Epidural 
55 0 8 0 5 Oxycodone 
56 0 0 3 0 Oxycodone 
57 0 Mild* Mild* 0 Morphine 
 
 
Table 9.10: Statistical data for differences in pain for all treatment groups 
in microarray patient cohort. (Mor = morphine group, oxy = oxycodone 
group; bup = bupivacaine group) 
Time 
point 
Treatment 
group N Mean SD Median 25 % 75 % ANOVA KW 
0 hr Mor 15 0 0 0 0 0 0.14 0.14 
 Oxy 16 0 0 0 0 0   
 Bup 8 0.25 0.71 0.00 0 0   
2 hr Mor 14 0.57 1.50 0 0 0 0.801 0.89 
 Oxy 16 1.06 2.72 0 0 0   
 Bup 8 0.63 1.77 0 0 0   
6 hr Mor 14 3.36 2.50 3.00 1.00 5.25 0.81 0.87 
 Oxy 16 2.94 2.29 2.50 1.10 5.00   
 Bup 8 3.63 3.25 2.50 0.50 7.00   
24 hr Mor 15 2.57 2.57 0 3.00 4.00 0.88 0.67 
 Oxy 16 2.94 2.21 1.00 2.00 4.75   
 Bup 6 3.00 1.55 3.00 1.75 4.25   
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Table 9.11: Cumulative opioid doses for morphine and opioid patients of 
microarray patient cohort.  
Subject  Cumulative opioid dose 
number Treatment Intraoperative By 2 hr By 6 hr By 24 hr 
1 Morphine 12 12 27 47 
2 Morphine 20 20 34 44 
13 Morphine 10 10 21 30 
14 Morphine 10 10 31 81 
21 Morphine 15 15 15 59 
22 Morphine 12 12 23 44 
31 Morphine 15 15 66 111.4 
35 Morphine 15 15 41.4 56.4 
40 Morphine 10 10 10 12 
47 Morphine 10 10 17 32 
48 Morphine 15 15 30 62 
50 Morphine 10 10 24 56 
52 Morphine 18 18 23 43 
53 Morphine 0 0 24 29 
57 Morphine 16 16 23 25 
3 Oxycodone 15 15 33 42 
6 Oxycodone 10 10 29.2 42.2 
9 Oxycodone 13 20 21 21 
15 Oxycodone 10 10 15 73 
18 Oxycodone 12 12 17 25 
19 Oxycodone 10 10 20 37 
23 Oxycodone 20 20 31 37 
26 Oxycodone 12 12 23 35 
29 Oxycodone 10 10 14 70 
30 Oxycodone 10 10 23 76 
33 Oxycodone 15 15 20 62 
34 Oxycodone 10 10 24 50 
44 Oxycodone 10 10 18 30 
49 Oxycodone 15 15 30 61 
55 Oxycodone 10 10 27 44 
56 Oxycodone 9 9 20 68 
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Table 9.12: Statistical data for differences in cumulative opioid doses 
between morphine and oxycodone groups, for microarray patient cohort.  
 
  
 Treatment  
 Morphine Oxycodone Statistics 
Dose N Mean SD SEM N Mean SD SEM Sig. (2-tailed) 
Intra-op 15 12.53 4.72 1.22 16 11.94 2.98 0.74 0.68 
By 2 hr 15 12.53 4.72 1.22 16 12.38 3.59 0.90 0.92 
By 6 hr 15 27.29 13.19 3.41 16 22.82 5.80 1.45 0.23 
By 24 hr 15 48.79 24.46 6.32 16 48.33 17.77 4.44 0.95 
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Table 9.13: Non-cumulative opioid doses for morphine and opioid patients 
of microarray patient cohort.  
Subject  Non-cumulative opioid doses 
number Treatment Intraoperative By 2 hr By 6 hr By 24 hr 
1 Morphine 12 0 15 20 
2 Morphine 20 0 14 10 
13 Morphine 10 0 11 9 
14 Morphine 10 0 21 50 
21 Morphine 15 0 0 44 
22 Morphine 12 0 11 21 
31 Morphine 15 0 51 45.4 
35 Morphine 15 0 26.4 15 
40 Morphine 10 0 0 2 
47 Morphine 10 0 7 15 
48 Morphine 15 0 15 32 
50 Morphine 10 0 14 32 
52 Morphine 18 0 5 20 
53 Morphine 0 0 24 5 
57 Morphine 16 0 7 2 
3 Oxycodone 15 0 18 9 
6 Oxycodone 10 0 19.2 13 
9 Oxycodone 13 7 1 0 
15 Oxycodone 10 0 5 58 
18 Oxycodone 12 0 5 8 
19 Oxycodone 10 0 10 17 
23 Oxycodone 20 0 11 6 
26 Oxycodone 12 0 11 12 
29 Oxycodone 10 0 4 56 
30 Oxycodone 10 0 13 53 
33 Oxycodone 15 0 5 42 
34 Oxycodone 10 0 14 26 
44 Oxycodone 10 0 8 12 
49 Oxycodone 15 0 15 31 
55 Oxycodone 10 0 17 17 
56 Oxycodone 9 0 11 48 
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Table 9.14: Statistical data for differences in non-cumulative opioid doses 
between morphine and oxycodone groups, for microarray patient cohort. 
 
 
 
 
  
 Treatment  
 Morphine Oxycodone Statistics 
Dose N Mean SD SEM N Mean SD SEM Sig. (2-tailed) 
Intra-op 15 12.53 4.72 1.22 16 11.94 2.98 0.74 0.68 
By 2 hr 15 0 0 0 16 0.44 1.75 0.44 0.34 
By 6 hr 15 14.76 12.69 3.28 16 10.45 5.44 1.36 0.22 
By 24 hr 15 21.49 15.86 4.09 16 25.50 19.71 4.93 0.54 
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 Appendix B 
Table 10.1: RNA quantity and absorbance measured on the Nanodrop 1000 
for all subjects, pre-amplification and pre-fragmentation of RNA. 
 
Pre-amplification  Pre-fragmentation 
RNA 
quantity 
(ng/µl) 
Absorbance 
(260/280) 
RNA 
quantity 
(ng/µl) 
Absorbance 
(260/280) 
Subject Time-point 
Cell 
type 
1 0 CD4 79.5 2 
1193.97 2.13  1 0 CD8 324.9 1.95 
1 0 NK 72.6 1.99 
1 2 CD4 20.7 1.97 
419.70 2.10 1 2 CD8 37.7 1.94 
1 2 NK 241 1.84 
1 6 CD4 16.7 1.85 
691.30 2.11 1 6 CD8 11.6 1.96 
1 6 NK 125.6 1.93 
1 24 CD4 132.5 2.04 
822.70 2.15 1 24 CD8 78 1.98 
1 24 NK 68.2 1.94 
2 0 CD4 59.4 2.1 
795.60 2.15 2 0 CD8 24.7 2.02 
2 0 NK 19.8 2.05 
2 2 CD4 35 2.02 
669.70 2.09 2 2 CD8 19.8 1.97 
2 2 NK 10.2 2.23 
2 6 CD4 22.6 1.98 
1049.10 2.16 2 6 CD8 5.7 1.7 
2 6 NK nk nk 
2 24 CD4 122.9 1.98 
876.20 2.15 2 24 CD8 33.4 2 
2 24 NK 3.30 3.94 
3 0 CD4 15.9 1.73 
2220.70 2.01 3 0 CD8 43.2 2.08 
3 0 NK 12.9 2.68 
3 2 CD4 6.6 2.04 
2262.70 2.00 3 2 CD8 52.3 1.89 
3 2 NK 47.5 1.9 
3 6 CD4 91.2 1.98 
2419.80 1.98 3 6 CD8 34.5 1.98 
3 6 NK 52.5 2 
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3 24 CD4 234.7 2.06 
2768.30 1.94 3 24 CD8 82.6 1.96 
3 24 NK 23.1 2.19 
5 0 CD4 11.2 2.12 
247.80 1.74 5 0 CD8 -0.9 1.63 
5 0 NK -1.5 1.48 
5 2 CD4 2.8 1.55 
597.20 2.14 5 2 CD8 -1.48 1.07 
5 2 NK 2.4 1.54 
5 6 CD4 10.1 1.87 
273.90 2.03 5 6 CD8 -0.8 1.26 
5 6 NK -0.3 -0.25 
5 24 CD4 nk   
403.40 2.06 5 24 CD8 -0.4 0.68 
5 24 NK 0.2 0.32 
6 0 CD4 63.5 2.06 
1707.50 2.08 6 0 CD8 32.6 1.92 
6 0 NK 63.6 16.58 
6 2 CD4 22.9 2.09 
977.90 2.11 6 2 CD8 14.1 2.23 
6 2 NK 51.9 5.53 
6 6 CD4 8.9 2.31 
1127.50 2.09 6 6 CD8 7 2.18 
6 6 NK 20.7 6.69 
6 24 CD4 150.5 2.08 
2331.10 2.00 6 24 CD8 40.4 2.03 
6 24 NK 18.1 11.08 
9 0 CD4 24.4 1.8 
1016.44 2.08 9 0 CD8     
9 0 NK     
9 2 CD4 44.76 2.13 
2503.93 1.97 9 2 CD8     
9 2 NK     
9 6 CD4 33.85 2.43 
2238.35 1.99 9 6 CD8     
9 6 NK     
9 24 CD4 62.62 2.21 
1723.40 2.01 9 24 CD8     
9 24 NK     
13 0 CD4 61.17 5.9 
1113.20 2.16 13 0 CD8 21.88 2.96 
13 0 NK 20.35 3.13 
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13 2 CD4 14.51 6.15 
1315.63 2.14 13 2 CD8 15.82 3.15 
13 2 NK 30.09 2.38 
13 6 CD4 21.6 3.12 
974.68 2.20 13 6 CD8 34.08 8.72 
13 6 NK 56.24 4.11 
13 24 CD4 39.13 2.5 
2156.56 2.10 13 24 CD8 132.8 8.43 
13 24 NK 109.9 8.99 
14 0 CD4 104.34 1.98 
1606.30 2.09 14 0 CD8 77.2 2.02 
14 0 NK 19 3.44 
14 2 CD4 82.2 2.21 
416.50 1.99 14 2 CD8 516.7 2.89 
14 2 NK     
14 6 CD4 63.1 5.58 
563.00 2.12 14 6 CD8 70.6 12.05 
14 6 NK 112.9 8.23 
14 24 CD4 87.5 9.61 
394.00 2.02 14 24 CD8 113.5 7.45 
14 24 NK     
15 0 CD4 108.56 8.42 
1614.73 2.15 15 0 CD8 32.31 2.16 
15 0 NK 33.07 2.67 
15 2 CD4 49.13 3.11 
1901.14 2.10 15 2 CD8 29.18 2.24 
15 2 NK 118.44 5.1 
15 6 CD4 17.35 1.73 
1217.81 2.18 15 6 CD8 12.31 1.61 
15 6 NK 1.85 0.44 
15 24 CD4 4.41 1.16 
931.53 2.19 15 24 CD8 2.4 1.76 
15 24 NK 21.56 1.67 
18 0 CD4 44.1 1.98 
940.80 2.12 18 0 CD8 20 2.11 
18 0 NK 29.4 2.11 
18 2 CD4 14.6 2.25 
1139.20 2.10 18 2 CD8 12.3 2.21 
18 2 NK 30.4 2.1 
18 6 CD4 6.2 2.52 
1276.80 2.11 18 6 CD8 6.4 1.88 
18 6 NK 14.6 2.05 
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18 24 CD4 19.8 2.37 
1163.50 2.12 18 24 CD8 25.3 2.22 
18 24 NK 3.1 1.56 
19 0 CD4 32 2.04 
1855.30 2.07 19 0 CD8 14.7 2.35 
19 0 NK 24.1 1.98 
19 2 CD4 13.5 2.41 
1987.60 2.07 19 2 CD8 29 1.9 
19 2 NK 13.7 2.12 
19 6 CD4 11.8 2.22 
1586.00 2.12 19 6 CD8 9 2.56 
19 6 NK 19.7 2.31 
19 24 CD4 38.4 2.11 
2441.10 2.02 19 24 CD8 13.1 1.93 
19 24 NK 31.3 2.17 
21 0 CD4 28.2 2.03 
1569.80 2.11 21 0 CD8 11.8 2.35 
21 0 NK 13.1 1.46 
21 2 CD4 5.1 2.07 
1234.90 2.10 21 2 CD8 2.8 6.45 
21 2 NK 11.6 1.77 
21 6 CD4 6.8 2.85 
886.40 2.07 21 6 CD8 13.2 2.61 
21 6 NK 2.2 7.01 
21 24 CD4 26.2 2.05 
1174.70 2.09 21 24 CD8 14.2 2.49 
21 24 NK 24.3 2.07 
22 0 CD4 19.8 2.88 
1097.40 2.10 22 0 CD8 19.3 2.05 
22 0 NK 16 1.68 
22 2 CD4 3.9 7.15 
590.50 2.17 22 2 CD8 18.2 2.25 
22 2 NK 8.9 2.23 
22 6 CD4 -1.3 0.65 
965.70 2.12 22 6 CD8 0.8 -2.36 
22 6 NK 4.8 4.61 
22 24 CD4 1.7 -20.8 
1024.70 2.12 22 24 CD8 5.6 2.92 
22 24 NK 1.1 -2.14 
23 0 CD4 46.8 1.97 
1732.50 2.09 23 0 CD8 8.5 2.12 
23 0 NK 14.7 1.77 
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23 2 CD4 19.7 1.86 
899.30 2.13 23 2 CD8   2.01 
23 2 NK 9 1.54 
23 6 CD4 13.4 1.9 
1851.80 2.08 23 6 CD8 19.8 1.91 
23 6 NK 24.2 1.96 
23 24 CD4 25 1.97 
2140.70 2.05 23 24 CD8 31.6 1.75 
23 24 NK 116.3 1.96 
24 0 CD4 17.1 2.23 
1040.40 2.15 24 0 CD8 40.1 2.1 
24 0 NK 29.3 2.08 
24 2 CD4 5.4 2.55 
1288.60 2.14 24 2 CD8 16.1 2.28 
24 2 NK 4.3 2.59 
24 6 CD4 -0.2 0.23 
679.50 2.18 24 6 CD8 2.9 1.78 
24 6 NK 12.2 2.92 
control         
3029.90 1.86 24 24 CD8     
24 24 NK     
26 0 CD4 48.4 1.98 
516.90 2.10 26 0 CD8 31 1.98 
26 0 NK 0.6 1.12 
26 2 CD4 13.4 1.86 
667.60 2.15 26 2 CD8 13.9 7.88 
26 2 NK 8.45 2.22 
26 6 CD4 20.7 1.68 
1593.10 2.08 26 6 CD8 22.4 1.95 
26 6 NK 24.6 1.83 
26 24 CD4 28.9 1.81 
1948.90 2.06 26 24 CD8 14.1 1.98 
26 24 NK 24.4 1.9 
29 0 CD4 2.27 0.72 
517.82 2.42 29 0 CD8 2.28 0.95 
29 0 NK 16.3 1.73 
29 2 CD4 1.93 0.77 
628.57 2.27 29 2 CD8 4.21 1.21 
29 2 NK 67.12 1.82 
29 6 CD4 3.42 1.26 
335.16 2.22 29 6 CD8 0.11 0.14 
29 6 NK 27.91 1.75 
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29 24 CD4 2.16 0.94 
224.39 2.31 29 24 CD8 11.94 1.24 
29 24 NK 3.91 1.35 
30 0 CD4 39.4 1.8 
2422.50 1.99 30 0 CD8 27.8 2.09 
30 0 NK 0.6 0.27 
30 2 CD4 14.7 1.85 
1661.70 2.08 30 2 CD8 25.9 2.38 
30 2 NK 24.2 1.59 
30 6 CD4 20 2.67 
2308.20 1.99 30 6 CD8 18.4 2.06 
30 6 NK 29.6 1.84 
30 24 CD4 29.6 1.91 
2360.90 1.99 30 24 CD8 12.6 1.99 
30 24 NK 5.8 1.55 
31 0 CD4 150.7 1.94 
2092.10 2.04 31 0 CD8 35.2 1.96 
31 0 NK 3.8 1.33 
31 2 CD4 47.5 1.99 
1831.00 2.07 31 2 CD8 15 1.75 
31 2 NK 28.3 2.04 
31 6 CD4 79 1.95 
2753.90 1.97 31 6 CD8 40.8 1.97 
31 6 NK 33.7 1.91 
31 24 CD4 20.9 1.9 
2311.60 2.01 31 24 CD8 60.8 2.04 
31 24 NK 1.4 1.26 
32 0 CD4 18.92 1.68 
1584.75 2.18 32 0 CD8 13.71 1.42 
32 0 NK 11.12 1.52 
32 2 CD4 18.94 2.05 
1833.04 2.16 32 2 CD8 12.38 1.53 
32 2 NK 7.51 1.43 
32 6 CD4 85.84 1.92 
2358.47 2.03 32 6 CD8 15.99 1.64 
32 6 NK 4.92 1.44 
32 24 CD4 110.86 2 
2323.62 2.05 32 24 CD8     
32 24 NK 31.78 1.71 
33 0 CD4 56.7 1.97 
2613.60 1.93 33 0 CD8 65.2 1.94 
33 0 NK 1.6 0.7 
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33 2 CD4 80.3 1.95 
2524.30 1.95 33 2 CD8 16.4 1.73 
33 2 NK 18.1 1.66 
33 6 CD4 13.2 1.73 
1381.50 2.10 33 6 CD8 16.5 1.71 
33 6 NK 6.7 1.46 
33 24 CD4 116.9 2.72 
671.30 2.06 33 24 CD8 70.2 1.99 
33 24 NK 17.5 1.87 
34 0 CD4 46.72 1.98 
2247.74 1.94 34 0 CD8 41.2 2.02 
34 0 NK 22.73 2.3 
34 2 CD4 29.62 2.18 
1324.83 2.08 34 2 CD8 37.7 1.93 
34 2 NK 16.66 2.08 
34 6 CD4 5.17 2.07 
1471.69 2.00 34 6 CD8 8.88 1.86 
34 6 NK 24.16 2.19 
34 24 CD4 52.7 1.94 
1931.56 2.03 34 24 CD8 41.92 2.65 
34 24 NK -2.18 14.75 
35 0 CD4 86.5 2.05 
2103.30 2.04 35 0 CD8 37 1.93 
35 0 NK 1.7 1.34 
35 2 CD4 100 3.06 
289.00 1.95 35 2 CD8 8.5 1.81 
35 2 NK 25.6 2.14 
35 6 CD4 33.3 1.94 
1977.00 2.04 35 6 CD8 6.5 1.64 
35 6 NK 33.9 2.02 
35 24 CD4 43.6 1.96 
1668.50 2.07 35 24 CD8 22.1 1.96 
35 24 NK 1.4 1.77 
36 0 CD4 129.7 2.02 
2558.80 1.98 36 0 CD8 50.2 2.03 
36 0 NK 2.4 4.04 
36 2 CD4 88.1 2.05 
2386.30 2.00 36 2 CD8 75.9 2.06 
36 2 NK 37.7 2.19 
36 6 CD4 101.8 2.09 
1387.40 2.02 36 6 CD8 60.9 2.09 
36 6 NK 26.5 2.25 
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36 24 CD4 16.1 3.18 
1497.20 2.02 36 24 CD8 214.2 2.01 
36 24 NK 40.3 2.03 
38 6 CD4     
   38 6 CD8     
38 6 NK     
38 24 CD4       
  
  
 38 24 CD8     
38 24 NK     
39 0 CD4 49.8 1.99 
1689.20 2.09 39 0 CD8 24.5 2 
39 0 NK 11.3 1.66 
39 2 CD4 50.4 1.8 
1171.80 2.14 39 2 CD8 44.5 1.88 
39 2 NK 39 1.81 
39 6 CD4 62.5 1.84 
1353.60 2.10 39 6 CD8 29.9 1.93 
39 6 NK 1.6 0.91 
39 24 CD4 40 1.97 
2267.20 2.08 39 24 CD8 30.6 1.84 
39 24 NK 35.5 1.72 
40 0 CD4 73.73 2.1 
1841.37 1.92 40 0 CD8 75.29 1.95 
40 0 NK 2.84 1.27 
40 2 CD4 40.1 1.96 
1962.94 1.99 40 2 CD8 93.09 1.91 
40 2 NK 79.79 1.73 
40 6 CD4 17.29 1.81 
2017.23 1.98 40 6 CD8 21.36 1.82 
40 6 NK 5.32 1.38 
40 24 CD4 23.03 1.98 
2182.53 1.95 40 24 CD8 24.47 2.16 
40 24 NK 3.58 1.2 
41 0 CD4 52.25 2.1 
1163.60 1.99 41 0 CD8 29.97 1.85 
41 0 NK 11.07 1.49 
41 2 CD4 11.25 1.74 
2140.82 1.95 41 2 CD8 11 1.61 
41 2 NK 493.93 2.11 
41 6 CD4 12.17 1.81 
2959.71 1.90 41 6 CD8 12.12 1.87 
41 6 NK 96.48 1.99 
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41 24 CD4       
  
  
 41 24 CD8     
41 24 NK     
43 0 CD4       
  
  
 43 0 CD8     
43 0 NK     
43 2 CD4       
  
  
 43 2 CD8     
43 2 NK     
43 6 CD4       
  
  
 43 6 CD8     
43 6 NK     
43 24 CD4       
  
  
 43 24 CD8     
43 24 NK     
44 0 CD4 4.7 2.63 
2261.90 1.97 44 0 CD8 -94.1 2.1 
44 0 NK -7.2 2.94 
44 2 CD4 2.7 2.03 
227.00 1.97 44 2 CD8 0.5 -1.21 
44 2 NK 0.8 -1.48 
44 6 CD4 -0.5 1.22 
970.90 2.13 44 6 CD8 1.1 5.25 
44 6 NK 0.9 -3.68 
44 24 CD4 34.1 1.94 
1409.70 2.11 44 24 CD8 7.5 1.65 
44 24 NK 2.7 1.18 
45 0 CD4 38.2 2.02 
2060.30 2.01 45 0 CD8 4.1 1.52 
45 0 NK 3.5 1.43 
45 2 CD4 29.8 1.98 
1526.50 2.04 45 2 CD8 16.3 1.69 
45 2 NK 36.1 1.8 
45 6 CD4 10.5 2.19 
1307.10 2.02 45 6 CD8 10.1 1.64 
45 6 NK 2.2 1.09 
45 24 CD4 20.1 1.74 
1981.40 2.00 45 24 CD8 15.5 1.64 
45 24 NK 3.3 1.18 
46 0 CD4 14.8 1.09 
1586.30 2.05 46 0 CD8 13.7 1.1 
46 0 NK 21.4 1.03 
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46 2 CD4 8 0.93 
1272.60 2.09 46 2 CD8 9.3 0.93 
46 2 NK 2 0.65 
46 6 CD4 1.1 0.25 
971.70 2.10 46 6 CD8 2.2 0.3 
46 6 NK -0.12 -0.05 
46 24 CD4 20 1.35 
1779.80 2.05 46 24 CD8 17.3 1.19 
46 24 NK 7.5 0.97 
47 0 CD4 104.56 2.18 
2433.67 1.95 47 0 CD8 33.62 1.71 
47 0 NK 17.85 1.55 
47 2 CD4 32.41 1.78 
2043.63 1.97 47 2 CD8 19.68 1.67 
47 2 NK 17.94 2.15 
47 6 CD4 2.92 1.26 
1548.52 2.01 47 6 CD8 4.04 2.03 
47 6 NK 2.13 7.59 
47 24 CD4 44 1.92 
1945.57 1.97 47 24 CD8 23.58 1.8 
47 24 NK -0.11 -0.15 
48 0   113.4 1.99 
2532.50 1.97 48 0   62.1 2.06 
48 0   10.4 1.51 
48 2 CD4 19.2 1.84 
475.80 2.03 48 2 CD8 24 1.7 
48 2 NK 14.6 1.48 
48 6 CD4 7.9 1.21 
351.30 2.01 48 6 CD8 7 1.43 
48 6 NK 9.1 1.15 
48 24 CD4 19 1.65 
1454.30 2.09 48 24 CD8 45.4 1.9 
48 24 NK 4.3 1 
49 0 CD4 60.6 1.96 
1509.10 2.05 49 0 CD8 36.6 1.83 
49 0 NK 18.1 1.72 
49 2 CD4 30.5 1.88 
1573.50 2.06 49 2 CD8 30 1.85 
49 2 NK 24.3 1.78 
49 6 CD4 3.2 1.35 
1138.10 2.11 49 6 CD8 4.4 1.79 
49 6 NK 14 1.73 
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49 24 CD4 4.5 0.7 
753.60 2.12 49 24 CD8 51.8 1.91 
49 24 NK 11.5 1.4 
50 0 CD4 43.7 1.93 
982.40 2.10 50 0 CD8 28.2 1.89 
50 0 NK 14.8 1.75 
50 2 CD4 45.8 1.86 
1395.30 2.09 50 2 CD8 37.1 1.93 
50 2 NK 19.9 1.84 
50 6 CD4 17.2 1.68 
1405.60 2.11 50 6 CD8 9.5 1.49 
50 6 NK 17.2 1.62 
50 24 CD4 13.2 1.81 
1483.34 2.07 50 24 CD8 16.8 2 
50 24 NK 3.4 1.38 
52 0 CD4 52.23 1.95 
2337.02 2.06 52 0 CD8 22.4 1.77 
52 0 NK 6.75 1.51 
52 2 CD4 8.16 1.75 
1694.02 2.15 52 2 CD8 10.47 1.79 
52 2 NK 25.33 1.61 
52 6 CD4 5.54 1.46 
888.28 2.27 52 6 CD8 8.25 1.39 
52 6 NK 3.43 1.5 
52 24 CD4 19.9 2 
1543.48 2.24 52 24 CD8 24.16 1.81 
52 24 NK 22.37 1.52 
53 0 CD4 25.9 1.46 
1761.23 2.19 53 0 CD8 17.11 1.47 
53 0 NK 5.99 14.1 
53 2 CD4 11.59 0.94 
1947.53 2.15 53 2 CD8 13.3 1.41 
53 2 NK 7.11 1.96 
53 6 CD4 5.67 1.42 
1479.49 2.23 53 6 CD8 4.87 4.37 
53 6 NK 1.8 20.43 
53 24 CD4 6.97 2.04 
1018.77 2.43 53 24 CD8 2.63 1.6 
53 24 NK     
54 0 CD4 20.31 1.85 
1289.85 2.31 54 0 CD8 3.88 0.67 
54 0 NK 1.63 1.14 
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54 2 CD4 16.82 2.28 
1764.23 2.16 54 2 CD8 6.14 1.63 
54 2 NK 17.06 1.85 
54 6 CD4 4.44 0.87 
2017.17 2.15 54 6 CD8 8.14 1.95 
54 6 NK 22.13 1.94 
55 0 CD4 21.2 1.81 
1886.72 2.14 55 0 CD8 22.7 1.58 
55 0 NK 16.3 2.72 
55 2 CD4 12.09 1.15 
1504.10 2.23 55 2 CD8 1.89 0.49 
55 2 NK 28.76 1.92 
55 6 CD4 8.58 1.52 
1104.75 2.30 55 6 CD8 2.23 3.09 
55 6 NK 15.28 1.61 
55 24 CD4 21.83 1.86 
462.41 2.00 55 24 CD8 13.13 1.78 
55 24 NK 2.77 0.81 
56 0 CD4 8.96 -3.85 
1480.92 2.20 56 0 CD8 21.88 1.88 
56 0 NK 5.1 1.09 
56 2 CD4 19.37 1.96 
1462.90 2.21 56 2 CD8 11.07 1.62 
56 2 NK 8.94 1.24 
56 6 CD4 24.06 1.7 
2176.21 2.13 56 6 CD8 26.15 1.74 
56 6 NK 3.58 1.13 
56 24 CD4 25.02 2.35 
1847.29 2.17 56 24 CD8 24.75 1.67 
56 24 NK 7.34 0.83 
57 0 CD4 15.2 1.09 
1579.80 2.04 57 0 CD8 4.7 0.74 
57 0 NK 3.12 0.42 
57 2 CD4 -0.1 -0.02 
1164.10 2.06 57 2 CD8 9.3 0.91 
57 2 NK 10.2 0.97 
57 6 CD4 2.7 0.76 
647.80 2.00 57 6 CD8 -0.8 0.23 
57 6 NK 0.6 0.12 
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Table 10.2: RNA integrity numbers for microarray patient cohort measured 
on Agilent Bioanalyzer pre-amplification of combined cell sub-types. 
Subject Treatment  0 hr 2 hr 6 hr 24 hr
1 Morphine 3.8 3.1 3 4.6 
2 Morphine 7.6 6.3 7.3 6.8 
3 Oxycodone 8 7.5 6.6 8.2 
6 Oxycodone 5.3 2.7 2.8 9.4 
9 Oxycodone 7.2 7.8 6.6 5.9 
13 Morphine 5.8 3.8 6.3 2.7 
14 Morphine 4.3 2.7 6 4 
15 Oxycodone N/A 2.8 5.6 2.6 
18 Oxycodone 4.7 2.5 2.3 4 
19 Oxycodone 6.9 5.5 7.2 6.7 
21 Morphine 5.8 5.7 N/A 5.4 
22 Morphine 4.4 2.1 2.7 N/A 
23 Oxycodone 2.5 5.5 4.5 3.9 
24 Epidural 5.9 6.4 N/A N/A 
26 Oxycodone 8.9 2.4 5.3 8.7 
29 Oxycodone 1.1 2.3 2.2 1.1 
30 Oxycodone 8.3 2.7 2.6 5.8 
31 Morphine 5.9 8.8 6.3 N/A 
32 Epidural 6.8 6.3 5.3 7.2 
33 Oxycodone 8.5 N/A 3.2 5.9 
34 Oxycodone 3.7 2.6 2.3 7.6 
35 Morphine 9.2 5.7 6.7 9.4 
36 Epidural 3.5 5.4 4 6 
39 Epidural 3.7 3.8 2.9 2.9 
40 Morphine 2.5 2.6 2.8 4.2 
41 Epidural 3.5 2.7 3.8 N/A 
44 Oxycodone 8.7 1.3 N/A 5.1 
45 Morphine 8.8 5.2 3.8 5.3 
46 Epidural 2.8 2.3 N/A 2.2 
47 Morphine 4.4 6.7 1.2 5.6 
48 Morphine 7.2 4.1 N/A N/A 
49 Oxycodone 2.3 3 3.2 2.9 
50 Morphine 2.6 2.5 2.6 7 
51 Epidural 2.2 N/A 2.4 2.5 
52 Morphine 8.7 7.2 N/A 2.8 
53 Morphine 4.2 5.4 2.6 3 
54 Epidural 6.5 5.4 2.6 N/A 
55 Oxycodone 2.7 3 N/A N/A 
56 Oxycodone 1.8 2.1 5.1 3.5 
57 Morphine 1.6 2.7 N/A N/A 
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Figure 10.1: Spectrophotograms of fragmented RNA. RNA was analysed on 
the Bioanalyzer to determine that fragmentation had occurred, which was 
confirmed by the distinctive shape of the spectrophotogram.  
 
 
Table 10.3: Statistical data for differences in RIN for all treatment groups at 
each timepoint, for microarray patient cohort only.  
Time-
point 
Treatment 
group N Mean SD Median 25 % 75 % ANOVA KW 
0 hr 
Mor 16 5.42 2.35 5.10 3.90 7.43 
0.64 0.56 Oxy 15 5.37 2.85 5.30 2.50 8.30 
Bup 8 4.36 1.77 3.60 2.98 6.35 
2 hr 
Mor 16 4.66 2.00 4.65 2.70 6.15 
0.23 0.21 Oxy 15 3.58 1.20 2.70 2.40 5.50 
Bup 7 4.61 1.68 5.40 2.70 6.30 
6 hr 
Mor 12 4.28 2.08 3.40 2.63 6.30 
0.55 0.66 Oxy 14 4.25 1.80 3.85 2.53 5.85 
Bup 6 3.50 1.09 3.35 2.55 4.33 
24 hr 
Mor 12 5.07 1.98 4.95 3.25 6.50 
0.54 0.56 Oxy 15 5.42 2.43 5.80 3.50 7.60 
Bup 5 4.16 2.28 2.90 2.35 6.60 
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Table 10.4: Statistical data for differences in RIN between all timepoints for 
each treatment group, for microarray patient cohort only.  
 
Treatment 
group 
Time-
point N Mean SD 
Med-
ian 25 % 75 % ANOVA KW 
Mor 
0 hr 16 5.43 2.36 5.10 3.90 7.50 
0.08 0.17 2 hr 16 4.66 2.00 4.65 2.70 6.15 6 hr 16 3.21 2.62 2.75 0.30 6.23 
24 hr 15 4.05 2.73 4.20 2.70 5.60 
Oxy 
0 hr 16 5.04 3.06 5.00 2.35 8.22 
0.13 0.14 2 hr 16 3.36 2.13 2.70 2.33 4.88 6 hr 16 3.72 2.22 3.20 2.30 5.53 
24 hr 16 5.08 2.71 5.45 3.05 7.38 
Bup 
0 hr 8 4.36 1.77 3.60 2.98 6.35 
0.34 0.49 2 hr 8 4.04 2.25 4.60 2.40 6.08 6 hr 8 2.63 1.86 2.75 0.60 4.33 
24 hr 5 4.16 2.28 2.90 2.35 6.60 
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Table 10.5: Biological pathways enriched in genes deregulated by morphine 
at 2 hour (Mor0-2: 520 genes / 576 probes), identified using DAVID 
ontological software (p≤0.01).  
Biological processes Genes
% of 
total 
input p value 
translation 28 5.7 7.80E-07 
ribonucleoprotein complex biogenesis 18 3.6 1.40E-05 
regulation of apoptosis 45 9.1 1.90E-05 
regulation of programmed cell death 45 9.1 2.40E-05 
regulation of cell death 45 9.1 2.60E-05 
RNA processing 32 6.5 1.80E-04 
cellular macromolecular complex assembly 22 4.4 2.80E-04 
cellular macromolecular complex subunit organization 23 4.6 5.10E-04 
positive regulation of apoptosis 26 5.3 5.20E-04 
positive regulation of programmed cell death 26 5.3 5.80E-04 
positive regulation of cell death 26 5.3 6.30E-04 
mRNA metabolic process 23 4.6 8.40E-04 
apoptosis 32 6.5 9.30E-04 
programmed cell death 32 6.5 1.20E-03 
cell death 36 7.3 1.20E-03 
death 36 7.3 1.30E-03 
RNA splicing, via transesterification reactions with bulged 
adenosine as nucleophile 13 2.6 1.30E-03 
RNA splicing, via transesterification reactions 13 2.6 1.30E-03 
nuclear mRNA splicing, via spliceosome 13 2.6 1.30E-03 
electron transport chain 11 2.2 1.40E-03 
cellular respiration 10 2 1.70E-03 
induction of apoptosis 20 4 1.90E-03 
induction of programmed cell death 20 4 2.00E-03 
ncRNA metabolic process 16 3.2 2.30E-03 
macromolecular complex assembly 33 6.7 2.30E-03 
regulation of T cell receptor signaling pathway 4 0.8 2.30E-03 
ribosome biogenesis 11 2.2 2.40E-03 
regulation of leukocyte activation 13 2.6 2.70E-03 
positive regulation of leukocyte activation 10 2 3.10E-03 
positive regulation of immune system process 16 3.2 3.20E-03 
regulation of lymphocyte activation 12 2.4 3.20E-03 
macromolecular complex subunit organization 34 6.9 3.40E-03 
generation of precursor metabolites and energy 19 3.8 3.50E-03 
activation of caspase activity 7 1.4 4.00E-03 
regulation of antigen receptor-mediated signaling 
pathway 4 0.8 4.10E-03 
regulation of cell activation 13 2.6 4.10E-03 
positive regulation of cell activation 10 2 4.20E-03 
positive regulation of T cell activation 8 1.6 5.60E-03 
negative regulation of apoptosis 20 4 5.70E-03 
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mitochondrion organization 11 2.2 5.80E-03 
regulation of T cell activation 10 2 5.90E-03 
positive regulation of lymphocyte activation 9 1.8 6.10E-03 
positive regulation of peptidase activity 7 1.4 6.20E-03 
positive regulation of caspase activity 7 1.4 6.20E-03 
negative regulation of programmed cell death 20 4 6.60E-03 
negative regulation of cell death 20 4 6.80E-03 
positive regulation of catalytic activity 26 5.3 6.80E-03 
ncRNA processing 13 2.6 6.90E-03 
spliceosomal snRNP biogenesis 5 1 7.50E-03 
energy derivation by oxidation of organic compounds 11 2.2 7.70E-03 
cellular macromolecule catabolic process 33 6.7 8.40E-03 
mitotic cell cycle 20 4 9.00E-03 
respiratory electron transport chain 7 1.4 9.20E-03 
positive regulation of adaptive immune response based 
on somatic recombination of immune receptors built from 
immunoglobulin superfamily domains 5 1 9.60E-03 
mRNA processing 18 3.6 9.90E-03 
interphase 9 1.8 1.00E-02 
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Table 10.6: Biological pathways enriched in genes deregulated by morphine 
at 6 hour (Mor0-6: 113 genes / 149 probes), identified using DAVID 
ontological software (p≤0.01). 
GOTERM_BP_FAT  
Biological processes Genes
% of 
total 
input p value 
response to wounding 21 19.6 2.00E-10 
response to organic substance 19 17.8 9.90E-07 
inflammatory response 13 12.1 1.50E-06 
defense response 17 15.9 2.60E-06 
innate immune response 9 8.4 3.70E-06 
negative regulation of cytokine production 6 5.6 4.90E-06 
immune response 7 6.5 1.20E-05 
response to lipopolysaccharide 17 15.9 1.10E-05 
response to molecule of bacterial origin 7 6.5 2.20E-05 
response to insulin stimulus 7 6.5 5.30E-05 
organic acid biosynthetic process 8 7.5 7.60E-05 
carboxylic acid biosynthetic process 8 7.5 7.60E-05 
positive regulation of developmental process 10 9.3 9.50E-05 
positive regulation of molecular function 14 13.1 1.30E-04 
fatty acid biosynthetic process 9 8.4 1.80E-04 
positive regulation of immune system process 8 7.5 2.00E-04 
regulation of cytokine production 6 5.6 1.80E-04 
regulation of phosphorylation 12 11.2 2.60E-04 
response to endogenous stimulus 12 11.2 3.60E-04 
regulation of phosphate metabolic process 12 11.2 3.60E-04 
regulation of phosphorus metabolic process 11 10.3 3.50E-04 
response to peptide hormone stimulus 7 6.5 5.60E-04 
positive regulation of fat cell differentiation 12 11.2 6.50E-04 
positive regulation of catalytic activity 15 14 8.10E-04 
response to hormone stimulus 3 2.8 6.50E-04 
negative regulation of multicellular organismal 
process 15 14 9.00E-04 
protein kinase cascade 15 14 9.30E-04 
regulation of transferase activity 8 7.5 8.70E-04 
regulation of apoptosis 10 9.3 8.10E-04 
positive regulation of kinase activity 10 9.3 7.80E-04 
regulation of programmed cell death 8 7.5 9.80E-04 
regulation of cell death 10 9.3 7.40E-04 
positive regulation of response to stimulus 7 6.5 7.80E-04 
positive regulation of transferase activity 7 6.5 1.10E-03 
regulation of cell activation 8 7.5 1.10E-03 
lipid biosynthetic process 9 8.4 1.40E-03 
response to steroid hormone stimulus 7 6.5 1.80E-03 
response to bacterium 7 6.5 1.80E-03 
response to cytokine stimulus 5 4.7 1.90E-03 
fatty acid metabolic process 7 6.5 2.00E-03 
activation of MAPK activity 5 4.7 2.20E-03 
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negative regulation of immune system process 5 4.7 2.30E-03 
regulation of MAP kinase activity 7 6.5 2.50E-03 
anti-apoptosis 9 8.4 2.60E-03 
regulation of kinase activity 6 5.6 2.50E-03 
positive regulation of immune response 6 5.6 2.80E-03 
membrane invagination 7 6.5 3.50E-03 
endocytosis 7 6.5 3.50E-03 
positive regulation of protein kinase activity 7 6.5 3.70E-03 
phagocytosis 4 3.7 4.00E-03 
acute inflammatory response 5 4.7 4.10E-03 
positive regulation of cell differentiation 7 6.5 4.20E-03 
positive regulation of MAP kinase activity 5 4.7 4.70E-03 
regulation of fat cell differentiation 6 5.6 5.00E-03 
regulation of leukocyte activation 3 2.8 4.90E-03 
fat cell differentiation 4 3.7 5.20E-03 
regulation of interleukin-12 production 3 2.8 5.60E-03 
positive regulation of multicellular organismal 
process 7 6.5 5.70E-03 
regulation of protein amino acid phosphorylation 6 5.6 5.90E-03 
positive regulation of cell activation 5 4.7 6.40E-03 
leukotriene biosynthetic process 3 2.8 7.00E-03 
alkene biosynthetic process 3 2.8 7.00E-03 
sulfur metabolic process 5 4.7 7.20E-03 
MAPKKK cascade 6 5.6 7.60E-03 
regulation of protein kinase activity 8 7.5 8.10E-03 
positive regulation of response to external stimulus 4 3.7 8.90E-03 
negative regulation of apoptosis 3 2.8 9.30E-03 
leukotriene metabolic process 8 7.5 9.20E-03 
negative regulation of programmed cell death 8 7.5 1.00E-02 
negative regulation of cell death 3 2.8 1.00E-02 
response to nutrient levels 6 5.6 1.00E-02 
cellular alkene metabolic process 8 7.5 1.00E-02 
negative regulation of cell proliferation 8 7.5 9.90E-03 
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Table 10.7: Biological pathways enriched in genes deregulated by 
oxycodone at 6 hour (Oxy0-6: 559 genes / 810 probes), identified using 
DAVID ontological software (p≤0.01). 
Biological processes Genes
% of 
total 
input p value 
response to wounding 53 11 1.60E-15 
defense response 54 11.2 1.80E-13 
inflammatory response 37 7.6 1.50E-12 
immune response 48 9.9 1.30E-08 
innate immune response 18 3.7 3.00E-07 
positive regulation of immune system process 23 4.8 9.00E-07 
protein kinase cascade 28 5.8 5.40E-06 
positive regulation of cytokine production 13 2.7 7.30E-06 
negative regulation of cytokine production 9 1.9 8.10E-06 
regulation of cytokine production 18 3.7 1.30E-05 
positive regulation of multicellular organismal 
process 21 4.3 1.70E-05 
regulation of programmed cell death 45 9.3 1.80E-05 
regulation of cell death 45 9.3 2.00E-05 
response to molecule of bacterial origin 12 2.5 2.60E-05 
response to bacterium 18 3.7 3.00E-05 
regulation of apoptosis 44 9.1 3.10E-05 
positive regulation of response to stimulus 20 4.1 3.60E-05 
response to lipopolysaccharide 11 2.3 5.30E-05 
positive regulation of immune response 15 3.1 5.50E-05 
response to organic substance 40 8.3 5.80E-05 
detection of biotic stimulus 6 1.2 1.10E-04 
anti-apoptosis 17 3.5 2.20E-04 
positive regulation of cell activation 12 2.5 2.70E-04 
adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains 10 2.1 2.80E-04 
adaptive immune response 10 2.1 2.80E-04 
immune effector process 13 2.7 3.70E-04 
regulation of T-helper 2 cell differentiation 4 0.8 4.10E-04 
leukocyte mediated immunity 10 2.1 6.50E-04 
JAK-STAT cascade 7 1.4 6.80E-04 
regulation of adaptive immune response based on 
somatic recombination of immune receptors built 
from immunoglobulin superfamily domains 8 1.7 8.00E-04 
regulation of adaptive immune response 8 1.7 9.00E-04 
intracellular signalling cascade 55 11.4 9.00E-04 
positive regulation of defense response 9 1.9 9.50E-04 
negative regulation of apoptosis 22 4.5 9.90E-04 
membrane organization 23 4.8 1.10E-03 
negative regulation of programmed cell death 22 4.5 1.20E-03 
negative regulation of cell death 22 4.5 1.20E-03 
activation of immune response 10 2.1 1.20E-03 
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regulation of cell activation 14 2.9 1.30E-03 
regulation of interferon-gamma production 6 1.2 1.30E-03 
regulation of erythrocyte differentiation 5 1 1.30E-03 
regulation of tumor necrosis factor production 6 1.2 1.50E-03 
response to cytokine stimulus 9 1.9 1.60E-03 
acute inflammatory response 10 2.1 1.70E-03 
positive regulation of cell motion 10 2.1 1.70E-03 
positive regulation of T cell differentiation 6 1.2 1.80E-03 
regulation of lymphocyte differentiation 8 1.7 1.80E-03 
negative regulation of multicellular organismal 
process 13 2.7 2.20E-03 
regulation of T-helper cell differentiation 4 0.8 2.20E-03 
regulation of T-helper 2 type immune response 4 0.8 2.20E-03 
positive regulation of lymphocyte differentiation 6 1.2 2.70E-03 
regulation of T cell differentiation 7 1.4 2.80E-03 
positive regulation of leukocyte activation 10 2.1 2.90E-03 
hexose metabolic process 14 2.9 2.90E-03 
response to steroid hormone stimulus 14 2.9 2.90E-03 
cell activation 18 3.7 3.00E-03 
regulation of cell motion 14 2.9 3.10E-03 
cell activation during immune response 6 1.2 3.10E-03 
leukocyte activation during immune response 6 1.2 3.10E-03 
regulation of myeloid cell differentiation 8 1.7 3.30E-03 
lymphocyte mediated immunity 8 1.7 3.30E-03 
leukocyte activation 16 3.3 3.40E-03 
immunoglobulin mediated immune response 7 1.4 3.80E-03 
neuron projection regeneration 4 0.8 3.90E-03 
defense response to bacterium 10 2.1 4.10E-03 
fructose 2,6-bisphosphate metabolic process 3 0.6 4.50E-03 
JAK-STAT cascade involved in growth hormone 
signalling pathway 3 0.6 4.50E-03 
B cell mediated immunity 7 1.4 4.60E-03 
negative regulation of transport 11 2.3 4.60E-03 
regulation of alpha-beta T cell differentiation 5 1 4.80E-03 
positive regulation of programmed cell death 23 4.8 5.10E-03 
positive regulation of cell death 23 4.8 5.50E-03 
positive regulation of lymphocyte activation 9 1.9 5.70E-03 
positive regulation of interleukin-1 beta production 4 0.8 6.30E-03 
regulation of leukocyte activation 12 2.5 7.00E-03 
negative regulation of CD4-positive, alpha beta T 
cell differentiation 3 0.6 7.40E-03 
negative regulation of T-helper cell differentiation 3 0.6 7.40E-03 
detection of molecule of bacterial origin 3 0.6 7.40E-03 
regulation of germinal center formation 3 0.6 7.40E-03 
negative regulation of interleukin-12 production 3 0.6 7.40E-03 
positive regulation of molecular function 28 5.8 7.60E-03 
regulation of interleukin-8 production 4 0.8 7.70E-03 
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macrophage activation 4 0.8 7.70E-03 
regulation of CD4-positive, alpha beta T cell 
differentiation 4 0.8 7.70E-03 
enzyme linked receptor protein signalling pathway 19 3.9 7.80E-03 
regulation of cell migration 12 2.5 7.90E-03 
activation of MAPK activity 8 1.7 7.90E-03 
I-kappaB kinase/NF-kappaB cascade 7 1.4 8.10E-03 
negative regulation of immune system process 8 1.7 8.50E-03 
regulation of lymphocyte activation 11 2.3 8.70E-03 
positive regulation of response to external stimulus 7 1.4 8.80E-03 
myeloid leukocyte activation 6 1.2 8.90E-03 
cytokine production 6 1.2 8.90E-03 
positive regulation of innate immune response 6 1.2 8.90E-03 
endocytosis 14 2.9 9.00E-03 
membrane invagination 14 2.9 9.00E-03 
response to vitamin D 4 0.8 9.20E-03 
positive regulation of inflammatory response 5 1 9.30E-03 
positive regulation of apoptosis 22 4.5 9.50E-03 
lipid biosynthetic process 18 3.7 9.50E-03 
regulation of phosphate metabolic process 24 5 9.60E-03 
regulation of phosphorus metabolic process 24 5 9.60E-03 
monosaccharide metabolic process 14 2.9 9.70E-03 
icosanoid metabolic process 6 1.2 9.70E-03 
 
 
 
Table 10.8: Biological pathways enriched in genes deregulated by 
bupivacaine at 6 hour (Bup0-6: 44 genes / 49 probes), identified using 
DAVID ontological software (p≤0.01). 
 
Biological processes Genes
% of 
total 
input p value 
enzyme linked receptor protein signaling pathway 5 12.8 5.10E-03 
positive regulation of cell proliferation 5 12.8 9.90E-03 
negative regulation of signal transduction 4 10.3 1.00E-02 
 
 
  
Mary Elizabeth Demopoulos Appendices 
© Mary Demopoulos 2010-2017 295
Table 10.9: Pre- and post-surgical serum cortisol concentrations for all 
patient samples used for cortisol ELISA.  
 
 Cortisol 
concentration 
 
 (ng/ml) 
Subject 0 hr 6 hr Treatment
13 29.58 106.19 Morphine 
14 27.65 30.43 Morphine 
22 35.49 128.05 Morphine 
31 28.75 30.63 Morphine 
35 45.44 29.90 Morphine 
40 27.12 17.38 Morphine 
43 26.62 19.77 Morphine 
47 77.76 349.24 Morphine 
50 92.51 372.39 Morphine 
52 48.16 55.58 Morphine 
57 77.21 20.63 Morphine 
19 57.69 28.88 Oxycodone 
23 21.22 40.71 Oxycodone 
26 79.44 53.24 Oxycodone 
29 32.51 61.84 Oxycodone 
30 33.17 185.63 Oxycodone 
33 78.06 27.54 Oxycodone 
34 6.93 8.30 Oxycodone 
44 53.10 17.60 Oxycodone 
49 53.79 92.00 Oxycodone 
56 39.53 36.23 Oxycodone 
5 3.78 4.47 Oxycodone 
24 27.48 27.30 Bupivacaine
25 14.11 112.66 Bupivacaine
32 31.87 182.90 Bupivacaine
38 91.24 21.73 Bupivacaine
39 46.83 25.11 Bupivacaine
41 48.16 320.28 Bupivacaine
45 56.25 80.85 Bupivacaine
51 89.76 22.83 Bupivacaine
54 44.29 830.07 Bupivacaine
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Table 10.10: Statistical data for differences in serum cortisol concentration 
between timepoints and treatment groups. 
 
 
 
Table 10.11: Serum IL-2 concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance.  
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 0 0 0.16 0.08 0 0.60 
 0 0 0.51 0.06 0 0 
 0.03 0.11 0.21 0.18 0 0.03 
 0.03 0.24 0.24 0.26 0 0 
 0.06 0.06 0.03 0.26 0.11 0.11 
 0 0.08     0.46 0.24 
 0.11 0.11     0.16 0.06 
 0.26 0.03         
Mean 0.06 0.08 0.23 0.17 0.10 0.15 
StDev 0.08 0.07 0.16 0.09 0.16 0.20 
 
  
 0 hr 6 hr  
Treatment N Mean SD SEM N Mean SD SEM Sig. (2-tailed) 
Mor 11 46.94 24.26 7.32 11 105.47 131.50 39.65 0.12 
Oxy 11 41.75 25.51 7.69 11 50.58 51.37 15.49 0.61 
Bup 9 50.00 26.20 8.72 9 180.42 263.08 87.69 0.19 
All 
ANOVA ANOVA 
 
0.76 0.23 
 Levene’s test Levene’s test 
Mor v oxy 0.86 0.03 
Mor v bup 0.97 0.22 
Oxy v bup 0.86 0.02 
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Table 10.12: Serum IL-4 concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 0.15 0 0.31 0.5 0 0 
 0 0 0.47 0.04 0 0 
 0.01 0.23 0.31 0.26 0.18 0 
 0.04 0.15 0.2 0.04 0.34 0 
 0.23 0.31 0.12 0.2 0.18 0.31 
 0.42 0.04     0.36 0.15 
 0.12 0.45     0.36 0.42 
 0.28 0.23         
Mean 0.16 0.18 0.28 0.21 0.20 0.13 
StDev 0.14 0.15 0.12 0.17 0.15 0.16 
 
 
Table 10.13: Serum IL-6 concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 0.3 95.2 1.51 25.15 1.63 22.62 
 1.57 33.61 0.33 0.11 1.36 12.67 
 0.43 16.5 1.78 14.96 0.93 12.52 
 2.92 30.03 2.11 32.93 3.21 50.21 
 1.06 16.26 0.39 23.64 5.1 26.57 
 1.63 89.6     1.1 8.75 
 0.73 18.79     0.81 27.88 
 0.2 123.31         
Mean 1.11 52.91 1.22 19.36 2.02 23.03 
StDev 0.86 40.03 0.73 11.19 1.46 13.08 
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Table 10.14: Serum IL-10 concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 2.10 22.45 1.32 13.62 1.26 5.54 
 0.83 6.52 0.51 0.24 1.01 5.41 
 0.57 16.36 0.98 30.97 0.67 5.44 
 0.79 13.87 1.38 15.42 1.35 13.69 
 0.92 8.42 0.61 1.62 1.32 31.9 
 0.83 27.7     0.44 1.44 
 1.65 7.62     0.86 3.59 
 0.06 13.72         
Mean 0.97 14.58 0.96 12.37 0.99 9.57 
StDev 0.59 6.98 0.36 11.13 0.32 9.77 
 
 
Table 10.15: Serum IL-17a concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 9.06 10.75 12.85 10.75 20.54 8.22 
 9.90 12.01 45.47 19.68 11.59 10.32 
 7.38 15.82 13.28 14.55 12.85 10.32 
 10.75 12.01 16.25 12.01 15.4 17.10 
 14.97 12.43 9.06 12.85 10.75 12.85 
 9.90 14.12 13.28 9.06 
 13.70 13.28 12.01 10.32 
 18.39 13.70  
Mean 11.76 13.02 19.38 13.97 13.77 11.17 
StDev 3.40 1.46 13.24 3.11 3.08 2.76 
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Table 10.16: Serum IFN-γ concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 0.10 0 0.19 0.04 0.19 0.06 
 0.08 0.06 0.40 0 0.1 0 
 0 0.08 0.19 0.26 0 0.01 
 0.10 0.15 0.21 0.08 0.10 0.04 
 0.15 0.35 0 0.21 0.37 0.17 
 0.01 0.06 0.17 0.10 
 0.17 0.01 0.24 0.19 
 0.06 0.10  
Mean 0.084 0.10 0.20 0.12 0.17 0.08 
StDev 0.06 0.10 0.13 0.10 0.11 0.07 
 
 
Table 10.17: Serum TNFα concentration measured using cytometric bead 
array (CBA). Data is given for each treatment group at each timepoint and 
paired per subject. Shaded cells indicate values below theoretical level of 
significance. 
 
 Morphine Oxycodone Bupivacaine 
 0 hr 6 hr 0 hr 6 hr 0 hr 6 hr 
 0.13 0.44 0.65 7.39 0.13 0.27 
 0.33 0.20 0.81 0 0.13 0.13 
 0.20 0.38 0.76 0.55 0.13 0 
 0.27 0.06 0.33 0.20 0.13 0.27 
 0.33 0.60 1.89 0.60 0.33 0.20 
 0.06 0.44     0.33 0.65 
 0.60 0.20     0.27 0.33 
 0.27 0.38         
Mean 0.27 0.34 0.89 1.75 0.21 0.26 
StDev 0.15 0.16 0.53 2.83 0.09 0.19 
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Table 10.18: P-values for dependent-samples t-tests performed across 
timepoints for each cytokine per treatment group. Shaded numbers are 
statistically insignificant. 
  
Treatment N IL-2 IL-4 IL-6 1L-10 IL-17a IFNγ TNFα
Morphine 8 0.70 0.81 0.01 0.001 0.41 0.67 0.54 
Oxycodone 5 0.60 0.53 0.03 0.11 0.36 0.49 0.59 
Bupivacaine 7 0.67 0.27 0.01 0.07 0.20 0.01 0.39 
 
 
 
Table 10.19: Results for ANOVA performed across treatment groups at each 
timepoint for all 7 cytokines. Shaded numbers are statistically insignificant. 
  
Treatment IL-2 IL-4 IL-6 1L-10 IL-17a IFNγ TNFα 
0 hr 0.15 0.35 0.31 1 0.25 0.15 0.003 
6 hr 0.50 0.71 0.09 0.63 0.20 0.82 0.22 
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Table 10.20: Statistical data from ROC curve analysis, for all genes analysed 
Probeset ID Gene Time-point
Group 
comparison AUC Std. Error 95% CI P value Controls Patients  
1554503_a_at OSCAR 0 hr O v M+B 0.5026 0.09554 0.3153 to 0.6899 0.978 24 16 
1554503_a_at OSCAR 2 hr O v M+B 0.5703 0.09087 0.3922 to 0.7485 0.4561 24 16 
1554503_a_at OSCAR 6 hr  O v M+B 0.5547 0.09221 0.3739 to 0.7355 0.5621 24 16 
1554503_a_at OSCAR 24 hr O v M+B 0.5281 0.1036 0.3250 to 0.7313 0.7745 20 16 
201887 il13ra1 0 hr O v M+B 0.5443 0.09697 0.3542 to 0.7344 0.6389 24 16 
201887 il13ra2 2 hr O v M+B 0.5938 0.0968 0.4040 to 0.7835 0.3203 24 16 
201887 il13ra3 6 hr  O v M+B 0.6563 0.08877 0.4822 to 0.8303 0.09769 24 16 
201887 il13ra4 24 hr O v M+B 0.5375 0.1046 0.3325 to 0.7425 0.7025 20 16 
201888 il13ra1 0 hr O v M+B 0.5521 0.0994 0.3572 to 0.7470 0.5809 24 16 
201888 il13ra2 2 hr O v M+B 0.6146 0.09283 0.4326 to 0.7966 0.2245 24 16 
201888 il13ra3 6 hr  O v M+B 0.6615 0.09071 0.4836 to 0.8393 0.08702 24 16 
201888 il13ra4 24 hr O v M+B 0.5063 0.1028 0.3048 to 0.7077 0.9492 20 16 
211612 il13ra1 0 hr O v M+B 0.5443 0.09781 0.3525 to 0.7360 0.6389 24 16 
211612 il13ra2 2 hr O v M+B 0.6276 0.09451 0.4423 to 0.8129 0.1762 24 16 
211612 il13ra3 6 hr  O v M+B 0.6484 0.09076 0.4705 to 0.8264 0.1156 24 16 
211612 il13ra4 24 hr O v M+B 0.5 0.1031 0.2980 to 0.7020 1 20 16 
231990 USP15 0 hr O v M+B 0.625 0.09775 0.4334 to 0.8166 0.1852 24 16 
231990 USP16 2 hr O v M+B 0.5391 0.09537 0.3521 to 0.7260 0.6788 24 16 
231990 USP17 6 hr  O v M+B 0.6302 0.09529 0.4434 to 0.8170 0.1675 24 16 
231990 USP18 24 hr O v M+B 0.6313 0.09741 0.4403 to 0.8222 0.1813 20 16 
219471 C13orf18 0 hr O v M+B 0.6068 0.0925 0.4254 to 0.7881 0.2577 24 16 
219471 C13orf18 2 hr O v M+B 0.5859 0.09014 0.4092 to 0.7627 0.3623 24 16 
219471 C13orf18 6 hr  O v M+B 0.763 0.07591 0.6142 to 0.9118 0.005317 24 16 
219471 C13orf18 24 hr O v M+B 0.55 0.09767 0.3585 to 0.7415 0.6105 20 16 
44790 C13orf18 0 hr O v M+B 0.5729 0.09327 0.3901 to 0.7558 0.4395 24 16 
44790 C13orf18 2 hr O v M+B 0.5313 0.09256 0.3498 to 0.7127 0.7404 24 16 
44790 C13orf18 6 hr  O v M+B 0.7188 0.08246 0.5571 to 0.8804 0.02043 24 16 
44790 C13orf18 24 hr O v M+B 0.5563 0.09926 0.3616 to 0.7509 0.5666 20 16 
1559573_at C13orf18 0 hr O v M+B 0.5573 0.09589 0.3693 to 0.7453 0.5436 24 16 
1559573_at C13orf18 2 hr O v M+B 0.5964 0.09259 0.4148 to 0.7779 0.3071 24 16 
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1559573_at C13orf18 6 hr  O v M+B 0.7109 0.08965 0.5352 to 0.8867 0.02538 24 16 
1559573_at C13orf18 24 hr O v M+B 0.5719 0.09684 0.3820 to 0.7617 0.4641 20 16 
229879_at C13orf18 0 hr O v M+B 0.5078 0.09925 0.3132 to 0.7024 0.934 24 16 
229879_at C13orf18 2 hr O v M+B 0.7083 0.08697 0.5378 to 0.8788 0.02725 24 16 
229879_at C13orf18 6 hr  O v M+B 0.6797 0.08854 0.5061 to 0.8533 0.05684 24 16 
229879_at C13orf18 24 hr O v M+B 0.5031 0.1002 0.3067 to 0.6995 0.9746 20 16 
232958_at C13orf18 0 hr O v M+B 0.6224 0.08862 0.4487 to 0.7961 0.1945 24 16 
232958_at C13orf18 2 hr O v M+B 0.5339 0.09442 0.3488 to 0.7190 0.7197 24 16 
232958_at C13orf18 6 hr  O v M+B 0.5651 0.1077 0.3539 to 0.7763 0.4901 24 16 
232958_at C13orf18 24 hr O v M+B 0.5594 0.09921 0.3649 to 0.7539 0.5453 20 16 
234196_at C13orf18 0 hr O v M+B 0.6875 0.08461 0.5216 to 0.8534 0.04689 24 16 
234196_at C13orf18 2 hr O v M+B 0.5677 0.09526 0.3809 to 0.7545 0.4729 24 16 
234196_at C13orf18 6 hr  O v M+B 0.7995 0.07559 0.6513 to 0.9477 0.001508 24 16 
234196_at C13orf18 24 hr O v M+B 0.575 0.09879 0.3813 to 0.7687 0.4449 20 16 
226364 HIP1 0 hr O v M+B 0.526 0.09483 0.3401 to 0.7120 0.7825 24 16 
226364 HIP1 2 hr O v M+B 0.5078 0.09714 0.3174 to 0.6983 0.934 24 16 
226364 HIP1 6 hr  O v M+B 0.5365 0.09962 0.3412 to 0.7318 0.6991 24 16 
226364 HIP1 24 hr O v M+B 0.5594 0.1004 0.3625 to 0.7562 0.5453 20 16 
222630 RFX7 0 hr M v O+B 0.5026 0.09505 0.3163 to 0.6890 0.978 24 16 
222630 RFX7 2 hr M v O+B 0.6354 0.09378 0.4516 to 0.8193 0.1512 24 16 
222630 RFX7 6 hr  M v O+B 0.5313 0.09262 0.3497 to 0.7128 0.7404 24 16 
222630 RFX7 24 hr M v O+B 0.5587 0.09764 0.3673 to 0.7501 0.5528 21 15 
226679 SLC26A11 0 hr M v O+B 0.5182 0.09503 0.3319 to 0.7045 0.8468 24 16 
226679 SLC26A11 2 hr M v O+B 0.6042 0.09291 0.4220 to 0.7863 0.2695 24 16 
226679 SLC26A11 6 hr  M v O+B 0.6536 0.09101 0.4752 to 0.8321 0.1034 24 16 
226679 SLC26A11 24 hr M v O+B 0.6063 0.0946 0.4209 to 0.7918 0.2825 21 15 
226272 RCAN3 0 hr M v O+B 0.6107 0.09023 0.4338 to 0.7876 0.2407 24 16 
226272 RCAN3 2 hr M v O+B 0.5729 0.09329 0.3900 to 0.7558 0.4395 24 16 
226272 RCAN3 6 hr  M v O+B 0.6615 0.09247 0.4802 to 0.8427 0.08702 24 16 
226272 RCAN3 24 hr M v O+B 0.527 0.09731 0.3362 to 0.7178 0.7851 21 15 
39248 AQP3 0 hr M v O+B 0.5521 0.09514 0.3656 to 0.7386 0.5809 24 16 
39248 AQP3 2 hr M v O+B 0.6536 0.08683 0.4834 to 0.8239 0.1034 24 16 
39248 AQP3 6 hr  M v O+B 0.6302 0.09655 0.4409 to 0.8195 0.1675 24 16 
39248 AQP3 24 hr M v O+B 0.5111 0.09868 0.3176 to 0.7046 0.9106 21 15 
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205898 CX3CR1 0 hr M v O+B 0.5234 0.09412 0.3389 to 0.7080 0.8038 24 16 
205898 CX3CR1 2 hr M v O+B 0.6927 0.08551 0.5251 to 0.8604 0.04111 24 16 
205898 CX3CR1 6 hr  M v O+B 0.612 0.09062 0.4343 to 0.7896 0.2352 24 16 
205898 CX3CR1 24 hr M v O+B 0.5524 0.0965 0.3632 to 0.7416 0.5965 21 15 
201990 CREBL2 0 hr M v O+B 0.526 0.09272 0.3443 to 0.7078 0.7825 24 16 
201990 CREBL2 2 hr M v O+B 0.638 0.08885 0.4638 to 0.8122 0.1435 24 16 
201990 CREBL2 6 hr  M v O+B 0.5885 0.09392 0.4044 to 0.7727 0.3479 24 16 
201990 CREBL2 24 hr M v O+B 0.546 0.09714 0.3556 to 0.7365 0.6418 21 15 
209670 TRAC 0 hr M v O+B 0.5417 0.09419 0.3570 to 0.7263 0.6587 24 16 
209670 TRAC 2 hr M v O+B 0.6354 0.08847 0.4620 to 0.8089 0.1512 24 16 
209670 TRAC 6 hr  M v O+B 0.6094 0.09207 0.4289 to 0.7899 0.2463 24 16 
209670 TRAC 24 hr M v O+B 0.5524 0.09731 0.3616 to 0.7432 0.5965 21 15 
202393 KLF10 0 hr M v O+B 0.6068 0.09071 0.4289 to 0.7846 0.2577 24 16 
202393 KLF10 2 hr M v O+B 0.5521 0.09521 0.3654 to 0.7387 0.5809 24 16 
202393 KLF10 6 hr  M v O+B 0.6276 0.0919 0.4474 to 0.8078 0.1762 24 16 
202393 KLF10 24 hr M v O+B 0.5841 0.09794 0.3921 to 0.7761 0.3952 21 15 
219528 BCL11B 0 hr M v O+B 0.5182 0.09414 0.3337 to 0.7028 0.8468 24 16 
219528 BCL11B 2 hr M v O+B 0.6042 0.08996 0.4278 to 0.7805 0.2695 24 16 
219528 BCL11B 6 hr  M v O+B 0.625 0.09522 0.4383 to 0.8117 0.1852 24 16 
219528 BCL11B 24 hr M v O+B 0.5492 0.09799 0.3571 to 0.7413 0.619 21 15 
206545 CD28 0 hr M v O+B 0.5521 0.09738 0.3612 to 0.7430 0.5809 24 16 
206545 CD28 2 hr M v O+B 0.5599 0.09332 0.3770 to 0.7428 0.5255 24 16 
206545 CD28 6 hr  M v O+B 0.6328 0.09346 0.4496 to 0.8160 0.1592 24 16 
206545 CD28 24 hr M v O+B 0.5238 0.09841 0.3309 to 0.7167 0.8098 21 15 
223244 NDUFA12 0 hr M v O+B 0.5885 0.09182 0.4085 to 0.7685 0.3479 24 16 
223244 NDUFA12 2 hr M v O+B 0.5599 0.09345 0.3767 to 0.7431 0.5255 24 16 
223244 NDUFA12 6 hr  M v O+B 0.6432 0.0917 0.4635 to 0.8230 0.129 24 16 
223244 NDUFA12 24 hr M v O+B 0.5619 0.09688 0.3720 to 0.7518 0.5315 21 15 
229629 229629 0 hr M v O+B 0.5208 0.09262 0.3393 to 0.7024 0.8252 24 16 
229629 229629 2 hr M v O+B 0.638 0.09205 0.4576 to 0.8185 0.1435 24 16 
229629 229629 6 hr  M v O+B 0.5286 0.09391 0.3445 to 0.7127 0.7614 24 16 
229629 229629 24 hr M v O+B 0.5841 0.09603 0.3959 to 0.7724 0.3952 21 15 
1562255_at SYTL3 0 hr M v O+B 0.5703 0.09746 0.3793 to 0.7614 0.4561 24 16 
1562255_at SYTL3 2 hr M v O+B 0.5313 0.09815 0.3388 to 0.7237 0.7404 24 16 
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1562255_at SYTL3 6 hr  M v O+B 0.5365 0.09334 0.3535 to 0.7195 0.6991 24 16 
1562255_at SYTL3 24 hr M v O+B 0.5524 0.09738 0.3615 to 0.7433 0.5965 21 15 
204266 CHKA 0 hr M v O+B 0.5938 0.09301 0.4114 to 0.7761 0.3203 24 16 
204266 CHKA 2 hr M v O+B 0.6406 0.08942 0.4653 to 0.8159 0.1361 24 16 
204266 CHKA 6 hr  M v O+B 0.5677 0.09153 0.3883 to 0.7471 0.4729 24 16 
204266 CHKA 24 hr M v O+B 0.6794 0.09068 0.5016 to 0.8571 0.0699 21 15 
210244 CAMP 0 hr M v O+B 0.5208 0.09546 0.3337 to 0.7080 0.8252 24 16 
210244 CAMP 2 hr M v O+B 0.513 0.1002 0.3166 to 0.7095 0.8902 24 16 
210244 CAMP 6 hr  M v O+B 0.5833 0.093 0.4010 to 0.7657 0.377 24 16 
210244 CAMP 24 hr M v O+B 0.5556 0.09899 0.3615 to 0.7496 0.5745 21 15 
1556202_at SRGAP2 0 hr M v O+B 0.5286 0.09541 0.3416 to 0.7157 0.7614 24 16 
1556202_at SRGAP2 2 hr M v O+B 0.5547 0.09157 0.3752 to 0.7342 0.5621 24 16 
1556202_at SRGAP2 6 hr  M v O+B 0.5234 0.09339 0.3403 to 0.7065 0.8038 24 16 
1556202_at SRGAP2 24 hr M v O+B 0.5429 0.09835 0.3500 to 0.7357 0.6649 21 15 
240038_at 240038_at 0 hr M v O+B 0.5521 0.09631 0.3633 to 0.7409 0.5809 24 16 
240038_at 240038_at 2 hr M v O+B 0.5911 0.09051 0.4137 to 0.7686 0.334 24 16 
240038_at 240038_at 6 hr  M v O+B 0.5078 0.0925 0.3265 to 0.6892 0.934 24 16 
240038_at 240038_at 24 hr M v O+B 0.5143 0.09783 0.3225 to 0.7061 0.8852 21 15 
235592_at 235592_at 0 hr M v O+B 0.5547 0.09651 0.3655 to 0.7439 0.5621 24 16 
235592_at 235592_at 2 hr M v O+B 0.6302 0.09044 0.4529 to 0.8075 0.1675 24 16 
235592_at 235592_at 6 hr  M v O+B 0.5833 0.0936 0.3998 to 0.7668 0.377 24 16 
235592_at 235592_at 24 hr M v O+B 0.6222 0.09422 0.4375 to 0.8069 0.2168 21 15 
207384 PGLYRP1 0 hr M v O+B 0.5964 0.0919 0.4162 to 0.7765 0.3071 24 16 
207384 PGLYRP2 2 hr M v O+B 0.5651 0.09737 0.3742 to 0.7560 0.4901 24 16 
207384 PGLYRP3 6 hr  M v O+B 0.5885 0.09294 0.4063 to 0.7707 0.3479 24 16 
207384 PGLYRP4 24 hr M v O+B 0.5651 0.1001 0.3689 to 0.7613 0.5107 21 15 
205239 AREG 0 hr M v O+B 0.5729 0.09364 0.3893 to 0.7565 0.4395 24 16 
205239 AREG 2 hr M v O+B 0.5573 0.09499 0.3711 to 0.7435 0.5436 24 16 
205239 AREG 6 hr  M v O+B 0.5703 0.09478 0.3845 to 0.7561 0.4561 24 16 
205239 AREG 24 hr M v O+B 0.5683 0.09974 0.3727 to 0.7638 0.4903 21 15 
237618_at 237618_at 0 hr O v M+B 0.5313 0.1003 0.3347 to 0.7278 0.7404 24 16 
237618_at 237618_at 2 hr O v M+B 0.5677 0.09159 0.3882 to 0.7472 0.4729 24 16 
237618_at 237618_at 6 hr  O v M+B 0.8464 0.06512 0.7187 to 0.974 0.0002 24 16 
237618_at 237618_at 24 hr O v M+B 0.5719 0.09848 0.3789 to 0.7649 0.464 20 16 
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200796 MCL1 0 hr O v M+B 0.6094 0.0945 0.4242 to 0.7946 0.2462 24 16 
200796 MCL1 2 hr O v M+B 0.6875 0.0867 0.5176 to 0.8574 0.0468 24 16 
200796 MCL1 6 hr  O v M+B 0.7656 0.07772 0.6133 to 0.918 0.0049 24 16 
200796 MCL1 24 hr O v M+B 0.6938 0.09072 0.5159 to 0.8716 0.0484 20 16 
214465 ORM1/ORM2 0 hr O v M+B 0.5339 0.1 0.3378 to 0.7299 0.7197 24 16 
214465 ORM1/ORM2 2 hr O v M+B 0.5313 0.09331 0.3484 to 0.7141 0.7404 24 16 
214465 ORM1/ORM2 6 hr  O v M+B 0.7031 0.086 0.5346 to 0.8717 0.0313 24 16 
214465 ORM1/ORM2 24 hr O v M+B 0.7375 0.0821 0.5766 to 0.8984 0.0155 20 16 
229817 ZNF608 0 hr O v M+B 0.5521 0.09219 0.3714 to 0.7328 0.5808 24 16 
229817 ZNF608 2 hr O v M+B 0.5443 0.09513 0.3578 to 0.7307 0.6388 24 16 
229817 ZNF608 6 hr  O v M+B 0.6979 0.08842 0.5246 to 0.8712 0.0359 24 16 
229817 ZNF608 24 hr O v M+B 0.5625 0.09994 0.3666 to 0.7584 0.5243 20 16 
209840 LRRN3 0 hr O v M+B 0.6406 0.09408 0.4562 to 0.825 0.136 24 16 
209840 LRRN3 2 hr O v M+B 0.5703 0.09209 0.3898 to 0.7508 0.456 24 16 
209840 LRRN3 6 hr  O v M+B 0.599 0.09194 0.4188 to 0.7792 0.2941 24 16 
209840 LRRN3 24 hr O v M+B 0.5875 0.1011 0.3893 to 0.7857 0.3727 20 16 
212414 GLYR1 /// SEPT6 0 hr O v M+B 0.5807 0.09706 0.3904 to 0.7710 0.3921 24 16 
212414 GLYR1 /// SEPT6 2 hr O v M+B 0.5677 0.09534 0.3808 to 0.7546 0.4729 24 16 
212414 GLYR1 /// SEPT6 6 hr  O v M+B 0.6276 0.09114 0.4489 to 0.8063 0.1762 24 16 
212414 GLYR1 /// SEPT6 24 hr O v M+B 0.6406 0.0995 0.4456 to 0.8357 0.152 20 16 
205006 NMT2 0 hr O v M+B 0.5651 0.09241 0.3839 to 0.7463 0.4901 24 16 
205006 NMT2 2 hr O v M+B 0.5885 0.09187 0.4084 to 0.7687 0.3479 24 16 
205006 NMT2 6 hr  O v M+B 0.5781 0.09307 0.3957 to 0.7606 0.4076 24 16 
205006 NMT2 24 hr O v M+B 0.6313 0.09639 0.4423 to 0.8202 0.1813 20 16 
209604 GATA3 0 hr O v M+B 0.5104 0.09658 0.3211 to 0.6998 0.9121 24 16 
209604 GATA3 2 hr O v M+B 0.6146 0.09504 0.4283 to 0.8009 0.2245 24 16 
209604 GATA3 6 hr  O v M+B 0.5807 0.09272 0.3989 to 0.7625 0.3921 24 16 
209604 GATA3 24 hr O v M+B 0.7063 0.08869 0.5324 to 0.8801 0.03568 20 16 
236796 BACH2 0 hr O v M+B 0.5234 0.09383 0.3395 to 0.7074 0.8038 24 16 
236796 BACH2 2 hr O v M+B 0.5 0.09407 0.3156 to 0.6844 1 24 16 
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236796 BACH2 6 hr  O v M+B 0.5599 0.09553 0.3726 to 0.7472 0.5255 24 16 
236796 BACH2 24 hr O v M+B 0.7563 0.08039 0.5986 to 0.9139 0.009067 20 16 
231124_x_at LY9 0 hr O v M+B 0.6458 0.08896 0.4714 to 0.8202 0.1222 24 16 
231124_x_at LY9 2 hr O v M+B 0.5807 0.09534 0.3938 to 0.7676 0.3921 24 16 
231124_x_at LY9 6 hr  O v M+B 0.612 0.09507 0.4256 to 0.7984 0.2352 24 16 
231124_x_at LY9 24 hr O v M+B 0.6594 0.09659 0.4700 to 0.8487 0.1045 20 16 
235122_at HIVEP3 0 hr O v M+B 0.5521 0.1045 0.3473 to 0.7569 0.5809 24 16 
235122_at HIVEP3 2 hr O v M+B 0.638 0.09164 0.4584 to 0.8177 0.1435 24 16 
235122_at HIVEP3 6 hr  O v M+B 0.6068 0.09666 0.4173 to 0.7963 0.2577 24 16 
235122_at HIVEP3 24 hr O v M+B 0.5438 0.1013 0.3452 to 0.7423 0.6558 20 16 
242761_s_at ZNF420 0 hr O v M+B 0.5755 0.09267 0.3938 to 0.7572 0.4234 24 16 
242761_s_at ZNF420 2 hr O v M+B 0.6224 0.09391 0.4383 to 0.8065 0.1945 24 16 
242761_s_at ZNF420 6 hr  O v M+B 0.6198 0.09561 0.4324 to 0.8072 0.2042 24 16 
242761_s_at ZNF420 24 hr O v M+B 0.6031 0.1033 0.4006 to 0.8057 0.2935 20 16 
213164_at SLC5A3 0 hr O v M+B 0.526 0.1044 0.3213 to 0.7308 0.7825 24 16 
213164_at SLC5A3 2 hr O v M+B 0.5755 0.09444 0.3904 to 0.7607 0.4234 24 16 
213164_at SLC5A3 6 hr  O v M+B 0.6146 0.09528 0.4278 to 0.8014 0.2245 24 16 
213164_at SLC5A3 24 hr O v M+B 0.6875 0.09453 0.5022 to 0.8728 0.05617 20 16 
228320_x_at CCDC64 0 hr O v M+B 0.6458 0.09287 0.4638 to 0.8279 0.1222 24 16 
228320_x_at CCDC64 2 hr O v M+B 0.5208 0.09955 0.3257 to 0.7160 0.8252 24 16 
228320_x_at CCDC64 6 hr  O v M+B 0.5208 0.6563 0.08856 0.4826 to 0.8299   24 
228320_x_at CCDC64 24 hr O v M+B 0.6156 0.1018 0.4160 to 0.8152 0.2389 20 16 
225612_s_at B3GNT5 0 hr O v M+B 0.5182 0.09694 0.3282 to 0.7083 0.8468 24 16 
225612_s_at B3GNT5 2 hr O v M+B 0.5729 0.0983 0.3802 to 0.7656 0.4395 24 16 
225612_s_at B3GNT5 6 hr  O v M+B 0.6641 0.08987 0.4879 to 0.8403 0.08204 24 16 
225612_s_at B3GNT5 24 hr O v M+B 0.5156 0.09786 0.3238 to 0.7075 0.8735 20 16 
222528 SLC25A37 0 hr O v M+B 0.5547 0.097 0.3645 to 0.7449 0.5621 24 16 
222528 SLC25A37 2 hr O v M+B 0.6042 0.09389 0.4201 to 0.7882 0.2695 24 16 
222528 SLC25A37 6 hr  O v M+B 0.7292 0.0844 0.5637 to 0.8946 0.01515 24 16 
222528 SLC25A37 24 hr O v M+B 0.5188 0.1005 0.3216 to 0.7159 0.8485 20 16 
219669_at CD177 0 hr O v M+B 0.5182 0.09468 0.3326 to 0.7038 0.8468 24 16 
219669_at CD177 2 hr O v M+B 0.5 0.09342 0.3169 to 0.6831 1 24 16 
219669_at CD177 6 hr  O v M+B 0.638 0.09466 0.4524 to 0.8236 0.1435 24 16 
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219669_at CD177 24 hr O v M+B 0.5875 0.09803 0.3953 to 0.7797 0.3728 20 16 
203765_at GCA 0 hr O v M+B 0.5365 0.09493 0.3503 to 0.7226 0.6991 24 16 
203765_at GCA 2 hr O v M+B 0.5599 0.09649 0.3707 to 0.7491 0.5255 24 16 
203765_at GCA 6 hr  O v M+B 0.6029 0.09359 0.4194 to 0.7863 0.2755 24 16 
203765_at GCA 24 hr O v M+B 0.5438 0.09988 0.3479 to 0.7396 0.6558 20 16 
204351_at S100P 0 hr O v M+B 0.5182 0.09521 0.3316 to 0.7049 0.8468 24 16 
204351_at S100P 2 hr O v M+B 0.5313 0.09384 0.3473 to 0.7152 0.7404 24 16 
204351_at S100P 6 hr  O v M+B 0.6224 0.09913 0.4281 to 0.8167 0.1945 24 16 
204351_at S100P 24 hr O v M+B 0.5469 0.09934 0.3521 to 0.7416 0.633 20 16 
205863_at S100A12 0 hr O v M+B 0.5547 0.09294 0.3725 to 0.7369 0.5621 24 16 
205863_at S100A12 2 hr O v M+B 0.5339 0.09258 0.3524 to 0.7154 0.7197 24 16 
205863_at S100A12 6 hr  O v M+B 0.5729 0.09369 0.3893 to 0.7566 0.4395 24 16 
205863_at S100A12 24 hr O v M+B 0.525 0.09961 0.3297 to 0.7203 0.799 20 16 
205041_s_at ORM1/ORM2 0 hr O v M+B 0.5833 0.09109 0.4048 to 0.7619 0.377 24 16 
205041_s_at ORM1/ORM2 2 hr O v M+B 0.5521 0.09448 0.3669 to 0.7373 0.5809 24 16 
205041_s_at ORM1/ORM2 6 hr  O v M+B 0.6667 0.0936 0.4832 to 0.8502 0.07731 24 16 
205041_s_at ORM1/ORM2 24 hr O v M+B 0.6719 0.09185 0.4918 to 0.8519 0.08001 20 16 
206522_at MGAM 0 hr O v M+B 0.526 0.09377 0.3422 to 0.7099 0.7825 24 16 
206522_at MGAM 2 hr O v M+B 0.5026 0.09421 0.3179 to 0.6873 0.978 24 16 
206522_at MGAM 6 hr  O v M+B 0.6536 0.09347 0.4704 to 0.8369 0.1034 24 16 
206522_at MGAM 24 hr O v M+B 0.5188 0.1022 0.3184 to 0.7191 0.8485 20 16 
201963 ACSL1 0 hr O v M+B 0.5495 0.09614 0.3610 to 0.7380 0.5999 24 16 
201963 ACSL1 2 hr O v M+B 0.5391 0.09351 0.3557 to 0.7224 0.6788 24 16 
201963 ACSL1 6 hr  O v M+B 0.6146 0.09533 0.4277 to 0.8015 0.2245 24 16 
201963 ACSL1 24 hr O v M+B 0.5125 0.1005 0.3154 to 0.7096 0.8987 20 16 
209369_at ANXA3 0 hr O v M+B 0.5339 0.09298 0.3516 to 0.7161 0.7197 24 16 
209369_at ANXA3 2 hr O v M+B 0.5469 0.0937 0.3632 to 0.7306 0.6193 24 16 
209369_at ANXA3 6 hr  O v M+B 0.6302 0.09205 0.4497 to 0.8107 0.1675 24 16 
209369_at ANXA3 24 hr O v M+B 0.5344 0.09802 0.3422 to 0.7265 0.7262 20 16 
210640_s_at GPER 0 hr B v O+B 0.6992 0.08652 0.5296 to 0.8688 0.08469 32 8 
210640_s_at GPER 2 hr B v O+B 0.5156 0.123 0.2745 to 0.7568 0.8924 32 8 
210640_s_at GPER 6 hr  B v O+B 0.5391 0.1364 0.2717 to 0.8064 0.7353 32 8 
210640_s_at GPER 24 hr B v O+B 0.7935 0.08286 0.6311 to 0.9560 0.03746 31 5 
227984_at LMF1 0 hr B v O+B 0.7188 0.1244 0.4748 to 0.9627 0.05835 32 8 
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227984_at LMF1 2 hr B v O+B 0.5039 0.1198 0.2691 to 0.7387 0.973 32 8 
227984_at LMF1 6 hr  B v O+B 0.625 0.118 0.3938 to 0.8562 0.2793 32 8 
227984_at LMF1 24 hr B v O+B 0.7226 0.1608 0.4074 to 1.038 0.1146 31 5 
1562731_s_at MDS2 0 hr B v O+B 0.7969 0.1026 0.5958 to 0.9980 0.01021 32 8 
1562731_s_at MDS2 2 hr B v O+B 0.5938 0.1248 0.3490 to 0.8385 0.4171 32 8 
1562731_s_at MDS2 6 hr  B v O+B 0.5547 0.1187 0.3221 to 0.7873 0.636 32 8 
1562731_s_at MDS2 24 hr B v O+B 0.729 0.1189 0.4959 to 0.9622 0.1045 31 5 
244798 LOC100507492 0 hr B v O+B 0.5391 0.14 0.2646 to 0.8135 0.7353 32 8 
244798 LOC100507492 2 hr B v O+B 0.5508 0.1205 0.3145 to 0.7870 0.6603 32 8 
244798 LOC100507492 6 hr  B v O+B 0.6602 0.1253 0.4145 to 0.9058 0.1657 32 8 
244798 LOC100507492 24 hr B v O+B 0.5032 0.09299 0.3209 to 0.6855 0.9818 31 5 
221221 KLHL3 0 hr B v O+B 0.7148 0.1087 0.5017 to 0.9280 0.06299 32 8 
221221 KLHL3 2 hr B v O+B 0.5195 0.1245 0.2754 to 0.7637 0.8658 32 8 
221221 KLHL3 6 hr  B v O+B 0.5508 0.1193 0.3168 to 0.7847 0.6603 32 8 
221221 KLHL3 24 hr B v O+B 0.7742 0.1301 0.5191 to 1.029 0.05194 31 5 
219671 HPCAL4 0 hr B v O+B 0.6445 0.1146 0.4199 to 0.8691 0.211 32 8 
219671 HPCAL4 2 hr B v O+B 0.5391 0.1209 0.3020 to 0.7762 0.7353 32 8 
219671 HPCAL4 6 hr  B v O+B 0.6914 0.09265 0.5098 to 0.8730 0.09762 32 8 
219671 HPCAL4 24 hr B v O+B 0.6516 0.1114 0.4333 to 0.8699 0.2824 31 5 
1555883_s_at SPIN3 0 hr B v O+B 0.6406 0.1393 0.3675 to 0.9137 0.2236 32 8 
1555883_s_at SPIN3 2 hr B v O+B 0.625 0.1268 0.3764 to 0.8736 0.2793 32 8 
1555883_s_at SPIN3 6 hr  B v O+B 0.6367 0.1319 0.3782 to 0.8952 0.2367 32 8 
1555883_s_at SPIN3 24 hr B v O+B 0.671 0.1332 0.4099 to 0.9321 0.2255 31 5 
40837_at TLE2 0 hr B v O+B 0.6563 0.1197 0.4217 to 0.8908 0.1763 32 8 
40837_at TLE2 2 hr B v O+B 0.5078 0.1285 0.2558 to 0.7598 0.9461 32 8 
40837_at TLE2 6 hr  B v O+B 0.5 0.1155 0.2735 to 0.7265 1 32 8 
40837_at TLE2 24 hr B v O+B 0.729 0.1384 0.4577 to 1.000 0.1045 31 5 
219308_s_at AK5 0 hr B v O+B 0.6758 0.1138 0.4526 to 0.8990 0.1282 32 8 
219308_s_at AK5 2 hr B v O+B 0.5469 0.1223 0.3072 to 0.7866 0.6849 32 8 
219308_s_at AK5 6 hr  B v O+B 0.6523 0.09769 0.4608 to 0.8439 0.1873 32 8 
219308_s_at AK5 24 hr B v O+B 0.6387 0.1402 0.3638 to 0.9136 0.3254 31 5 
1564155_x_at 1564155_x_at 0 hr B v O+B 0.6367 0.1083 0.4243 to 0.8491 0.2367 32 8 
1564155_x_at 1564155_x_at 2 hr B v O+B 0.5156 0.1083 0.3033 to 0.7280 0.8924 32 8 
1564155_x_at 1564155_x_at 6 hr  B v O+B 0.6719 0.1068 0.4626 to 0.8812 0.1369 32 8 
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1564155_x_at 1564155_x_at 24 hr B v O+B 0.6774 0.1122 0.4575 to 0.8974 0.2085 31 5 
203184_at FBN2 0 hr M v O+B 0.5443 0.09349 0.3610 to 0.7276 0.6389 24 16 
203184_at FBN2 2 hr M v O+B 0.6797 0.0891 0.5050 to 0.8544 0.05684 24 16 
203184_at FBN2 6 hr  M v O+B 0.6615 0.08937 0.4862 to 0.8367 0.08702 24 16 
203184_at FBN2 24 hr M v O+B 0.6 0.1008 0.4024 to 0.7976 0.3122 21 15 
227038_at SGMS2 0 hr M v O+B 0.5625 0.09169 0.3827 to 0.7423 0.5076 24 16 
227038_at SGMS2 2 hr M v O+B 0.5052 0.09529 0.3184 to 0.6920 0.956 24 16 
227038_at SGMS2 6 hr  M v O+B 0.599 0.09201 0.4186 to 0.7793 0.2942 24 16 
227038_at SGMS2 24 hr M v O+B 0.5937 0.1001 0.3974 to 0.7899 0.3439 21 15 
228285_at TDRD9 0 hr M v O+B 0.5443 0.09711 0.3539 to 0.7346 0.6389 24 16 
228285_at TDRD9 2 hr M v O+B 0.5234 0.09362 0.3399 to 0.7070 0.8038 24 16 
228285_at TDRD9 6 hr  M v O+B 0.6953 0.08537 0.5280 to 0.8627 0.03845 24 16 
228285_at TDRD9 24 hr M v O+B 0.5905 0.1014 0.3916 to 0.7893 0.3605 21 15 
1565162_s_at MGST1 0 hr M v O+B 0.6172 0.08872 0.4432 to 0.7911 0.2142 24 16 
1565162_s_at MGST1 2 hr M v O+B 0.6146 0.0897 0.4387 to 0.7904 0.2245 24 16 
1565162_s_at MGST1 6 hr  M v O+B 0.724 0.08492 0.5575 to 0.8904 0.01762 24 16 
1565162_s_at MGST1 24 hr M v O+B 0.6095 0.09634 0.4206 to 0.7984 0.2683 21 15 
226517_at BCAT1 0 hr M v O+B 0.5599 0.09537 0.3729 to 0.7469 0.5255 24 16 
226517_at BCAT1 2 hr M v O+B 0.5938 0.09374 0.4100 to 0.7775 0.3203 24 16 
226517_at BCAT1 6 hr  M v O+B 0.6432 0.08992 0.4669 to 0.8195 0.129 24 16 
226517_at BCAT1 24 hr M v O+B 0.6571 0.09428 0.4723 to 0.8420 0.1123 21 15 
235019_at CPM 0 hr M v O+B 0.599 0.09535 0.4120 to 0.7859 0.2942 24 16 
235019_at CPM 2 hr M v O+B 0.6042 0.0893 0.4291 to 0.7792 0.2695 24 16 
235019_at CPM 6 hr  M v O+B 0.6745 0.08743 0.5031 to 0.8459 0.06441 24 16 
235019_at CPM 24 hr M v O+B 0.6032 0.09597 0.4150 to 0.7913 0.2971 21 15 
211734_s_at FCER1A 0 hr M v O+B 0.5781 0.09042 0.4009 to 0.7554 0.4076 24 16 
211734_s_at FCER1A 2 hr M v O+B 0.5651 0.0949 0.3791 to 0.7511 0.4901 24 16 
211734_s_at FCER1A 6 hr  M v O+B 0.5078 0.09382 0.3239 to 0.6917 0.934 24 16 
211734_s_at FCER1A 24 hr M v O+B 0.5714 0.09711 0.3810 to 0.7618 0.4703 21 15 
234985_at LDLRAD3 0 hr M v O+B 0.5677 0.09028 0.3907 to 0.7447 0.4729 24 16 
234985_at LDLRAD3 2 hr M v O+B 0.7552 0.07739 0.6035 to 0.9069 0.006842 24 16 
234985_at LDLRAD3 6 hr  M v O+B 0.6693 0.08559 0.5015 to 0.8371 0.07279 24 16 
234985_at LDLRAD3 24 hr M v O+B 0.6063 0.1001 0.4101 to 0.8026 0.2825 21 15 
234985_at LDLRAD3 0 hr M v O+B 0.5846 0.09086 0.4065 to 0.7628 0.3696 24 16 
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234985_at LDLRAD3 2 hr M v O+B 0.6615 0.08824 0.4885 to 0.8344 0.08702 24 16 
205257 AMPH 6 hr  M v O+B 0.7266 0.0812 0.5674 to 0.8858 0.01635 24 16 
205257 AMPH 24 hr M v O+B 0.5079 0.101 0.3099 to 0.7060 0.9361 21 15 
206932_at CH25H 0 hr M v O+B 0.5547 0.09436 0.3697 to 0.7397 0.5621 24 16 
206932_at CH25H 2 hr M v O+B 0.5911 0.09397 0.4069 to 0.7754 0.334 24 16 
206932_at CH25H 6 hr  M v O+B 0.75 0.07869 0.5957 to 0.9043 0.008066 24 16 
206932_at CH25H 24 hr M v O+B 0.5556 0.1004 0.3588 to 0.7523 0.5745 21 15 
205977_s_at EPHA1 0 hr B v O+B 0.8281 0.09538 0.6412 to 1.015 0.0045 32 8 
205977_s_at EPHA1 2 hr B v O+B 0.5781 0.1053 0.3717 to 0.7846 0.4989 32 8 
205977_s_at EPHA1 6 hr  B v O+B 0.5664 0.1286 0.3144 to 0.8184 0.5654 32 8 
205977_s_at EPHA1 24 hr B v O+B 0.6323 0.1126 0.4115 to 0.853 0.3484 31 5 
202953_at C1QB 0 hr B v O+B 0.5898 0.1203 0.3541 to 0.8256 0.4368 32 8 
202953_at C1QB 2 hr B v O+B 0.7305 0.105 0.5246 to 0.9363 0.046 32 8 
202953_at C1QB 6 hr  B v O+B 0.668 0.121 0.4309 to 0.9051 0.146 32 8 
202953_at C1QB 24 hr B v O+B 0.5742 0.1414 0.297 to 0.8514 0.5989 31 5 
218424_s_at STEAP3 0 hr B v O+B 0.5742 0.104 0.3704 to 0.778 0.5206 32 8 
218424_s_at STEAP3 2 hr B v O+B 0.6992 0.1004 0.5024 to 0.896 0.0846 32 8 
218424_s_at STEAP3 6 hr  B v O+B 0.6094 0.1114 0.3909 to 0.8278 0.3438 32 8 
218424_s_at STEAP3 24 hr B v O+B 0.8129 0.09711 0.6226 to 1.003 0.0265 31 5 
238515 NUDT16 0 hr B v O+B 0.5156 0.1165 0.2873 to 0.744 0.8924 32 8 
238515 NUDT16 2 hr B v O+B 0.668 0.123 0.4269 to 0.909 0.146 32 8 
238515 NUDT16 6 hr  B v O+B 0.6563 0.1195 0.4221 to 0.8904 0.1762 32 8 
238515 NUDT16 24 hr B v O+B 0.7355 0.09415 0.551 to 0.92 0.095 31 5 
224357_s_at MS4A4A 0 hr B v O+B 0.5586 0.1186 0.3262 to 0.7909 0.612 32 8 
224357_s_at MS4A4A 2 hr B v O+B 0.6172 0.1086 0.4044 to 0.83 0.3104 32 8 
224357_s_at MS4A4A 6 hr  B v O+B 0.7695 0.07918 0.6143 to 0.9247 0.0196 32 8 
224357_s_at MS4A4A 24 hr B v O+B 0.6194 0.1238 0.3767 to 0.862 0.3974 31 5 
203910_at ARHGAP29 0 hr B v O+B 0.6367 0.1109 0.4194 to 0.854 0.2366 32 8 
203910_at ARHGAP29 2 hr B v O+B 0.5586 0.1264 0.311 to 0.8062 0.612 32 8 
203910_at ARHGAP29 6 hr  B v O+B 0.6719 0.1164 0.4438 to 0.9 0.1368 32 8 
203910_at ARHGAP29 24 hr B v O+B 0.8194 0.08423 0.6543 to 0.9844 0.0236 31 5 
206976 HSPH1 0 hr M v O+B 0.5286 0.0936 0.3452 to 0.7121 0.7614 24 16 
206976 HSPH1 2 hr M v O+B 0.6016 0.09315 0.419 to 0.7841 0.2816 24 16 
206976 HSPH1 6 hr  M v O+B 0.612 0.08964 0.4363 to 0.7877 0.2352 24 16 
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206976 HSPH1 24 hr M v O+B 0.5079 0.09718 0.3175 to 0.6984 0.9361 21 15 
213135 TIAM1 0 hr M v O+B 0.5807 0.09136 0.4017 to 0.7598 0.3921 24 16 
213135 TIAM1 2 hr M v O+B 0.5677 0.09368 0.3841 to 0.7513 0.4729 24 16 
213135 TIAM1 6 hr  M v O+B 0.6172 0.0949 0.4312 to 0.8032 0.2141 24 16 
213135 TIAM1 24 hr M v O+B 0.5032 0.0984 0.3103 to 0.696 0.9744 21 15 
221218 TPK1 0 hr M v O+B 0.5339 0.094 0.3496 to 0.7181 0.7197 24 16 
221218 TPK1 2 hr M v O+B 0.737 0.08104 0.5781 to 0.8958 0.012 24 16 
221218 TPK1 6 hr  M v O+B 0.5026 0.09283 0.3207 to 0.6845 0.978 24 16 
221218 TPK1 24 hr M v O+B 0.5492 0.09883 0.3555 to 0.7429 0.6189 21 15 
223182 AGPAT3 0 hr M v O+B 0.5182 0.09626 0.3296 to 0.7069 0.8468 24 16 
223182 AGPAT3 2 hr M v O+B 0.7083 0.08405 0.5436 to 0.8731 0.0272 24 16 
223182 AGPAT3 6 hr  M v O+B 0.5313 0.09311 0.3488 to 0.7137 0.7404 24 16 
223182 AGPAT3 24 hr M v O+B 0.5048 0.09765 0.3134 to 0.6962 0.9616 21 15 
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Figure 10.2: ROC curves for genes found to be significant through ROC analysis.  
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Figure 10.3: ROC curves for genes found to be significant through ROC analysis.  
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Table 10.21: Number of degranulation events for morphine group NK cell 
samples degranulated through CD107a assay. 
 
Morphine group 
  0 hr 6 hr 
Subject 
No Unstimulated Stimulated Unstimulated Stimulated
48 2063 1513 1067 1087 
50 959 974 1210 1313 
52 1294 1260 1294 1563 
53 1068 1174 1068 1071 
45 3500 3366 3895 3162 
Median 1294 1260 1210 1313 
% change 
between 
timepoints
-0.03   0.09   
 
 
Table 10.22: Number of degranulation events for oxycodone group NK cell 
samples degranulated through CD107a assay 
 
Oxycodone group 
  0 hr 6 hr 
Subject 
No Unstimulated Stimulated Unstimulated Stimulated
9 611 535 1.1 593 
44 1591 2236 0 545 
34 1110 0 0 8378 
33 984 1056 2041 2988 
49 899 599 783 1624 
6 3789 3762 4681 4457 
Median 1047 828 392 2306 
% change 
between 
timepoints
-0.21  4.88  
 
  
Mary Elizabeth Demopoulos Appendices 
© Mary Demopoulos 2010–2017 315
 
Table 10.23: Number of degranulation events for bupivacaine group NK cell 
samples degranulated through CD107a assay 
 
Bupivacaine group 
  0 hr 6 hr 
Subject 
No Unstimulated Stimulated Unstimulated Stimulated
32 517 518 1497 2932 
41 1149 2315 2978 1115 
46 2189 2648 2767 3087 
36 2077 1641 7123 7392 
Median 1613 1978 2873 3010 
% change 
between 
timepoints
0.23   0.05   
 
 
Table 10.24: Results of Wilcoxon signed ranks test for NK cell degranulation 
data 
 
 0 hr 6 hr 
Treat-
ment N 
Median 
Unstim 
Median 
Stim 
 Asymp 
sig N 
Median 
Unstim 
Median 
Stim 
Asymp 
sig 
M 5 1294 1260 0.35 5 1210 1313 0.50 
O 6 1047 828 0.46 6 392 2306 0.05 
B 4 1613 1978 0.27 4 2872 3010 0.72 
 
 
Table 10.25: Results of Kruskal Wallis test for NK cell degranulation data 
 
 
 
 
 
 
 
 
 Statistics 
Group Asymp sig
0 hr unstim 0.78 
0 hr stim 0.63 
6 hr unstim 0.11 
6 hr stim 0.53 
